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size and/or critical dielectric membrane breakdown voltage.
The invention enables effective cell separation without the
need to employ undesirable exogenous agents, such as toxins
or antibodies. The inventive method also enables relatively
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clinical medicine, research, etc., with two of the more impor-
tant foreseeable applications being stem cell enrichment/iso-
lation, and cancer cell purging.
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CELL SEPARATION USING ELECTRIC 	 deleterious cells (e.g. mature T cells for allogeneic trans-
FIELDS	 plants and residual cancerous cells for autologous trans-
plants). For example, for autologous adjuvant stem cell trans-
RELATED APPLICATIONS 	 plant therapy following myeloablative cancer treatments, it is
5 believed that reinfusion of residual tumor cells is a major
This application is a division of U.S. application Ser. No. 	 cause of post therapy relapse. Clearly, removing such cells
09/489,116, filed Jan. 21, 2000 and issued on Jul. 8, 2003 as 	 from transplanted tissue would be beneficial to the patient.
U.S. Pat. No. 6,589,786, which is a division of U.S. applica- 	 A number of cell isolation, cell separation, and cell purging
tion Ser. No. 09/148,620, filed Sep. 4, 1998 and issued on	 strategies have been employed in the prior art for purifying or
Mar. 28, 2000 as U.S. Pat. No. 6,043,066, which claims io removing cells from a suspension. Prior art cell separation
priority from provisional specification No. 60/057,809 filed	 methods used to isolate cells or purge cell suspensions typi-
Sep. 4, 1997, each of which is incorporated herein by refer- 	 cally fall into one of three broad categories: physical separa-
ence.
	
	 tion methods typically exploit differences in a physical prop-
erty between cell types, such as cell size or density (e.g.
STATEMENT REGARDING FEDERALLY 	 15 centrifugation or elutriation); chemical-based methods typi-
SPONSORED RESEARCH OR DEVELOPMENT
	
	
cally employ an agent that selectively kills or purges one or
more undesirable cell types; and affinity-based methods typi-
The U.S. Government has a paid-up license in this inven- 	 cally exploit antibodies that bind selectively to marker mol-
tion and the right in limited circumstances to require the	 ecules on a cell membrane surface of desired or undesired cell
patent owner to licence others on reasonable terms as pro- 20 types, which antibodies may subsequently enable the cells to
vided for by the terms of subcontract No. 04027 awarded the 	 be isolated or removed from the suspension. While physical
National Technology Transfer Center at Wheeling Jesuit Uni- 	 separation methods can be advantageous with regard to their
versity supported by the Ballistic Missile Defense Organiza- 	 ability to separate cells without causing undo damage to
tion, Technology applications Program NASA Cooperative 	 desired cells, current physical separation methods typically
Agreement no. NCC W-0065.	 25 have relatively poor specificity and do not typically yield
highly purified or highly purged cell suspensions. While
FIELD OF THE INVENTION	 many chemical and affinity methods have better selectivity
than typical physical methods, they can often be expensive or
This invention relates to methods and apparatuses for 	 time consuming to perform and can cause considerable dam-
selecting specific cell types from cell suspensions, specifi- 30 age to, or activation of, desired cells, for example stem cells,
cally those employing applied electric fields. 	 and/or can add undesirable agents to the purified or isolated
cell suspensions (e.g. toxins, proliferation-inducing agents,
BACKGROUND OF THE INVENTION	 and/or antibodies). An additional potential problem with anti-
body-based cell separation techniques typically employed for
The ability to isolate specific sub-populations of cells from 35 purification of stem cells, is that they select stem cells solely
cell suspensions is of critical importance to many applica- 	 on the basis of cell surface markers (e.g., CD34) and will not
tions in the biological sciences as well as to many therapies in 	 select cells lacking such markers.
clinical medicine. For example, the basis of many medical	 In addition to cancer therapy, there are a number of other
therapies for treating a variety of human diseases and for 	 important medical therapies which exist, or are under devel-
countering the effects of a variety of physiological injuries 40 opment, that are based on cells derived from a variety of
involves the isolation, manipulation, expansion, and/or alter-	 different types of stem cells. Examples include pre-exposure
ation of specific biological cells. One particularly important 	 prophylaxis or post-exposure therapies under development
example involves the reconstitution of the hematopoietic sys- 	 for a variety of biological exposures that may occur naturally
tem via bone marrow or progenitor cell transplantation. More	 (e.g., viral exposure for example with Ebola, etc.) or be
specific examples include: autologous, syngeneic, and allo- 45 inflicted by mankind (i.e., biological warfare agents). A vari-
genic stem cell transplants for immune system reconstitution	 ety of gene therapies involving genetically manipulated stem
following the myeloablative effects of severe high dose che- 	 cells, are being contemplated or are under development for
motherapy or therapeutic irradiation; severe exposure to cer- 	 treating a variety of blood-related diseases (e.g., AIDS, leu-
tain chemical agents; or severe exposure to environmental 	 kemia, other cancers, etc.). Gene therapy techniques based on
radiation, for example from nuclear weapons or accidents 50 genetically manipulated stem and/or germ cells may also be
involving nuclear power generators. 	 useful in cloning organisms, such as animals. However,
Intensive chemotherapy and/or irradiation for the treat-	 genetically manipulating stem cells using many current tech-
ment of a variety of cancers, including breast cancer, has 	 nologies is difficult, typically employing viruses or gene car-
become a commonly used approach in cancer care centers. 	 riers that can be time consuming and expensive, or may be
Such treatments are associated with severe ablation of the 55 dangerous to perform and may not have high yields. Current
bone marrow cells required for function of the blood and	 research findings also suggest that the practical implementa-
immune systems. Such bone marrow cells are derived from a 	 tion of animal organ transplants into human recipients also
small number of progenitor cells known as hematopoietic 	 may require procedures involving stem cells from both the
stem cells in the normal bone marrow. Therefore, patients 	 donor and recipient. Many of these promising therapies
receiving such therapies require life-saving transplants of 60 would require cryopreservation and storage of donor speci-
stem cells in order to survive the effects of the treatment. Stem 	 mens including human stem cells, for example, as derived
cell containing tissue for transplant may be derived from	 from the stem cell-rich umbilical cord blood of newborns,
donor marrow (allogeneic transplant) or from the patient's 	 which can provide such donors with a therapeutic basis for
own bone marrow or peripheral blood after mobilization (au- 	 hematopoietic reconstitution or gene therapy should a health
tologous transplant). In both instances, there is a need for 65 emergency occur later in life. If such storage demands are to
effective cell separation methods to enrich the transplant tis- 	 be realistically met, the specimens will need to have minimal
sue in stem cells and reduce the number of undesirable and 	 volume, and, therefore, successful implementation of such
US 7,572,623 B2
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technologies may rest on the development and availability of
effective methods for isolating trace numbers of stem cells
from sources such as umbilical cord blood and the fetal liver.
In order to achieve broad implementation of the therapies
discussed above and others, rapid and cost effective methods
are needed to isolate, with high purity, desired target cells
from suspensions having a diverse mix of cell types and
concentrations.
The use of applied electric fields to physically manipulate
cells is known. Applied electric fields have been employed in
the prior art for cell inactivation and sub-lethal cell membrane
electroporation. For example, U.S. Pat. No. 5,048,404 to
Bushnell discloses a system and method for sterilizing liquid
foodstuffs by killing microorganisms with exposure to pulsed
electric fields.
Sale and Hamilton ("Effects of High Electric Fields on
Microorganisms 1. Killing of Bacteria and Yeasts," Biochim
et Biophys Acta, 148:781 (1967); and "Effects of High Elec-
tric Fields on Microorganisms 11. Mechanism of Action of
the Lethal Effect," Biochim etBiophys Acta, 148:789 (1967))
studied the effect of pulsed electric fields on suspensions of
bacteria or suspensions of yeasts. Specifically, they investi-
gated the effect on the degree of cell kill by the field as a
function of field strength and exposure time. The effect of
pulsed electric fields on the killing of bacteria was also stud-
ied by Hiilsheger et al. ("Lethal Effects of High-Voltage
Pulses on E. Coli K12," Radiat Environ Biophys, 18:281
(1980); and "Killing of Bacteria with Electric Pulses of High
Field Strength," Radiat Environ Biophys, 20:53 (1981)).
Hiilsheger et al. studied the effects on bacterial cell death of a
variety of experimental parameters and were able to demon-
strate a 99.9% reduction inthe number of living bacterial cells
in suspensions after exposure to certain pulsed electric field
parameters.
The lysis of erythrocytes in erythrocyte suspensions by
pulsed electric fields has also been studied both for bovine
(Sale and Hamilton, "Effects of High Electric Fields on
Microorganisms III. Lysis of Erythrocytes and Protoplasts,"
Biochem et Biophys Acta, 163:37 (1967)) and human (Ki-
nosita and Tsong, "Voltage-Induced Pore Formation and
Hemolysis of Human Erythrocytes," Biochim et Biophys
Acta, 471:227 (1977); and Kinosita and Tsong, "Hemolysis
of Human Erythrocytes by a Transient Electric Field," Proc
Nad Acad Sci. 74:1923 (1977)) erythrocytes. Knowledge
derived from the studies above indicates that applied electric
fields resulting in cellular transmembrane potentials on the
order of I Volt can result in colloidal osmotic lysis of the
erythrocytes.
Electric fields have also been used to sublethally porate the
plasma membrane of nucleated cells, such as leukocytes and
Chinese Hamster Ovary (CHO) cells (Sixou and Teissie,
"Specific Electropermeabilization of Leukocytes in a Blood
Sample and Application to Large Volumes of Cells," Biochim
et Biophys Acta, 1028:154 (1990)). Sixou and Teissie inves-
tigated electropermeabilization conditions to enable revers-
ibleporation of cell membranes, while maintaining long-term
cell viability, for the purpose of enabling the reversibly
porated cells to uptake drugs and act as immunocompatible
drug delivery vehicles within the body. Sixou and Teissie
studied the effect of pulsed electric field parameters on the
reversible poration of suspensions comprising single cell
types and suspensions comprising mixtures of two cell types
(e.g. CHO cells and erythrocytes, and leukocytes and eryth-
rocytes). The authors showed that reversible electroperme-
abilization is a function of the cell size and that large cells are
reversibly porated at lower electric field strengths than small
cells.
4
While the above mentioned methods and systems for cell
separation and cell electropermeabilization represent, in
some cases, valuable and useful techniques for some appli-
cations, there remains a need in the art for simple, fast, and
5 clean methods to selectively isolate or remove specific cell
sub-populations from cell suspensions without causing undo
damage or activation to the remaining cells and without
employing undesirable or toxic agents.
10	 SUMMARY OF THE INVENTION
Accordingly, the present invention can provide relatively
simple, fast, and clean methods for cell isolation or purging
based on physical differences between different cell types
is present in a suspension. Furthermore, the invention provides
systems and methods that enable selective isolation of viable
cells, selective cell inactivation, as well as stem cell electrop-
ermeabilization, using applied electric fields.
In one aspect, the invention provides a method for creating20 from a biological sample having a given cell population, a
suspension of cells that contain a selected viable subpopula-
tion of the given cell population. The method is based on a
characteristic electroporation threshold of the cells. The sub-
25 population of cells selected by the method is substantially
limited to cells that have a characteristic electroporation
threshold that is greater than a predetermined electroporation
threshold. The selected suspension of cells is produced from
the biological sample by first subjecting the sample to an
30 electric field that has a magnitude that is sufficient to porate a
substantial fraction of the cells in the sample that have a
characteristic electroporation threshold less than the prede-
termined electroporation threshold. The electric field, how-
ever, does not porate a substantial fraction of cells that have a
35 characteristic electroporation threshold greater than the pre-
determined electroporation (threshold. Essentially, all of the
porated cells in the sample that is subjected to the electric field
are also inactivated.
In another aspect, the invention provides a method for
40 creating a selected subpopulation of discreet objects from a
sample having a given population of discreet objects. A dis-
creet object comprises an inner conductive core which is
surroundedby a dielectric membrane. The method is based on
a characteristic electroporation threshold of the discrete
45 objects. The subpopulation of discrete objects selected by the
method is substantially limited to discrete objects that have a
characteristic electroporation threshold that is greater than a
predetermined electroporation threshold. The selected sus-
pension of discrete objects is produced from the sample by
50 first subjecting the sample to an electric field that has a mag-
nitude that is sufficient to cause irreversible dielectric break-
down of the dielectric membrane of a substantial fraction of
the discrete objects in the sample that have a characteristic
electroporation threshold less than the predetermined elec-
55 troporation threshold. The electric field, however, does not
cause irreversible dielectric breakdown of the dielectric
membrane of a substantial fraction of cells that have a char-
acteristic electroporation threshold greater than the predeter-
mined electroporation threshold.
60 In yet another aspect, the invention provides a method for
porating cells. The method includes supplying a suspension
of cells in a treatment volume, where the treatment volume
includes at least two electrodes that are in fluid contact with
the suspension. The method further involves applying a time
65 varying bi-polar electrical potential across the electrodes that
is sufficient to create an electric field that is sufficient to porate
at least one cell in the suspension. The bi-polar electrical
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potential is varied so that the average current across the
sample over the entire treatment time is essentially zero.
In another aspect, the invention provides a method for
reversibly porating stem cells. The method involves supply-
ing in a treatment volume a suspension of cells including a
plurality of stem cells, which stem cells have a characteristic
size, a characteristic shape, a plasma membrane, and a
nuclear membrane. A pulsed electric field that has a pulse
duration and magnitude sufficient to porate the plasma mem-
brane of a cell having a characteristic size and shape essen-
tially identical to the stem cells, but having an effective mem-
brane thickness substantially exceeding the average
membrane thickness of the plasma membrane of the stem
cells is then applied to the suspension.
In another aspect, the invention involves a system for cre-
ating from a biological sample having a given cell population,
a suspension containing a selected viable subpopulation of
the given cell population. The selected cell population is
substantially limited to cells that have a characteristic elec-
troporation threshold greater than a predetermined electropo-
ration threshold. The system functions by inactivating a sub-
stantial fraction of the cells in the sample not included in the
selected subpopulation. The system includes a generating
mechanism that generates an electric field of a magnitude and
duration sufficient to irreversibly porate a substantial fraction
of the cells not included in the selected subpopulation, while
not irreversibly porating a substantial fraction of the cells
included in the selected subpopulation. The system further
includes a treatment cell that is electrically connected to the
generating mechanism and is adapted to contain a cell sus-
pension.
In yet another aspect, the invention provides a system for
selectively inactivating biological cells based on a difference
in a characteristic electric poration threshold. The system
includes a generating mechanism that generates an electric
signal constructed and arranged to create desired electric field
parameters. The system also includes a treatment cell that is
electrically connected to the generating mechanism, includes
at least one electrode, and includes a treatment volume
adapted to contain a cell suspension. The electrode is in fluid
contact with the cell suspension during operation of the sys-
tem and is constructed of a porous, biocompatible material,
which is sealed in order to reduce the release of gases from the
electrode during operation of the system.
In another aspect, the invention involves a cell suspension
comprising a plurality of biological cells suspended in a liq-
uid. The suspension includes one population of cells, which
have a maximum of characteristic size not more than a pre-
determined value, that are substantially viable, and another
population of cells, having a maximum characteristic size
greater than the predetermined value, that are substantially
non-viable. The cell suspension is obtained from a precursor
suspension of substantially viable cells that contains as sub-
populations the two cell populations mentioned above. The
cell suspension is obtained by subjecting the precursor cell
suspension to an electric field having a magnitude and dura-
tion that is sufficient to irreversibly porate a substantial frac-
tion of the cells in the precursor suspension that have a maxi-
mum characteristic size above the predetermined value.
In yet another aspect, the invention involves a cell suspen-
sion comprising a plurality of biological cells suspended in a
liquid where each of the biological cells is enclosed by a
plasma membrane. The cell suspension includes a subpopu-
lation of biological cells that possess a maximum character-
istic size in excess of a predetermined value. Furthermore, the
cells in the subpopulation of cells having a maximum char-
acteristic size in excess of the predetermined value also have
6
a maximum transmembrane electrical potential that exceeds
that required to cause irreversible dielectric breakdown of the
plasma membrane of the cells.
In another aspect, the invention provides a cell suspension
5 comprising a plurality of non-cultured biological cells,
including a plurality of viable stem cells that have a given
characteristic size, suspended in a liquid. The cell suspension
further includes a plurality of irreversibly porated cells,
essentially all of which irreversibly porated cells have a char-
10 acteristic size that is greater than the characteristic size of the
stem cells.
In another embodiment, the invention provides a cell sus-
pension including a plurality of viable, reversibly electropo-
rated stem cells.
15 In yet another aspect, the invention involves a suspension
comprising viable, human pluripotent lympho-hematopoietic
stem cells, which are capable of differentiating into members
of the lymphoid, erythroid, and myeloid lineages. The sus-
pension is essentially free of mature and lineage committed
20 cells and is derived from a precursor cell suspension compris-
ing substantially viable cells. The suspension is derived from
the precursor suspension by subjecting the precursor suspen-
sion to an electric field of sufficient duration and magnitude to
inactivate a substantial fraction of the mature and lineage
25 committed cells in the precursor suspension.
Other advantages, novel features, and objects of the inven-
tion will be become apparent from the following detailed
description of the invention when considered in conjunction
with the accompanied drawings, which are schematic and
30 which are not intended to be drawn to scale. In the figures,
each identical or nearly identical component is illustrated in
various figures is represented by a single numeral. For pur-
poses of clarity, not every component is labeled in every
figure.
35
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. la is a schematic illustration showing a cross-section
of a cell suspended in an electric field between two electrodes;
40 FIG. lb is a schematic illustration of a portion of the cell
membrane from the cell in FIG.1 for an applied electric field
strength of zero;
FIG. lc is a schematic illustration of a portion of the cell
membrane from the cell in FIG.1 for an applied electric field
45 strength less than the critical applied electric field strength;
FIG. ld is a schematic illustration of a portion of the cell
membrane from the cell in FIG.1 for an applied electric field
strength approximately equal to the critical applied electric
field strength;
50	 FIG. le is a schematic illustration of a portion of the cell
membrane from the cell in FIG.1 for an applied electric field
strength exceeding the critical applied electric field strength;
FIG. 2a is a schematic illustration showing a cross-section
55 
of a typical stem cell;
FIG. 2b is an electrical circuit diagram illustrating how a
cell charges in response to an applied electric field;
FIG. 3 is a flow chart outlining the steps of certain embodi-
ments of the inventive method;
60	 FIG. 4 is a schematic illustration of a batch treatment
system according to one embodiment of the invention;
FIG. 5 is a schematic illustration showing a cross-sectional
view of an electrode enclosure assembly according to one
embodiment of the invention;
65 FIG. 6 is a schematic illustration showing a perspective
view of a disassembled test cell according to one embodiment
of the invention;
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FIG. 7 is a schematic illustration of a continuous flow
treatment system according to one embodiment of the inven-
tion;
FIG. 8 is a schematic block diagram showing the compo-
nents of a pulse driver system according to one embodiment
of the invention;
FIG. 9 is a graph showing a bipolar electric field pulse
according to one embodiment of the invention;
FIG. 10 is a graph showing a unipolar electric field pulse
according to one embodiment of the invention;
FIG. 11 is a graph showing surviving cells as a function of
PEF electric field exposure time and magnitude for cells
treated according to one embodiment of the invention;
FIG. 12a is a viability scatter plot derived from flow cytom-
etry data for a control cell specimen;
FIG. 12b is a viability scatter plot derived from flow cytom-
etry data for a PEF-treated cell specimen for cells treated
according to one embodiment of the invention;
FIG. 12c is a viability scatterplot derived from flow cytom-
etry data for a PEF-treated cell specimen for cells treated
according to one embodiment of the invention;
FIG. 12d is a viability scatter plot derived from flow cytom-
etry data for a PEF-treated cell specimen for cells treated
according to one embodiment of the invention;
FIG. Da is a scatter plot of data obtained with flow cytom-
etry for a control cell suspension;
FIG. 13b is a scatter plot of data obtained with flow cytom-
etry for a PEF-treated cell suspension for cells treated accord-
ing to one embodiment of the invention;
FIG. 13c is a scatter plot of data obtained with flow cytom-
etry for a PEF-treated cell suspension for cells treated accord-
ing to one embodiment of the invention;
FIG. 13dis a scatter plot of data obtained with flow cytom-
etry for a PEF-treated cell suspension for cells treated accord-
ing to one embodiment of the invention;
FIG. 14 is a graph showing surviving cells as a function of
PEF electric field exposure time and magnitude for cells
treated according to one embodiment of the invention;
FIG. 15a is a forward scatter histogram derived from flow
cytometry data for monocytes in a control cell suspension;
FIG. 15b is a forward scatter histogram derived from flow
cytometry data for monocytes in a PEF-treated cell suspen-
sion for cells treated according to one embodiment of the
invention;
FIG. 15c is a forward scatter histogram derived from flow
cytometry data for monocytes in a PEF-treated cell suspen-
sion for cells treated according to one embodiment of the
invention;
FIG. 15d is a forward scatter histogram derived from flow
cytometry data for monocytes in a PEF-treated cell suspen-
sion for cells treated according to one embodiment of the
invention;
FIG. 15e is a forward scatter histogram derived from flow
cytometry data for monocytes in a PEF-treated cell suspen-
sion for cells treated according to one embodiment of the
invention;
FIG. 15f is a forward scatter histogram derived from flow
cytometry data for lymphocytes in a control cell suspension;
FIG. 15g is a forward scatter histogram derived from flow
cytometry data for lymphocytes in a PEF-treated cell suspen-
sion for cells treated according to one embodiment of the
invention;
FIG. 15h is a forward scatter histogram derived from flow
cytometry data for lymphocytes in a PEF-treated cell suspen-
sion for cells treated according to one embodiment of the
invention;
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FIG. 15i is a forward scatter histogram derived from flow
cytometry data for lymphocytes in a PEF-treated cell suspen-
sion for cells treated according to one embodiment of the
invention;
s FIG. 15j is a forward scatter histogram derived from flow
cytometry data for lymphocytes in a PEF-treated cell suspen-
sion for cells treated according to one embodiment of the
invention;
FIG. 16 is a graph showing lymphocyte enrichment as a
io function of electric field exposure time and magnitude for
cells treated according to one embodiment of the invention;
FIG. 17 is a bar chart showing surviving fraction of cells
and stem cell enrichment as a function of electric field
strength for cells treated according to one embodiment of the
15 invention;
FIG. 18a is a light scatter plot derived from flow cytometry
data for input CMK cells to be treated according to one
embodiment of the invention;
FIG. 18b is a viability stain histogram derived from flow
20 cytometry data for input CMK cells to be treated according to
one embodiment of the invention;
FIG. 18c is a light scatter plot derived from flow cytometry
data for input PBMC cells to be treated according to one
embodiment of the invention;
25 FIG. 18d is a viability stain histogram derived from flow
cytometry data for input PBMC cells to be treated according
to one embodiment of the invention;
FIG. 18e is a light scatter plot derived from flow cytometry
data for an input CMK/PBMC cell mixture to be treated
so according to one embodiment of the invention;
FIG. 18f is a viability stain histogram derived from flow
cytometry data for an input CMK/PBMC cell mixture to be
treated according to one embodiment of the invention;
FIG. 19a is a light scatter plot derived from flow cytometry
35 data for a control cell specimen containing a CMK/PBMC
cell mixture;
FIG. 19b is a bivariate plot derived from flow cytometry
data for a control cell specimen containing a CMK/PBMC
cell mixture;
40 FIG. 19c is a viability histogram derived from flow cytom-
etry data for a control cell specimen containing a CMK/
PBMC cell mixture;
FIG. 19d is a light scatter plot derived from flow cytometry
data for a PEF-treated cell specimen containing a CMK/
45 PBMC cell mixture for cells treated according to one embodi-
ment of the invention;
FIG. 19e is a bivariate plot derived from flow cytometry
data for a PEF-treated cell specimen containing a CMK/
PBMC cell mixture for cells treated according to one embodi-
50 ment of the invention;
FIG. 19fis a viability histogram derived from flow cytom-
etry data for a PEF-treated cell specimen containing a CMK/
PBMC cell mixture for cells treated according to one embodi-
ment of the invention;
55 FIG. 20a is a light scatter plot derived from flow cytometry
data for a control cell specimen containing a CMK/PBMC
cell mixture;
FIG. 20b is a bivariate plot derived from flow cytometry
data for a control cell specimen containing a CMK/PBMC
60 cell mixture;
FIG. 20c is a viability histogram derived from flow cytom-
etry data for a control cell specimen containing a CMK/
PBMC cell mixture;
FIG. 20d is a light scatter plot derived from flow cytometry
65 data for a PEF-treated cell specimen containing a CMK/
PBMC cell mixture for cells treated according to one embodi-
ment of the invention;
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FIG. 20e is a bivariate plot derived from flow cytometry	 understood that the invention is not so limited and that the
data for a PEF-treated cell specimen containing a CMK/
	
invention may similarly be applied to discrete objects, as
PBMC cell mixture for cells treated according to one embodi- 	 defined herein, other than cells. Also, whenever the tern "dis-
ment of the invention; 	 crete object' is used herein, it should be understood that the
FIG. 20fis a viability histogram derived from flow cytom- s term includes, as a subset, biological cells. The term "dielec-
etry data for a PEF-treated cell specimen containing a CMK/ 	 tric layer," or "dielectric membrane," or "membrane" as used
PBMC cell mixture for cells treated accordingto one embodi- 	 herein refers to a continuous layer or coating having a finite
ment of the invention; 	 thickness and having an electrical resistivity (Q-cm) exceed-
FIG. 21 is a graph showing surviving cells as a function of
	
ing that of a conducting core which the membrane encloses.
PEE electric field magnitude for three types of cells for cells io Typically, the electrical resistivity of the dielectric layer will
treated according to one embodiment of the invention; 	 exceed that of the inner conducting core by at least a factor of
FIG. 22 is a graph showing surviving cells as a function of 	 10, and more typically, for example as is the case with most
PEE electric field magnitude and pulse duration for cells	 biological cells, by at least a factor of 10 4-109 . In the context
treated according to one embodiment of the invention. 	 of biological cells, the dielectric layer is defined by at least
15 one lipid bilayer membrane, together with any associated
DETAILED DESCRIPTION OF THE INVENTION	 structures or substances associated therewith which affect the
effective membrane thickness or resistivity of the dielectric
The present invention provides novel methods and systems 	 layer. "Effective," as used herein in the context of membrane
for selectively inactivating biological cells, or any discrete	 thickness orresistivity, refers to a thickness orresistivity of an
objects having an inner conducting core surrounded by a 20 equivalent membrane not possessing any associated struc-
dielectric layer, for example a lipid bilayer membrane. Spe- 	 tures or substances affecting its dielectric properties associ-
cifically the invention provides methods and apparatus for 	 ated therewith that possesses the same dielectric properties as
selectively inactivating such cells or discrete objects by sub- 	 the actual membrane having such associated structures or
jecting a suspension containing such cells or discrete objects 	 substances.
to an applied electric field of sufficient duration and magni- 25	 The term "inactivating" as used herein refers to destruction
tude to cause dielectric breakdown or electroporation of the 	 of at least one property of a discrete object. In the context of
dielectric layer. The methods provided by the present inven- 	 biological cells, inactivating is equivalent to rendering unvi-
tion can be used advantageously to selectively inactivate sub- 	 able, or killing the cell. As applied to non-cell discrete
populations of cells or discrete objects from a precursor popu- 	 objects, inactivate can refer to physical destruction of the
lation that contains a mixture of different cells or discrete 30 object, or simply a destruction of the permi-selective diffu-
objects, or mixtures of cells and non-cell discrete objects, on 	 sional barrier properties of the dielectric layer with respect to
the basis of a characteristic electroporation threshold, thus	 at least one molecular, ionic, or atomic species. In certain
providing a means for selectively purging or isolating cells or	 embodiments involving cells, inactivation may involve not
discrete objects from larger populations. One embodiment of	 only rendering the cells non-viable, but also irreparably lys-
the inventive method involves subjecting a sample having a 35 ing and physically disrupting and destroying the physical
given population of cells or discrete objects to electric field 	 structure of the cell.
conditions sufficient to porate a substantial fraction of cells or 	 The invention provides, in some embodiments, relatively
discrete objects that have a characteristic electroporation 	 fast and effective methods for purifying certain desired cells
threshold below a selected predetermined value, while not 	 in a viable state from a suspension or eliminating certain
simultaneously porating a substantial fraction of the cells or 40 undesired cells from a cell population. As mentioned, the
discrete objects having a characteristic electroporation above 	 methods involve exposing a suspension containing a popula-
the predetermined value, and subsequently, or simulta- 	 tion of cells to an applied electric field, which field has a
neously inactivating the porated cells or discrete objects. 	 magnitude and is applied for a duration selected to porate, and
The term "biological cell' or "cell' as used herein has its 	 in some embodiments inactivate, a substantial fraction of
commonly understood meaning and includes viable, poten- 45 certain subpopulations of cells based on their characteristic
tially viable, or previously viable cells derived from a bio-	 electroporation threshold. The term "suspension of cells" as
logical sample. Such cells include prokaryotic cells such as 	 used herein refers to a mixture of cells suspended in a carrier
bacteria, and algae, and eukaryotic cells, such as yeasts, fun-	 liquid. The carrier liquid may be naturally part of the biologi-
gus, plant cells, and animal cells. Such cells typically have an 	 cal sample from which the cells derive, for example blood is
inner, electrically conducting core comprised of cytoplasm, 5o a suspension of blood cells suspended in plasma, or, for cells
surrounded and enclosed by at least one dielectric membrane, 	 which are not normally present in a suspension, the carrier
for example the cytoplasmic or, equivalently, plasma mem-	 liquid can be any suitable diluent or medium. Preferred car-
brane. Eukaryotic cells, in addition, typically also possess a 	 rier fluids are non-toxic and physiologically compatible with
dielectric nuclear membrane surrounding a conductive	 the cells they suspend, at least for a time period equal to that
nucleus within the interior of the cell. 	 55 of the electric field application procedure. Preferred carrier
The term "discrete objects having an inner conducting core 	 fluids are also electrically conductive. The electrical conduc-
surrounded by a dielectric layer" or simply "discrete object' 	 tivity can be any value greater than zero, but preferably will
as used herein refers to any object comprising a substance 	 range from about 10%-200% that of the conductive core of
exhibiting a relatively low electrical resistivity surrounded 	 the cell. In certain embodiments, the conductivity or resistiv-
and enclosed by a dielectric layer or dielectric membrane 60 ity of the carrier fluid will be essentially equal to that of the
having a much higher electrical resistivity. Such discrete	 conductive core of the cell. In other embodiments, in order to
objects include biological cells as previously described, but 	 reduce the power consumption of the electric field generating
also include objects such as certain viruses, sub-cellular 	 apparatus and/or reduce the degree of heating of the cell
organelles, liposomes, micelles, and others. Throughout the	 suspension, as will discussed in greater detail herein, it can be
remainder of this detailed description, many of the methods 65 preferable to utilize a carrier fluid having a resistivity that is
and apparatus of the invention are described in relation to	 greater than that of the conductive core of the cell. In order to
biological samples comprising biological cells. It should be 	 provide a more uniform electrical field throughout a cell
US 7,572,623 B2
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suspension being treated according to the invention, the cell	 other side of the geometric center of the cell or object. For
suspension shouldbe essentially free of gas bubbles. The cells 	 example, for a spherical cell or object, the characteristic size
in the suspension should also be individually suspended and 	 would be the external diameter of the cell or object. Specifi-
as free from clumping and aggregation as possible during 	 cally, the method involves porating and inactivating a sub-
application of the electric field in order to provide the maxi-  5 stantial fraction of discrete objects above a certain predeter-
mum resolution and selectivity attainable for a given set of 	 mined threshold size, which is a function of the electric field
electric field exposure conditions. The concentration of cells	 and suspension properties as discussed, while leaving in an
in a cell suspension, as will be discussed in more detail, can 	 uninactivated state a significant fraction of discrete objects
also affect the selection and performance of the applied elec- 	 below the threshold size. The method can be used, for
tric field. Typically, for mammalian cells, the range of total io example, to inactivate cells present in viral preparations used
cell concentrations in treated samples can range from about	 in treatment, diagnosis, or research of viral diseases such as
102-10 10 cells/ml, with preferred suspensions having from	 AIDS. It is often desirable to obtain suspensions of pure virus
about 104_1011	 that are essentially uncontaminated with viable cells infected
The term "substantial fraction" or "substantially depleted"	 with suchvirus. Because virus-carrying cells will typically be
as used herein, in the context of discrete objects having a 15 substantially larger than viruses, the inventive method can be
characteristic electroporation threshold less than a predeter- 	 use to selectively inactivate the cells without causing undue
mined value, refers to at least 25% of such cells being porated	 damage to the virus. Another application involves isolation of
by the applied electric field and inactivated, preferably at least 	 certain sub-cellular organelles from cells. In this case, the
50%, more preferably at least 90%, in some embodiments 	 cells can initially be porated using the inventive method in
preferably at least 99%, in some embodiments preferably at 20 order to liberate the intracellular contents of the cells into the
least 99.99999%, and in some embodiments preferably 	 suspension. Subsequently, an electric field having different
essentially all of the discrete objects. The term "electropora- 	 parameters can be applied to the suspension to selectively
tion threshold" or "critical electroporation threshold" as used
	
isolate one or more subpopulations of organelles on the basis
herein refers to the susceptibility of a particular cell or sub-	 of a difference in a characteristic electroporation threshold,
population to membrane poration by an applied electric field. 25 for example due to a difference in characteristic size. An
As will be discussed in greater detail herein, the characteristic 	 example of the inventive method as applied to a non-biologi-
electroporation threshold of a cell or subpopulation of cells is 	 cal sample is the selective disruption of liposomes on the
a function of the physical and chemical properties of the cell
	
basis of size. Liposomes are commonly used as vehicles for
that influence its interaction with an applied electric field. 	 drug delivery or for transfection of genetic material into cells.
Differences between one or more of these properties between 3o The performance of the liposome for its intended task and
different cells or subpopulations may be advantageously 	 also potentially its pharmacokinetics within the body can be a
exploited to provide a basis for selective isolation and inac- 	 function of the size of the liposome. Thus, the current inven-
tivation according to the invention. Such properties include 	 tion can provide a relatively fast and easy means for perform-
characteristic cell size, effective dielectric membrane thick- 	 ing a size selection of manufactured liposomes.
ness, cell shape, cell and/or membrane morphology, cell 35	 Two important applications where the present invention
membrane capacitance, cytoplasmic electrical resistivity, etc. 	 has particular utility involve the purging of cancer cells from
The term "predetermined electroporation threshold" as used 	 cell suspensions and the isolation and enrichment of stem
herein refers to a chosen value of electroporation threshold	 cells or germ cells from cell suspensions. A "germ cell' as
below which a significant fraction of cells having such elec- 	 used herein, refers to haploid cells, or gametes, such as sperm
troporation thresholds will be porated by the applied electric 40 or egg cells. These applications are important components in
field, and above which a significant fraction of cells having	 many clinical treatment therapies involving, for example,
such electroporation thresholds will not be porated. The pre-	 cancer treatment, organ transplant, and gene therapy. The
determined electroporation threshold, as will be discussed in 	 present method exploits a difference in a critical electropora-
greater detail herein, can be a function of the parameters of the 	 tion threshold between the above mentioned cell types and the
applied electric field (e.g. field strength, field duration, etc.) 45 other cell types present in the cell suspension to effect a
and the electrical properties of the cell suspension (e.g. fluid 	 selection of desired cells and/or a purging of undesired cells.
carrier resistivity, total suspension capacitance, etc). An 	 In particular, in particular embodiments, differences in char-
important feature of the invention is the selection of such 	 acteristic cell size (e.g. average cell diameter) provide, at least
electric field parameters and suspension properties in order to 	 in part, for the above mentioned difference in critical elec-
provide conditions that selectively inactivate a significant 50 troporation threshold. Cancer cells, for example, are often
fraction of one or more subpopulations of cells in a sample 	 significantly larger than the desired population of cells, for
based on one or more differences in theirproperties that affect 	 example stem cells, in a sample and will generally have an
their characteristic electroporation threshold. 	 electroporation threshold below that of the desired cells.
The methods and apparatus provided by the present inven-	 Thus, by subjecting the suspension to a selected electric field
tion can be applied to a wide variety of discrete object sepa-  55 having predetermined characteristics, a substantial fraction
ration applications, and to a wide variety of biological and 	 of the cancer cells can be inactivated without inactivating the
non biological samples. One important embodiment of the 	 desirable cells. Preferably, when a suspension initially con-
invention provides a method of isolating or inactivating dis- 	 taining such cancer cells is subjected to the inventive cell
crete objects based on a characteristic size. "Characteristic 	 selection method, the concentration of viable cancer cells
size" or "size" as used herein with respect to dimensions of 6o remaining is decreased by at least a factor of 10 (1 log reduc-
cells or discrete objects, refers a linear dimension of a cell or 	 tion) and most preferably by at least a factor of 100,000 (5 log
discrete object as measured in the direction of an applied 	 reduction). Similarly, because for many biological samples
electric field to which the cells or objects are subjected and 	 stem cells are the smallest cells present, the inventive method
from an external surface of the outermost dielectric mem- 	 can be used to enrich such a sample in viable stem cells by
brane on one side of the geometric center of the cell or object, 65 selectively inactivating non-stem cells in the sample. Prefer-
through the geometric center of the cell or object, to an	 ably, the concentration of viable stem cells, with respect to the
external surface of the outermost dielectric membrane on the 	 total number of viable cells present in the sample, is increased
US 7,572,623 B2
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in the sample through application of the inventive method by 	 pre-exposure prophylaxes or post-exposure therapies, and
at least a factor of two, more preferably by at least a factor of
	
immune system reconstitution. Isolation of stem cells to high
five, and in certain preferred embodiments, by a factor of 106 	 purity prior to their genetic manipulation is essential for
or more, while, correspondingly, the concentration of viable	 eliminating the interference and complications that occur
non-stem cells in the sample is substantially depleted. One 5 should other leukocytes be present/viable during gene trans-
feature of the inventive method when applied to the purifica- 	 fection and expansion. Cryostorage of large numbers of stem
tion and enrichment of stem cells, is that unlike typical anti-	 cell specimens will be required for large scale implementa-
body-based stem cell isolation methods, isolation of stem	 tion of such stem cell-based-countermeasures. Efficient,
cells using applied electric fields does not rely on the presence 	 practical cryostorage of large numbers of specimens demands
of surface markers on the stem cells (e.g. CD34). The most io small specimen volumes. Since the relative concentrations of
primitive stem cells may not possess the cell surface markers 	 stem cells in bone marrow mononuclear cell (BMMC) and
targeted by typical antibody-based methods and thus, such	 mobilized peripheral blood mononuclear cells (MPBMC)
cells will not be recovered by those methods. Conversely, 	 specimens are approximately 1:105, stem cell isolation and
stem cells isolated by the present methods are selected on the	 enrichment will be important for achieving small specimen
basis of their critical electroporation threshold. Therefore, the 15 volumes advantageous for efficient cryostorage. To eliminate
stem cell suspensions provided according to the inventive	 interference from non-stem cells during expansion and gene
methods, will include stem cells that do not possess the sur- 	 transfection, and to reduce volume requirements for cryos-
face markers typically used by antibody-based methods to 	 torage, isolation strategies should be capable of enriching
select stem cells if such stem cells were initially present in the 	 stem cell concentrations by up to 106 for BMMC and
sample before application of the inventive methods. Specifi- 20 MPBMC specimens.
cally, one embodiment of the present invention can provide a 	 Many presently available methods typically in use for stem
suspension enriched in stem cells, which is essentially free of 	 cell isolation or cancer cell purging depend on antibody bind-
mature and lineage committed cells, and which includes as a 	 ing to cell surface structures or toxin-based cell inactivation
subpopulation, stem cells not expressing CD34 on their sur-	 strategies. These strategies can be sub-optimal for stem cell-
face.	 25 enrichment because they provide in some cases relatively low
The stem cell and/or cancer cell containing suspensions 	 degrees of enrichment and can add detrimental substances to
can be derived from a variety of sources including, but not 	 the suspension, such as exogenous antibodies or toxins, that
limited to, bone marrow, mobilized or unmobilized periph- 	 damage or can activate the isolated stem cells or be detrimen-
eral blood, umbilical cord blood, fetal liver tissue, other organ	 tal to a patient upon reinfusion of such cells. Other currently
tissue, skin, nerve tissue, etc. A variety of stem cells may 3o available stem cell isolation strategies involve a culture-based
advantageously be isolated and enriched according to the	 protocol requiring a long processing time, for example up to
invention including, but not limited to, hematopoietic stem 	 one week. In addition, many currently available cell isolation
cells, embryonic stem cells, mesenchymal stem cells, epithe- 	 methods do not easily scale, and, therefore, are not optimal
lial stem cells, gut stem cells, skin stem cells, neural stem 	 for handling the large throughput required for a widespread
cells, liver progenitor cells, and endocrine progenitor cells. 35 implementation of many stem-cell-based therapies. Thus, in
One embodiment of the invention involves the isolation of 	 the prior art, there exists a need for stem cell isolation strat-
lympho-hematopoietic stem cells, which are capable of dif-	 egies for effective implementation of the stem-cell-based
ferentiating into members of the lymphoid, erythroid, and 	 countermeasures, which the present invention, in some
myeloid lineages, from cell suspensions including mature 	 embodiments, potentially can fill.
and lineage committed cells to provide a suspension of lym-  40	 The methods and apparatus provided according to the
pho-hematopoietic stem cells that is essentially free of mature 	 present invention can provide significant improvements and
and lineage committed cells. The enriched stem cell suspen- 	 advantages over many prior art methods for performing cell
sions according to the present method will also be advanta- 	 separations and isolations. The present method is based on
geously enriched in pluripotent stem cells, which have the 	 intrinsic differences between cell types, for example charac-
ability to differentiate into the full complement of mature 45 teristic size and/or characteristics that effect the membrane
cells derived from a particular type of stem cell. Also, in some 	 breakdown voltage, such as the dielectric strength of the
embodiments, the enriched stem cell suspensions produced 	 membrane or the effective membrane thickness, and does not
according to the invention will contain, in addition to pluri-	 require, in many embodiments, the addition or use of exog-
potent stem cells, stem cells which are committed colony 	 enous agents, such as antibodies or toxins, which can
forming cells. For example, for samples including hemato- 5o adversely affect the viability or state of activation of the
poietic stem cells, the enriched suspensions can advanta- 	 isolated cell fraction. "Dielectric membrane breakdown volt-
geously include viable colony forming cells for granulocytes	 age" or "membrane breakdown voltage" refers the voltage
and macrophages (CFC-GM), colony forming cells for eryth- 	 across the dielectric membrane layer of a cell or discrete
rocytes (BFU-E), colony forming cells for eosinophils (CFC- 	 object at the onset of poration of the membrane. In addition,
Eo), multipotent colony forming cells (CFC-GEMM), and 55 the present method is substantially faster than many prior art
immature lymphoid precursor cells.	 cell separation techniques. Cell inactivation and isolation
Thus, it is apparent that the present invention provides a 	 using the inventive method can be performed in times ranging
novel method for cancer purging and stem cell isolation use-	 from milliseconds to minutes. Finally, with appropriate selec-
ful for a variety of medical therapies, an important one of	 tion of operating parameters, as discussed herein, and routine
which is stem cell transplantation for hematopoietic recon- 60 optimization of the selected parameters and method, the
stitution after myleoablative therapies. A particularly attrac- 	 inventive method can potentially provide high degrees of
tive application for the teachings of this invention is the 	 enrichment or purging of selected cell subpopulations.
isolation of hematopoietic stem cells from bone marrow, 	 As discussed in more detail later herein, cell selection with
mobilized peripheral blood, umbilical cord blood or fetal 	 electric fields according to the invention can be used as a stand
liver tissue, which is a crucial first step in an overall protocol 65 alone method or maybe combined with one or more other cell
for delivering genetically manipulated, stem-cell-based, 	 separation methods, such other methods being a pre-treat-
pathogen countermeasures that have the potential to provide	 ment or post-treatment step. Also the method according to the
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invention can be applied to a cell suspension so that the
applied electric field both porates and inactivates one or more
subpopulations of cells in a single step, or, alternatively, the
applied field may porate some or all of the cells to be inacti-
vated without inactivating all of such cells, with the inactiva-
tion step performed in a subsequent step. In the former case,
the applied electric field is sufficient, under the conditions of
its application, to cause irreversible breakdown or irreversible
poration of the dielectric membrane of the cell. "Irreversible
breakdown" or "irreversible poration" refers to poration that
is sufficient to cause death, inactivation, and/or physical dis-
ruption of a discrete object without a need for a secondary
inactivating step. Inactivation and cell death due to poration
are believed to be caused by a loss of the permi-selective
nature of the membrane leading to cell death and/or mem-
brane disruption, or a direct physical disruption of the mem-
brane causedby extensive poration. In the case of a loss of the
permi-selective nature of the membrane, the inactivation or
cell death is ultimately caused by diffusion of previously
excluded molecular species, especially small ionic species
such as Na', K', and Ca", across the membrane followed by
an uptake of water across the membrane into the cell in an
attempt to achieve osmotic equilibrium with the suspending
fluid medium, which can lead to colloidal osmotic lysis and
irreparable (fatal) cell lysis, orto a lethal disruption of cellular
metabolism. For embodiments involving a method where the
applied field porates some or all of the cells to be inactivated
without inactivating all of such cells, where the inactivation
step is performed in a subsequent step, the poration induced
by the applied field is typically less extensive and not irre-
versible, at least for a certain portion of the porated cells.
Given sufficient time, the reversibly porated cells in such
samples could seal their pores and retain long-term viability if
left in the same fluid carrier or suspending media in which
they were subjected to the electric field. The reversibly
porated cells may, however, be effectively inactivated by
resuspending them in a different post-poration media, adjust-
ing the temperature of the poration media, and/or adding a
supplemental agent to the poration media which accelerates
cell death, colloidal osmotic lysis, or prevents the resealing of
membrane pores. More specific techniques and conditions
are discussed below.
The electric field is preferably applied to the cell suspen-
sion within a spatially defined treatment cell. The treatment
cell can be designed as a static non-flow volumetric container
in which the cell suspension to be treated is placed, or more
preferably, the treatment cell will include an inlet and an
outlet constructed and arranged to enable a cell suspension to
continuously flow through the treatment volume. Systems
including flow-through treatment cells may be arranged so
that the cell suspension passes through the treatment cell only
once (one pass) or a plurality of times (recirculating). In
addition, either the flow or static systems may include mul-
tiple treatment cells. For flow systems, multiple treatment
cells can be arranged in a series or parallel configuration.
The treatment cell will include at least one electrode in
electrical communication with the cell suspension to be
treated. Preferably the treatment cell will include two elec-
trodes placed on either side of and in electrical communica-
tion with the cell suspension during operation to which an
electric potential is applied to produce an electric field within
the treatment volume. In preferred embodiments, the treat-
ment cell and electrodes are constructed and arranged to
impose an electric field that is substantially spatially uniform
within the treatment volume so that all cells in the suspension
are exposed to similar electric field conditions. In some
embodiments, the electric field applied to the cell suspension
16
is created by an electric signal applied to the electrodes;
however, it is also contemplated that the electric field can be
induced in the sample cell via induction by a magnetic field.
In order to reduce the tendency for the electrical potential
5 applied to the electrodes to discharge by arcing, and in order
to reduce the degree of electrical heating that occurs in the cell
suspension, in certain preferred embodiments, the applied
electric field is pulsed for short durations, such durations,
to except as otherwise described herein, being shorter than the
residence time of the treated cell suspension in the treatment
volume during the step of subjecting the suspension to the
applied electric field. Such electric fields are hereinafter
referred to as "pulsed electric fields" or PEFs. The shape of
15 the electric field pulse is preferably substantially rectangular
in shape, thus providing very short voltage rise and fall times
and a substantially constant magnitude over the entire pulse
length. Such rectangular pulse shapes yield the best perfor-
mance and poration threshold resolution obtainable with the
20 inventive method. While rectangular pulses are preferred, any
pulse shape known in the art may be employed in performing
the methods of the invention, especially when high resolution
is not required, as, for example, when inactivating a cell type
that is substantially larger than the desired cell type.
25 As described previously, the electric field parameters
required to effect a desired cell inactivation or isolation
depend upon the nature of the cells, the suspension and sus-
pending fluid, and the characteristics of the electric field
30 application apparatus. The exact parameters for any given
sample that will yield desired results must be found in prac-
tice via routine experimentation. What follows herein is a
theoretical development and description of the inventive
method, apparatus for performing the method, and important
35 parameters affecting the performance and selectivity of the
method to provide guidance to those of skill in the art in
selecting parameters to develop successful cell or discrete
object isolation and inactivation strategies.
40 The Fundamental Basis of Electric Field Cell Isolation
The mechanism by which electric fields, and particularly
pulsed electric fields (PEFs), isolate cells can be best under-
stood by examining the response of a single discrete object, as
exemplified by a biological cell, to an externally applied
45 electric field. A schematic illustration of such a system 50 is
shown in FIGS. la-e. The externally applied electric field 57
can be established by applying a constant voltage or voltage
pulse across a pair of electrodes 55 and 56 that are in electrical
communication with, and preferably in physical contact with,
5o a cellular suspension containing a plurality of cells, one of
which 51 is shown in FIG. la . Alternatively, the electric field
57 can be applied inductively by creating a time-varying
magnetic field throughout the cellular suspension. To pre-
serve the viability of the desired target cells, the carrying
55 fluids in whichthe biological cells are suspended are typically
buffered saline solutions having, in some embodiments, a
standard physiological osmolality (e.g. 275-300 mOs/kg-wa-
ter for most mammalian cells), and a pH in the physiological
range (e.g. about 7.0-7.6 for most mammalian cells). The
60 ionic strength of the solutions in certain embodiments is
essentially the same as the ionic strength of the intracellular
fluid 53 (e.g. about 0.15 M NaCl equivalent for most mam-
malian cells). As such, these are conducting solutions. Elec-
tric field effects on cells can be estimated from the potential
65 theory developed by Coulson (Coulson C A: Electricity,
Oliver and Boyd, London, Chapter 9, 1951) incorporated
herein by reference. This theory implies that induced trans-
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membrane potentials depend on cell size and shape. Formally,
the external electric field induces a potential across the cell
51, VC,,,, given by
18
or equivalently
V =3dE/4	 Eq.3
VV_ 11
 
= f lE where f= l A 13 d	 Eq. 1)
and where E is the field strength of the imposed electric field;
d is the cell diameter 54,1 is the projected length of the cell in
the electric field direction 57; and f is a form factor, which is
equal to 1.5 for a spherical cell (where 1 is equal to d) and is
approximately unity for large aspect ratio cylindrically
shaped cells (where 1»d). In the development to follow, the
cells of interest will be assumed to be spherical so that d will
be used for 1 in the following equations and f will be set equal
to 1.5. For a more detailed discussion on the effects of non-
spherical cell shape and angular orientation with the applied
electric field, the reader is referred to Kinosita and Tsong
(Kinosita K and Tsong T Y, Voltage-induced pore formation
and hemolysis of human erythrocytes, Biochim et Biophys
Acta. 471:227-242, 1977).
Biological cells have an outer, semipermeable plasma
membrane 52 that allows the cell to control its internal envi-
ronment by its selective permeability. The proper function of
this membrane is crucial to the viability of the cell. If the
function of this membrane is altered or destroyed, cell death
often follows. Plasma membranes are typically lipid bilayers
which behave electrically as dielectrics, i.e., they behave as
electrical insulators. For eukaryotic cells, as shown in FIG.
la, the cell nucleus 68 and accompanying nuclear membrane
69 reside within the outer membrane 52, with cytoplasm 53
filling the gap between the nuclear and outer membranes. For
prokaryotic cells, there is no nucleus or nuclear membrane, so
the cytoplasm, which supports the cell's genetic information
(one or more DNA molecules in the form of nucleoids) fills
the entire intracellular volume. Cytoplasm, which refers col-
lectively to the substance filling the gap 53 between the outer
and nuclear membrane for eukaryotic cells, or the entire
intracellular volume for prokaryotic cells, is mainly com-
posed of cytosol, which is a semifluid concentrate having an
electrical resistivity that is similar to that of aqueous solutions
having a standard physiological ionic strength. As such, the
cytosol is electrically conductive, which dictates that the
intracellular volume of both eukaryotic and prokaryotic cells
is electrically conductive. Thus, biological cells can be
viewed as a conducting intracellular region surrounded by a
dielectric (insulating) membrane 52. With this conceptual
view of biological cells, application of an external electric
field 57 causes charge separation to occur inside the biologi-
cal cell 51 resulting in a nearly constant intracellular potential
that has a value corresponding to the boundary average of the
potential established on the outer surface of the cell's dielec-
tric membrane 52. If the poles of the cell 51, of whichthere are
two, are defined as the two points formed on the surface of the
cell 51 by the intersection of a ray parallel to the electric field
direction passing through the center of the cell, then applica-
tion of an external electric field causes one half of the pole-
to-pole potential drop outside of the biological cell 51 to
develop across the membrane 52 at each pole of the cell. That
is, the externally applied electric field 57 produces a maxi-
mum transmembrane potential, Vm, at each pole of the cell 51
that scales as
V_ — V,,11 2 
	
Eq. 2
for a spherical cell.
5 Since, in response to an externally applied electric field 57,
the potential drop, VC,,,, that develops over a cell's diameter
54 or projected length is transferred approximately equally
across the two poles of the cell's membrane 52, the maximum
electric field thereby imparted to a cell's membrane 52 is
10
Em =V ,,,12 m,	 Eq. 4
or, for spherical cells
Em 3Ed/4tm	 Eq.5
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or equivalently
Em =V„ ftm	 Eq. 6
where Em is the electric field imparted to the membrane 52 for
20 an externally applied electric field 57 of strength E; d is the
diameter 54 of the biological cell 51; and tm is the thickness of
the membrane. Thus it is apparent from equation 5, that the
imposed electric field within the cell membrane is directly
proportional to cell size and applied electric field strength and
25 inversely proportional to the thickness of the cell membrane.
Since the size of many typical biological cells falls within a
range of I <d<50 µm and a typical thickness of cell membrane
52 lipid bilayer is approximately 5 mu, the electric field
strength imparted to the membrane 52 can be two to three
30 orders of magnitude greater than the strength of the externally
applied electric field 57. More specifically, for a typical lipid
bilayer membrane thickness of about 5 mu, a transmembrane
potential, Vm, of approximately one Volt will impart a 2
MV/cm electric field, E m, to the lipid bilayer membrane 52.
35 So for a 10 µm diameter spherical cell, which, for example, is
about the mean size of peripheral blood cells, a 2 kV/cm
externally applied electric field E would generate the 2
MV/cm electric field, E m, in the lipid bilayer membrane.
Since the dielectric strength of many polymers, in response to
electric fields, is in the range 0.1-0.5 MV/cm, it is reasonable
40 to expect that a 2 MV/cm electric field imparted to the mem-
brane 52 of a 10 µm diameter cell by an externally applied 2
kV/cm electric field 57 would produce membrane pores by
dielectric breakdown. Thus, the electric field magnification
providedby the electrical behavior of biological cells can lead
45 to the dielectric breakdown of a cell's membrane 52 when the
externally applied electric field has sufficient strength,
thereby forming irreversible pores in the membrane which
lead to cell death. From equations I and 5, it is apparent that
the susceptibility of a given cell to poration by an applied
50 electric field 57 is proportional to the magnitude of the
applied electric field, E, that is required to produce a given
electric field, Em, in the lipid bilayer membrane (which is
directly related to membrane poration) and is related to the
size of the cells, the thickness of the dielectric membrane, the
55 
dielectric strength of the membrane (V/m), the shape of the
cells and the orientation of non-spherical cells in the applied
electric field. Thus, a difference in one or more of these
properties between different cell types can lead to a difference
in their characteristic electroporation threshold and can
potentially be exploited to effect a selective cell isolation or
60 inactivation using an applied electric field, as described in
greater detail to follow. These relations are rigorously valid
when the cell is immersed in a conducting fluid, but such fluid
may not be required in some embodiments for the inventive
method to be functional.
65 For lipid bilayer membranes, which are typical of many
mammalian cells and bacterial cells, the onset of membrane
dielectric breakdown in response to an externally applied
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electric field has been relatively consistently observed in the
prior art when the transmembrane potential, Vm, reaches a
particular critical value, namely V_-V_,, where V_ is the
critical transmembrane potential for dielectric breakdown, or,
equivalently, the dielectric membrane breakdown voltage.
Table 1 summarizes data from cell poration experiments
assembled by Castro, et al. (Castro A J, et al: Microbial
Inactivation of Foods by Pulsed Electric Fields. Washington
State University, Department of Food Science and Human
Nutrition, Pullman, Wash., 99164-6376, 1993) (hereinafter
"Castro) showing the critical dimensions of various viable
cells and their critical membrane potentials for cell mem-
brane poration. The critical dielectric membrane breakdown
voltage V_ for these cells were obtained by using Eq. 3
together with results from cell inactivation experiments
which measured the critical threshold applied electric field,
E,.
TABLE 1
Cell size and induced membrane potential for several microoraanisms
Microorganism
d
(µm)
I
(µm)
v
(µm3) f
Vm1
(V)
E. coli (4 hr) 1.15 6.9 7.2 1.06 0.26
E. coli (30 hr) 0.88 2.2 1.4 1.15 1.05
K. pneumoniae 0.83 3.2 1.7 1.09 1.26
P. aeruginosa 0.73 3.9 1.6 1.07 1.26
S. aureus 1.08 n/a 0.6 1.50 1.00
L. monocytogenes I 0.76 1.7 0.8 1.17 0.99
C. albicans 4.18 n/a 38.0 1.50 2.63
In the table, v, is the volume of the cells. With the important
exception of young cells (e.g., E. coli, 4 hr culture, in the
logarithmic growth phase), the critical membrane potentials
V_ of cells in their stationary phase is approximately 1 Volt.
A variety of parameters can effect dielectric membrane
breakdown voltage, Vm,. Such parameters include, but are not
limited to, the membrane thickness, the dielectric strength of
the membrane, the dimensional and chemical uniformity of
the membrane, etc. Since, for a given dielectric material, the
threshold transmembrane electric field strength, E, for
dielectric breakdown is often similar, and since most of the
cells in Table 1 have similar dielectric membranes (lipid
bilayers together with any associated protein and/or carbohy-
drate components), Eq. 6 would suggest that the electrical
properties, specifically the membrane thickness, of the mem-
branes having similar V_ are similar. In addition to rapidly
growing cells, another important exception to the general rule
of 1 Volt being a critical transmembrane potential for cell
poration and inactivation are spores in their quiescent state
which have been shown to be much more insensitive to elec-
tric fields and appear to be sensitive only during germination
and outgrowth when the cortex disappears and the spore coat
layers dissolve as the cell swells (Hiilsheger H., Potel J., and
Niemann E-G. Electric Field Effects on Bacteria and Yeast
Cells, Radiat. Environ. Biophys. 22:149-162, 1983. (herein-
after "Hiilsheger 1983); and Grahl T., Sitzman W., Markl H.
Killing of Microorganisms in Fluid Media by High-Voltage
Pulses. Presented at 10th Dechema Annual Meeting of Bio-
technologists. Karlsruhe, Germany, Jun. 1-3, 1992.). This
behavior may be due to the quiescent spores having a much
thicker effective dielectric membrane thickness due to the
presence of the coat layers. Thus for a given critical trans-
membrane electric field strength, E m,, which is a function of,
for example the resistivity and material properties of the
dielectric layer, a larger effective membrane thickness would,
20
according to Eq. 6, yield a larger Vm,, and would thus require
a larger critical applied electric field, E ms, for cell inactivation
(see Eq. 3).
As shown in FIGS. lb-e, when Vm achieves the critical
5 value V„ ^, membrane dielectric breakdown results in the
formation of pores in the cell membrane 52, some of which
may reseal upon removal of the externally imposed electric
field. FIG. lb illustrates the condition of a section of cell
membrane 52 from near one pole of the cell with no external
10 applied electric field (E-0). When an external field is applied
that is below the critical field strength required for poration
(E<E, FIG. lc) there is a separation of charge across the
membrane 52 and a resulting transmembrane potential Vm but
no pore formation. This situation for the condition E=E, is
15 shown in FIG. ld, where E is the strength of the externally
applied electric field and, from Eq. 3:
E,- 4V ,13d	 Eq.7
which is the critical electric field strength for spherical cells
20 that defines the onset of membrane pore 58 formation for a
specific cell size and critical transmembrane potential. When
Vm is less than V_ (i.e., when E<E, in FIG. lc), pore forma-
tion, or at least irreversible pore formation, does not occur. As
Vm is increased beyond V_ (i.e., when E»E, in FIG. le),
25 membrane pores 59 become more numerous, larger, and irre-
versible. Thus, application of sufficiently strong electric
fields, or PEFs to cellular suspensions can result in the inac-
tivation of cells by the formation of irreversible pores which
can destroy the function of the semipermeable cell membrane
30 52. As noted earlier, the proper function of a cell's semiper-
meable membrane is required to control a cell's intracellular
environment and, therefore, to maintain its viability. The criti-
cal applied electric field, E,, necessary to form irreversible
pores is thus, as is apparent from Eq. 6, directly proportional
35 to the critical transmembrane potential V m,, and thus mem-
brane thickness, and inversely proportional to cell diameter d
for spherical cells.
PEE Parameters for Cell Purging and Cell Isolation
40 As noted above, the lethal effect of pulsed electric fields on
biological cells is caused by irreversible electroporation of
their semipermeable membranes or reversible poration fol-
lowed by a subsequent treatment to prevent membrane repair
or accelerate colloidal osmotic lysis and thereby cause cell
45 inactivation. An electric field applied across the cell electri-
cally polarizes the cell membrane causing charge separation
and build up of a transmembrane potential. The critical trans-
membrane potential required for membrane poration will be
a function of the nature and thickness of the membrane, as
50 previously mentioned, and must be determined experimen-
tally for any given system; however, as previously discussed
and illustrated by the data in Table 1, for a wide variety of
biological cells the critical transmembrane potential associ-
ated with an externally applied field is approximately V m,- 1
55 Volt. The pores resulting in the membrane structure of the cell
due to exposure to field strengths above the critical value can,
in certain cases, irreversibly increase cell membrane perme-
ability leading to cell death. The dielectric membrane break-
down concept of cell inactivation is illustrated in FIGS. lb-e.
60 Electric field strength, total exposure time, and pulse dura-
tion, for PEFs, can be selected to preferentially inactivate
biological cells in a suspension which are more susceptible to
electric fields due, for example, to their having one or more or
a combination of the following properties with respect to
65 other cells in the suspension: a larger average size; a thinner
effective dielectric membrane thickness; a more spherical
shape, etc. Of particular importance for many biological
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samples, especially those having cells with similar shapes,
such as roughly spherical, and similar dielectric membrane
thickness, is selective inactivation of cells based on a differ-
ence in characteristic size. Typically, the threshold electric
field required for cell inactivation is inversely proportional to
the characteristic size of the cell, i.e., from Eq. 7, E,(d)=4
V_,/3d, where V_,-1 Volt is the critical transmembrane
potential for the onset of irreversible pore formation for a
wide variety of cell types and d is the diameter or character-
istic size of the cell. If the undesirable cells are larger in
diameter than the desirable cells, then the pulsed electric field
method can be used to selectively inactivate the larger cells.
By operating at electric field strengths just below the charac-
teristic electroporation threshold for inactivation of the desir-
able cells, yet above the characteristic electroporation thresh-
old for the undesirable cells, a substantial fraction of the
undesirable cells can be preferentially inactivated while leav-
ing a substantial fraction of the desirable cells (primitive stem
cells for example) essentially unaltered and still viable. To
further illustrate the utility of the concept, a specific example
related to cell isolation from hematopoietic cell suspensions
will be illustrated. Table 2 lists the types of blood cells that
typically will be present in bone marrow specimens during
tumor cell purging and stem cell isolation processing. The cell
diameters, relative abundance, and projected threshold elec-
tric field strengths (E, as calculated from Eq. 7 assuming
V_,-1 volt) for the onset of membrane damage are also
provided in the table. Similar cell sizes as those listed would
be expected for hematopoietic cells derived from mobilized
peripheral blood, umbilical cord blood and fetal liver tissue,
although the relative abundance of each may differ. Table 2
clearly shows that the electric field damage threshold for stem
cells can be significantly greater than for the other leukocytes
present in bone marrow specimens. Furthermore, the electric
field threshold for stem cells can be more than a factor of two
greater than for breast cancer cells. Since, as will be discussed
below, the fraction of cells inactivated by an applied electric
field scales exponentially with electric field strength (Htilshe-
ger 1983) the factor of two difference in the critical electropo-
ration threshold should allow essentially complete inactiva-
tion of breast cancer cells with preservation of the viability of
the cells crucial for autologous transplantation (stem cells).
TABLE 2
Electric field damage thresholds for leukocvtes and stem cells
Cell Type
Characteristic
Size
(µm)
Relative
Abundance
N
Projected Electric
Field Damage
Threshold
(kV/cm)
Stem 6°,b 0.001° 2.2
Lymphocyte (resting) 7b 21' 1.9
Lymphocyte 12d n/a 1.1
(active)
Neutrophil 12d 73' 1.1
Eosinophil 13d 4' 1.0
Basophil 15d 0.1' 0.9
Monocyte 15d 2' 0.9
Breast Cancer >15' n/a <0.9
'Berardi AC, et al: Functional isolation and characterization of human
hematopoietic stem cells. Science, 267:104-108, 1995.
bZipori D, et al: Introduction of Interleukin-3 gene into stromal cells from
the bone marrow alters hematopoietic differentiation but does not modify
stem cell renewal. Blood 71:586, 1988.
`Jandl JH, Blood: Textbook of Hematology, Little, Brown and Company,
Boston/Toronto, 1987.
dHenry JB: Clinical Diagnosis and Management by Laboratory Methods,
16th Ed., W.B. Saunders Company, Philadelphia, PA, Vol. 1, 1979.
'from observations by inventors
Another feature which, in the present example, further can
enhance the ability to perform preferential electric field iso-
lation of stem cells and/or to purge relatively large tumor
cells, such as breast cancer cells, involves the quiescent nature
5 of stem cells. As discussed in Berardi, et al., stem cells are
quiescent and are unaffected by an anti-metabolite treatment,
whereas rapidly proliferating cells are inactivated by an anti-
metabolite treatment. A similar phenomenon has been
observed (Hiilsheger 1983) with PEE inactivation ofEscheri-
10 chia coli (E. coli). The observations of Hiilsheger 1983 indi-
cate that the stationary growth phase E. coli cells (quiescent
cells) are much less vulnerable to the lethal effects of PEF's
than are the larger, rapidly dividing E. coli cells that are in the
logarithmic growth phase. Based on these considerations, it is
15 expected that stem cells, due to their quiescent nature and
smaller size, will be much less vulnerable to the lethal effects
of electric fields and PEFs and that electric field strength can
be used to preferentially inactivate a substantial fraction of
non-stem cell leukocytes and tumor cells while leaving a
20 substantial fraction of the stem cells unharmed. Thus, it is
expected that the inventive methods will be an effective
approach for purging tumor cells from autologous transplant
tissue. Similarly, the inventive methods may be applied to
other cell suspensions or suspensions on non-cell discrete
25 objects having differences in characteristic size between sub-
populations in order to selectively isolate or inactivate
selected subpopulations.
In addition to performing a selective cell isolation or inac-
tivation on the basis of a difference in characteristic cell size
3o by selecting an appropriate applied electric field strength, the
method can also be employed to select cells that can be
similar in size based on a difference in dielectric membrane
breakdown voltage, for example, due to a difference in effec-
tive membrane thickness. For example, a variety of cells, such
35 as some epithelial cells and cancer cells, can have a layer of
mucopolysaccharide coating associated with their plasma
membrane which may increase the effective thickness of the
membrane and make the cells less susceptible to an applied
electric field than would be predicted by Eq. 7 with V_
4o assumed to be I Volt. In fact, assuming that the critical electric
field imparted to the membrane required for poration, E m,, is
similar for the cells present in the suspension, Eq. 6 indicates
that the critical transmembrane potential V_ will be directly
proportional to the effective thickness of the dielectric layer,
45 and, therefore, from Eq. 7, the critical applied electric field
strength, E,, for poration will also be directly proportional to
the effective membrane thickness. Thus, an applied electric
field strength may be chosen that is sufficient to inactivate a
substantial fraction of cells having an effective membrane
50 thickness below a certain predetermined threshold without
inactivating a substantial fraction of the cells having an effec-
tive membrane thickness above the threshold.
Although the threshold electric fields for the cells compris-
ing harvested human bone marrow, as exemplified above,
55 were theoretically estimated based on their size (see Table 1),
the critical threshold electric fields for the cells listed in Table
I have been previously measured. In addition to the impor-
tance of the magnitude of the applied electric field strength,
total exposure time of the cells to the electric field is also an
60 important parameter in determining the degree of inactivation
of a given population of cells. In general, for cells that are
selectively inactivated by electric fields on the basis of cell
size, the electric field strength determines the size below
which cells are preserved, and total electric field exposure
65 time determines the relative reduction in cells having sizes
above the critical size. Experiments in the prior art have been
conducted over a wide range of pulsed electric field strengths
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and number of applied pulses and have led to an empirical
model developed by Hnlsheger 1983, herein incorporated by
reference, for the surviving fraction of cells, s, following
electric field treatment, as a function of the peak applied
electric field strength, E, and the total time the cells are
exposed to the electric field, t. The time t in the following
model sums the on-time of the electric field over the total
number of pulses, so that t=Nptip, where NP is the number of
applied pulses and tip is the time duration of each pulse over
which E?E,. Hnlsheger 1983 demonstrated that bacterial
cell surviving fraction can be roughly modeled by an empiri-
cal expression that is a power law function of time and an
exponential function of electric field strength. Equation 8
provides a variant of Hiilsheger's rough model that behaves
correctly as the exposure time approaches zero for E>E,.
t	
-(E  E,)
	 Eq. 8
s=(i +1)
where, s is surviving fraction (ranging from 0-1), E, is the
threshold value of the electric field strength for membrane
breakdown, t, is an exposure tine normalization constant, and
k is an electric field normalization constant. E,, t, and k can be
empirically determined for a given cell suspension by fitting
Eq. 8, to data taken relating fractional inactivation as a func-
tion of exposure time and applied electric field strength using
any suitable regression analysis apparent to one of skill in the
art.
The equation for surviving fraction s can be utilized as a
tool to analyze data collected for the surviving fraction of a
particular cell population vs. applied electric field strength
and exposure time, generated for a given cell suspension, and
as a guide for selecting the field strength and duration
required to achieve a desired survival fraction for cells which
are to be porated and inactivated. By prescribing appropriate
values for the electric field strength and total exposure time,
required reductions in populations of cells of electroporation
threshold below a critical value, for example having sizes
larger than a critical diameter, can be achieved. Eq 8 indicates
that s is a strong exponential function of electric field strength
E and a weaker power law function of total electric field
exposure time E
Thus, isolation and inactivation of cells or discrete objects
by size differences according to the present invention pro-
ceeds by selecting an appropriate applied electric field
strength E, so that cells of size greater than (from Eq. 7),
d=4Vm,/3 E, will be inactivated and then applying an appro-
priate number of electric field pulses and/or total electric field
exposure time to reduce the viable fraction of cells above the
critical size to the desired level.
Table 3 presents the results of cell inactivation experiments
assembled by Castro on a variety of microorganisms using
Hiilsheger's original form of Eq. 8, which is obtained by
removing the factor "+1" in Eq. 8 (Hnlsheger 1983). The
threshold electric field E, derived from lethality measure-
ments for E. coli in the logarithmic growth phase is shown in
Table 3 to be 0.7 kV/cm, while the threshold field for E. coli
in the stationary phase is more than 10 times higher, i.e., 8.3
kV/cm. The lower threshold electric fields required to irrepa-
rably porate the membranes of growing cells are related to the
fact that growing cells are larger and must take in nutrients
from the external environment, making them more suscep-
tible to electric fields.
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TABLE 3
Experimental conditions, values, and confidence limits
for model parameters.5
E t E, t' k
Microorganism (kV/cm) (ms) (kV/cm) (ms) (kV/cm)
E. coli (4 hr) 4-20 0.7-1.1 0.7 ± 3.1 11 ± 9.6 8.1 ± 1.8
E. coli (30 hr) 10-20 0.7-1.1 8.3 ± 0.3 18 ± 5.7 6.3 ± 1.0
10 K. pneumoniae 8-20 0.7-1.1 7.2 ± 2.0 29 ± 16 6.6 ± 1.4
P. aeruginosa 8-20 0.7-1.1 6.0 ± 0.4 35 ± 6.1 6.3 ± 1.1
S. aureus 14-20 0.7-1.1 13 ± 0.9 58 ± 17 2.6 ± 0.7
L. monocytogenes 12-20 0.7-1.1 10 ± 2.6 63 ± 12 6.5 ± 2.5
I
C. albicans 10-20 0.7-1.1 8.4 ± 7.5 110 ± 33 2.2 ± 0.9
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One embodiment of the invention, involving cancer cell
purging and stem cell isolation by applied electric fields such
as pulsed electric fields, is based on the observation that
20 non-stem-cells are typically larger in size than stem cells;
therefore, Eq. 7 and the observation that V_ is typically about
1 Volt for a wide variety of cell types implies that an electric
field strength, E,, can be selected that will inactivate a sub-
stantial fraction of cells larger than the stem cell, including
25 contaminating tumor cells. After selecting an appropriatepre-determined critical electric field strength (which can be
approximately E=2-2.2 kV/cm to preserve stem cell viabil-
ity), total electric field exposure time, t, can then be selected
with guidance from Eq. 8, and routine experimental optimi-
30 zation, in order to achieve the desired reduction in the
unwanted, non-stem-cell populations, most importantly,
tumor cell populations. Therefore, electric field conditions
can be determined that lead to effective tumor cell inactiva-
tion and stem cell preservation, which is crucial for effective
35 transplant tissue purging.
Unlike stem cell isolation and purging strategies based on
anti-metabolites, mechanical cell sorting, or antibody bind-
ing strategies, the present invention has thepotential to isolate
stem cells without damage and without mutation of the basic
40 genetic molecules (DNA/RNA) within the cell. Most impor-
tantly, the genetic material is shielded from thepulsed electric
fields by the conductivity of the cell nucleus and cytoplasm.
Furthermore, at the electric field strengths of interest for
isolating stem cells (about 1-3 kV/cm), the potential devel-
45 oped across critical bonds in these complex RNA/DNA mol-
ecules is generally not sufficient to break these bonds. Hence,
stem cell isolation with pulsed electric fields should not cause
undo damage to the genetic material within the cells. An
additional advantage of using the electric-field-based tumor
50 cell purging, stem cell isolation strategy is centered onthe fact
that toxic or potentially activating agents, such as anti-me-
tabolites or exogenous antibodies, are typically not placed in
physical contact with the stem cells.
As previously mentioned, because of difficulties in apply-
55 ing a continuous potential across electrodes without arcing or
discharge, electrochemical reactions, and excessive heat gen-
eration, the applied electric field is preferably supplied to the
suspension as a series of short pulses, i.e. as a PEF. The
maximum electric field pulse duration is typically limited by
60 electric breakdown due to arcing between electrodes in the
treatment volume and by single pulse heating effects. The
pulse repetition rate is limited by the maximum temperature
rise that can be sustained without causing undo damage to the
sample. The minimum allowed pulse duration should be
65 greater than the time constant at which the dielectric mem-
brane charges in response to the electric field, as will be
discussed in greater detail herein.
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Thus far, the effect of applied electric field strength and
exposure time on the performance of the inventive methods
have been discussed in detail. In addition, as mentioned ear-
lier, a variety of other parameters related to the PEE, suspen-
sion, pulsing medium (fluid carrier), and other processing
steps can affect the performance of the inventive method and
should be considered when developing an effective isolation
or inactivation protocol. What follows is a description of a
number of what are believed are important factors related to
performance. Throughout the description, reference will be
made to one embodiment of tumor cell purging and stem cell
isolation from suspensions of hematopoietic cells in order to
illustrate the concepts with a concrete example. It should be
understood that the particular example chosen is purely
exemplary, and the methods may be practiced on a wide
variety of samples for a wide variety of desired applications.
Table 4 below summarizes some of the more important
parameters (column 2) that can influence PEE performance,
particularly as related to tumor cell purging and stem cell
isolation, along with contemplated preferred ranges (column
3) of some chosen parameters for tumor cell purging and stem
cell isolation. The table will serve as an outline for the dis-
cussion to follow. The "PEF" group includes parameters
related to the nature of the applied electric field. The "Pulsing
Medium" group includes parameters related to the properties
of the suspension. The "Post Processing" group discusses
optional treatments subsequent to electric field exposure that
can, in some cases, enhance performance, and the "Heat
Transfer" group includes parameters related to the heating
effects of the applied PEFs.
TABLE 4
Parameters influencing PEE tumor cell purging and
stem cell isolation efficacv.
Group	 Parameter Description Range
PEE	 Electric field pulse shape "Rectangular"
E	 Electric field strength 0.5-5 kV/cm
t	 Total electric field exposure time <10 ms
T,	 Electric field pulse duration 2-20 ps
Pulsing	 EP,	 Initial leukocyte concentration 106-10s cells/ml
Medium	 pp,	 Pulsing medium ionic strength 0.015-0.15 M KCI
equivalent
y,,	 Pulsing medium osmolality 1300 mOsm/
Agents for cell size modification kg-water
Agents for dielectric membrane
breakdown voltage modification
Post	 µZ,	 Inactivation medium ionic strength 0.15 M KCI
Processing	 and composition equivalent, Ca"
T,	 Inactivation medium residence
time
Collection protocol Gradient density
centrifugation
Heat	 I,	 Electric field pulse rate Apparatus &
pulsing
medium dependent
Transfer	 T,, Pulsing medium temperature 5-41 ° C.
For embodiments involving PEFs, a substantially rectan-
gular electric field pulse shape is preferred for achieving
optimum size selectivity. Rectangular pulses are those that
have rise and fall times that are short compared to the pulse
duration, and preferably shorter than the charging time scale
of the dielectric membrane of the cells or objects to be inac-
tivated (typically rise and fall times are X0.5 µs for most
applications of interest in the present invention), have essen-
tially no overshoot during the rise- and fall-time transients,
and have a substantially constant electric field strength
between the rise and fall transients; preferably the difference
in the maximum and minimum values in the substantially
constant field strength region is less than 3%. Non-rectangu-
lar-shaped pulses, such as half-sinewave shaped or exponen-
tially decaying pulses may be employed for some embodi-
ments but will not provide as clearly defined an electric field
5 strength, which can broaden the electroporation threshold
demarcation line between uninactivated and PEE inactivated
cells, thereby degrading the selectivity, resolution, and effi-
ciency of the PEE cell inactivation method.
The range of electric field strengths given in Table 4 is
10 based on the critical electric field strengths given in Table 2
and represents a reasonable range to employ for optimization
trials involving the inactivation of specific cell types listed in
Table 2 as a function of electric field strength and total expo-
sure time. With this electric field range, the range of inacti-
15 vation that can be expected would range from no lethal effects
on any cells to essentially total inactivation of all cell types.
Based on Eq. 8, total electric field exposure time t can be used
to achieve a desired reduction in the number of viable
unwanted cells. The maximum total electric field exposure
20 time typically will be less than about 10 ms for essentially
complete inactivation of tumor cell populations.
For embodiments involving PEFs, the inactivation of bio-
logical cells involves multiple steps which are dependent on
the duration of the individual electric field pulses TP . Early in
25 the pulse, the membrane of the cell charges, thereby produc-
ing an elevated transmembrane potential. The membrane
charging time scaleT_ for spherical cells is givenby (LynchP
T and Davey M R, Electrical Manipulation of Cells, Chap-
man and Hall, pp. 18-20, 1996.; and Tessie J and Tsong T Y,
30 Electric field induced transient pores in phospholipid bilayer
vesicles, Biochemistry 20:(6)1548-1554, 1981.):
Tm 
—112cmd(p,+p,12),	 Eq.9
35 where cm is the membrane specific capacitance (typically —1
l&CM2 for biological cell membranes (see Schanne OF and P.
Cerreti ER, Impedance Measurements in Biological Cells,
John Wiley and Sons, New York, p. 331, 1978.)), d is cell
diameter, p, is the resistivity of the intracellular fluid (typi-
40 cally, for cytosol, —100 Q-cm), and pp, is the resistivity of the
medium supporting the cells during PEE treatment (typical
range of about 70-500 Q-cm depending on the ionic strength
of the solution). For a typical cell as exemplified by a hemato-
poietic cell, the maximum charging time constant will be on
45 the order of about 0.5 µs. In preferred embodiments, in order
to achieve thorough membrane charging, the duration of the
portion of the electric field pulse supplying an electric field
strength greater than the critical field strength, E,, to porate
the cell, for example the flat-topped portion of a rectangular
50 fieldpulse, shouldbe at least three to fourtimes the membrane
charging time constant Tm , (i.e., for tim-0.4 µs, tiP >1.6 µs).
After membrane charging is complete, pore formation
begins and transport of ionic species between the inside of the
cell and the pulsing medium takes place. It is known (Kinosita
55 K and Tsong T Y, Voltage-induced pore formation and
hemolysis of human erythrocytes, Biochim et Biophys Acta.
471:227-242, 1977 (hereinafter "Kinosita 1977)). that ion
transport processes can enhance PEE cell lysis by disrupting
the osmotic balance across the cell membrane, which, in turn,
60 can lead to cell swelling and irreversible lysis due to the
uptake of water. It is also known (Kinosita 1977) that the
efficacy of inducing irreversible cell lysis by PEFs decreases
for human erythrocytes when the electric field pulse length is
decreased below about 10 µs and improves as the pulse length
65 is increased above 10 µs. This phenomenon probably reflects
the need for an electric field pulse duration that is sufficient to
allow extensive pore development and time for ion species
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transport. Based on these observations, reasonable pulse
durations for cells having a size range of between about 6 M
and 20 µm, typical for hematopoietic cells, can range from
about tiP=2 µs to about tiP 20 µs.
PEF cell inactivation and isolation efficacy can also be
affected by the total concentration of cells in the PEF treat-
ment volume. The effect of total concentration can be under-
stood by comparing the total electric charge (Qm) required to
charge the membranes of all of the cells in the treatment
volume to a transmembrane potential of V_, I Volt, with the
charge (QP) actually supplied to the test volume by the elec-
tric field pulse. Qm can be expressed as:
Q_—v7VTI,d2c_V ,/4,	 Eq. 10
where v TVis the volume of the PEF treatment cell (cm3), rl ' is
the concentration of cells in the PEF treatment volume (cells/
Cur) , d is the average diameter of the cells in the PEF treat-
ment volume (assume for purposes of illustration —10 µm), cm
is membrane specific capacitance (assume for purposes of
illustration —I µf/cm2), and V_ is the critical transmembrane
potential for the onset of irreversible pore formation (assume
for purposes of illustration that V_,-1 Volt). Note that Qm , is
proportional to the cell concentration,'q, QP canbe expressed
as:
Q,-,vzVE/p,,., 	 Eq. 11
where tiP is the electric field pulse length (sec), v TV is the PEF
treatment volume (cm3), E is the electric field strength
(V/cm), pp, is the resistivity of the medium supporting the
cells (typically about 70-500 Q-cm) in the PEF treatment
volume, and w is the separation distance between the elec-
trodes in the PEF treatment. Note that QP is proportional to the
electric field pulse length, tiP , and inversely proportional to
the pulsing medium resistivity, pPs . If the ratio Qm/(Qm +QP) is
not small, then cell concentration effects can degrade PEF cell
inactivation efficacy by significantly increasing the effective
charging time scale, ti m , of the cells in the treatment volume,
i.e., a significant amount of the total charge supplied to the
treatment volume is required to simply charge the cells. In
fact, as this ratio approaches unity, the cell membranes
approach the situation where they have just achieved com-
plete charging by the end of the electric field pulse, so there
wouldbe essentially no additional time forpore development
and transport of ionic species between the cell and the pulsing
medium to take place. For best performance, the ratio Qm/
(Qm +QP) is preferably within the range of about 0.0004 -Qm/
(Qm +QP)-_:0.74. The ratio Qm/(Qm +QP) can be kept constant
as the cell concentration ( ,q,) is increased by increasing the
pulse length (tiP) proportionally and/or by appropriately
reducing the pulsing medium resistivity (pp,), for example by
increasing the ionic strength. The upper limit of cell concen-
tration given in Table 4 (q,-10" cells/ml) has significance
relative to a clinical PEF tumor cell purging system embodi-
ment. For example, one liter of bone marrow, which is the
approximate volume harvested for autologous transplants,
contains approximately 10 10 mononuclear cells, which must
be purged before transplantation. If PEF conditions can be
defined that provide high PEF tumor cell inactivation efficacy
for a treatment volume cell concentration of 10 $ cells/ml, then
a 100 ml PEF treatment volume, or a flow-through system
able to process 100 ml of cell suspension, can be used to
process the entire bone marrow specimen, such a system is
reasonable both in terms of system size and electric field pulse
energy requirements.
In addition to the nature of the applied PEF, the medium
within which cells are suspended can be a significant factor in
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the performance and efficacy of the invention. The pulsing
medium, in which biological cells are suspended, in some
embodiments can have an osmolality that preserves the
osmotic balance between the intracellular and intercellular
5 fluids, in other words isotonic, where isotonic defines a solu-
tion with an osmotic strength (osmolality) similar to that of
the suspended cells so that the cells do not undergo substantial
osmotic pressure-driven cell volume regulation (-300
mOsm/kg-water for many mammalian cells, such as hemato-
io poietic cells). If the osmotic strength of the pulsing medium
differs substantially from that of the cytosol of the cell, the
cell can undergo changes in cell volume, such as shrinkage or
swelling that can be detrimental to cell viability and the
performance of the inventive method, especially for isola-
15 tions based on characteristic cell size. In some embodiments
however, it can be desirable to suspend a cell suspension in a
somewhat hypotonic medium either prior to pulsing, with
subsequent pulsing performed in isotonic medium, or during
the PEF treatment itself. In these embodiments, the suspend-
20 ing medium should have an ionic strength selected to enable
at least one cell type in the suspension to undergo osmotic
swelling, while not being low enough to cause rupture or a
substantial loss of viability to target cells within the time
frame of the treatment. Pre-treatment, or PEF treatment using
25 a hypotonic suspending fluid can potentially improve perfor-
mance for certain cell isolations by causing cells to become
larger and more spherical in shape, and thus potentially more
sensitive to the effects of an applied electric field. Treating
cell suspensions that are characterized by cells having a more
30 uniform spherical shape can also improve performance by
reducing the effects of cell orientation within the electric field
on poration.
The ionic strength of the pulsing medium can be altered,
while preserving the desired osmolality, by combining a solu-
35 tion comprising one or more solubilized electrolytes having a
desired osmolality (e.g. an isotonic saline solution) with a
solution comprising one or more solubilized non-electrolytes
having a desired osmolality (e.g. an isotonic sucrose solu-
tion). There are several reasons why, for some embodiments,
40 it can be desirable to reduce the ionic strength of the pulsing
medium from standard physiological conditions (e.g. equiva-
lent to a 0.15 M NaCl aqueous solution for many mammalian
cells, such as hematopoietic cells). One reason is that it has
been shown (Kinosita 1977) that PEF treatment using a puls-
45 ing solution having a below-physiological ionic strength fol-
lowed by resuspension of PEF-treated cells in a standard
physiological ionic strength solution can enhance cell
destruction by colloidal osmotic lysis and result in a more
rapid and extensive irreparable lysis of erythrocytes (red
5o blood cells). This phenomenon has also been observed in the
context of the present invention with leukocytes (white blood
cells), where the PEF porated cells were subsequently
reduced to small cell fragments by PEF treatment in low ionic
strength medium (e.g. 10 v % PBS, 90 v % isotonic sucrose)
55 followed by exposure to a physiological strength medium
(e.g., isotonic PBS or Iscove's Modified Dulbecco's Medium
(IMDM)). For embodiments of the inventive method utilizing
a relatively lower ionic strength pulsing medium followed by
exposure to a relatively higher ionic strength medium, the
60 particular ionic strengths chosen for the pulse and post-treat-
ment medium, and the exposure time of the PEF-treated cells
in the post-treatment buffer will be selected based on routine
experimentation with the particular cell suspension of interest
to determine the conditions that yield the highest levels of
65 inactivation of undesired cells with the best preservation of
the viability of desired cells. Typically, the post-treatment
medium will have an ionic strength similar to the physiologi-
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cal ionic strength of the cells in the treated suspension and the
pulse medium will have an ionic strength ranging between
10% and 90% that of the post-treatment medium. The expo-
sure time of the cells to the post-treatment medium can vary
from a few seconds to an essentially indefinite period. It is
important, however, that sufficient time be allowed for
adequate diffusion and colloidal osmotic lysis to take place.
In addition to, or instead of, having an ionic strength that is
higher than that of the pulsing medium, the post-treatment
medium may for some embodiments, have a higher osmola-
lity than the pulsing medium and/or contain an agent that
causes or enhances irreparable lysis of porated cells, such as,
in some preferred embodiments, calcium ions. For some
embodiments including a post-treatment step after PEE treat-
ment designed to enhance or cause irreparable cell lysis, the
cells porated by PEE exposure undergo irreversible poration
of the cell membrane during PEE treatment, and post-treat-
ment, as described, functions to irreparably lyse the cells that
have already been inactivated by the PEE exposure. In other
embodiments, exposure to the PEE porates, but does not
necessarily irreversibly porate, the membranes of the cells to
be inactivated, with inactivation and/or irreparable lysis
occurring during a post-treatment inactivation step.
For some embodiments, it may be desirable to remove any
inactivated cells, lysed cells, and cellular debris from PEE
treated specimens. Small cell fragments and debris generated
by cell rupture during irreparable cell lysis can be separated
from the viable cells using a variety of techniques known in
the art, for example single- or multi-gradient centrifugation
techniques. For embodiments where PEFs or post-treatment
can fragment affected cells, it is possible to separate viable
cells from cellular debris using standard gradient density
centrifugation techniques. For example, Ficoll-Paque gradi-
ent density centrifugation, which is a single gradient separa-
tion scheme can be used. Multi-gradient centrifugation can
also be used for other applications as apparent to one of skill
in the art. For embodiments where inactivated cells also
undergo irreparable cell lysis, characterized by cell rupture, it
can also be advantageous to add to the suspending medium an
agent that is able to degrade cellular debris. A variety of such
agents apparent to one of skill in the art can be employed to
reduce the cellular debris to its molecular components. Par-
ticularly preferred are enzymatic agents, and especially pre-
ferred is DNase to breakdown DNA dispersed in the pulsing
media, and trypsin digestion to breakdown cell membrane
and proteinaceous material. Such agents may be present dur-
ing the PEE treatment, or alternatively, may be added subse-
quent to PEE treatment.
Other advantages to reducing the ionic strength of the
pulsing medium for some embodiments are related to the
increased resistivity and reduced conductivity of pulsing
solutions having a reduced ionic strength. The power density
WP (J/cm3) and total charge density Q (Coulomb/cm 3) input
into the PEE treatment volume are both functions of the
resistivity of the pulsing medium:
WP E'c,Ip,,	 Eq. 12
Q=ET,lp,,	 Eq. 13
where E is the magnitude of the applied electric field, tiP is the
pulse duration, and pp, is the resistivity of the pulsing
medium. The resistivity of the pulsing medium varies
inversely with ionic strength. Thus, according to Eq. 12,
energy and power requirements of a PEE treatment cell can be
reduced by a factor of ten, for example, by using a mixture of
10% by volume aqueous isotonic phosphate buffered saline
and 90% by volume aqueous isotonic buffered sucrose as a
pulsing medium instead of a standard physiological ionic
strength medium. Additionally, reducing the ionic strength of
the pulsing medium increases the resistance of the PEE treat-
ment volume, which, for a given electric field strength and
5 pulse duration, reduces the electron charge driven throughthe
PEE treatment volume as shown by Eq. 13. Undesirable elec-
trochemical reactions, such as free radical production, are
typically proportional to the charge driven through the PEE
treatment volume. Thus, reducing the ionic strength of the
io pulsing medium can proportionally decrease the production
of free radicals, or other undesirable by-products of electro-
chemical reactions. Reduction of electrochemical reactions
occurring in the PEE treatment volume during treatment can
also reduce the pH swing of the pulsing medium during
15 pulsing and also reduce the production of chlorine and hydro-
gen bubbles. Formation of bubbles during treatment is very
undesirable, since the presence of bubbles can lead to non-
uniform field distribution within the treatment volume and
locally elevated electric field intensities, which can signifi-
20 cantly reduce the size selectivity of the inventive cell isolation
methods. In general, it is desirable to maintain the pH of the
pulsing medium relatively constant during PEE treatment and
within a range that is not detrimental to the viability of the
cells being treated (typically about pH 7-7.6). A variety of
25 buffer systems apparent to one of skill in the art for use in this
range that are sufficiently non-toxic to cells can be employed
including, but not limited to phosphate buffers, BES, MOPS,
TES, HEPES, DIPSO, and TAPSO. Preferred for embodi-
ments where precise pH control is especially important, are
3o buffer systems including one or more strong organic buffers
such as those referred to as "Good" buffers (Good, N. E., et
al., Biochemistry, 5:467(1966); Good, N. E., and Izawa, S.,
Meth. Enzymol., 24(Part B):53(1972); Ferguson, W. J. and
Good, N. E., Anal. Biochem., 104:300(1980)), and especially
35 N-[2-Hydroxyethyl]piperazine-N'-[2-ethanesulfonic acid]
(HEPES).
One important consideration in designing and implement-
ing a PEE isolation or inactivation strategy is heat effects and
temperature rise due to heat generated within the PEE treat-
40 ment cell due to the energy deposited into the treatment cell
by the electric field. One issue that depends heavily on heat
transfer effects is whether the total exposure time of the
treated suspension should be achieved with a single pulse or
with a series of pulses. Since many biological cells can be
45 non-selectively inactivated by overheating, which is not a
function of electroporation threshold, and since a single long
electric field pulse can, without sufficient heat removal, cause
a greater amount of heating of the cells for a given total
exposure time, it is preferable, for many embodiments, to
5o apply the total electric field exposure time as a series of
pulses, rather than as a single pulse of longer duration. Since
cyclic heating and cooling is particularly destructive for
blood cells, pulse duration should be kept short enough to
minimize cell and cell suspension temperature excursions
55 beyond the physiological range. The rate, or frequency, at
which electric field pulses may be applied is related to the
energy deposited in the pulsing medium per electric field
pulse (Joule heating), the geometric shape and heat transfer
characteristics of the particular PEE treatment volume and the
6o density and thermal conductivity of the pulsing medium
(which collectively dictate heat removal rates), and the heat
capacity of the pulsing medium. There are two components to
the total temperature rise in the PEE treatment volume as a
function of the electrical energy input: the temperature jump
65 AT (° C.) that occurs for each individual electrical pulse; and
the steady pulsing temperature rise AT,(' C.), which is a
function of the volume and heat transfer characteristics of the
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PEE treatment cell. Each time a pulse is applied to the pulsing
medium, the temperature will jump. The magnitude of the
temperature jump is proportional to the power density WP
given by Eq. 12, and can be expressed as:
AT,(' C.)-X1D,mp,,,,, 	 Eq. 14
where AT, is the temperature jump (° C.), tiP is the electric
field pulse length (with a typical range for cell isolations
involving hematopoietic cells of about for example 2-20 µs),
E is the electric field strength (with a typical range for cell
isolations involving hematopoietic cells of about for example
0.5-5 kV/cm), (D P-is the density of the pulsing medium
(typically —1 g/cm 3), pp, is the resistivity of the pulsing sus-
pension (with a typical range for cell isolations involving
hematopoietic cells of about for example 70-500 Q-cm), and
cP is the specific heat of the pulsing medium (typically —4.19
7/g ° C.). Under the most extreme conditions presented in
Table 4, and listed in parenthesis directly above, the maxi-
mum temperature jump per electric field pulse will be
AT,- 0.86' C. The steady temperature rise is a function of the
heat input per pulse, the number of pulses per unit time
(frequency), and the heat transfer rate of the PEE treatment
cell tending to remove heat from the treatment volume. One
dimensional conduction heat transfer considerations may be
applied for the static PEE treatment cell embodiment to deter-
mine the steady pulsing, time average temperature rise at the
midplane between the electrodes imparting the electric field
to the treatment volume relative to the temperature of the
bounding electrodes. This formulation assumes that convec-
tive transport driven by temperature induced density gradi-
ents are of negligible importance. Equation 14a below (see
Holman 7 P. Heat Transfer, 5th Ed., McGraw-Hill, Inc., New
York, 1981, p. 35) describes the average temperature rise for
one dimensional steady pulsing volumetric heat deposition
by PEFs into a treatment volume bounded by two plane
electrodes.
4T,, ,,, qVV'/8K	 Eq. 14a
Where q is the volumetric heat deposition rate given by:
q=FT,E 21r,	 Eq. 14b
And where w is the separation distance between the elec-
trodes, x is the thermal conductivity of the pulsing medium, F
is the pulse repetition frequency, tiP is the electric field pulse
length, E is the strength of the imposed electric field, and pp,
is the resistivity of the pulsing medium. Equations 14a and
14b indicate that the mid-plane temperature increases as the
square of the electrode separation distance, linearly with
pulse repetition frequency, the square of electric field
strength, and inversely proportional to the resistivity of the
pulsing medium. Since the average midplane temperature rise
given by Eq.'s 14a and 14b, which constitutes the maximum
average temperature rise in the PEE treatment volume, is
inversely proportional to the resistivity of the pulsing
medium, an increase in pulse repetition frequency by a factor
of ten can be realized while maintaining the same midplane
temperature rise by increasing the pulsing medium resistivity
by a factor often. This can be accomplished by decreasing the
ionic strength of the pulsing medium to 10% of standard
physiological ionic strength by the methods described previ-
ously. The temperature jump given by Eq. 14 in response to
the application of each electric field pulse can be imagined to
be superimposed on the average steady pulsing temperature
rise AT,,, Q1e as a periodic temperature spike with an expo-
nential decay and a frequency corresponding to electric field
pulse repetition frequency.
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For illustrative purposes, if the electrode spacing is 0.318
cm and using the most extreme conditions presented in Table
4, which gave a maximum temperature jump per electric field
pulse of AT, 0.86° C., the steady pulsing temperature rise at
5 the midplane between the two electrodes will be AT,,, a1,('
C.)=5.16 F (Hz). Thus, if the electrodes are maintained at a
temperature of 25° C. and one wishes not to exceed a mid-
plane peak temperature no greater than 37° C., then the aver-
age midplane temperature cannot exceed AT,, ­-37-25—
10 AT„ whichis AT,,, a1e 11.14° C., whichconstrains thepulse
repetition frequency to be no greater than F=11.14/5.16=2.16
Hz. If the ionic strength of the pulsing medium was reduced
by a factor of ten, the pulsing medium resistivity would
increase by a factor of ten, which would allow operating at a
15 pulse repetition frequency of 21.6 Hz for which AT,,, ­
would remain at 11.14° C.
For illustrative purposes, assuming a worst-case heating
situation by neglecting any PEE treatment volume heat
removal effects, the total electric field exposure time (t NP tiP,
20 where NP is the number of applied electric field pulses) that
may be applied without exceeding a predefined pulsing
medium temperature rise can be expressed as:
t=(DPm p,,c,AT _/E2,	 Eq. 15
25 where AT­ is the maximum predefined allowable tempera-
ture rise (° C.). For example, if pulsing is initiated with a PEE
treatment cell pulsing medium temperature of 25° C. and we
wish not to exceed a final pulsing medium temperature of 37°
30 C., then the predefined maximum allowable temperature riseis AT__-12' C. Based on AT_,,, and the strength of the
applied electric field the allowable total electric field expo-
sure time for a given cell suspension in a PEE treatment cell
can be determined by Eq. 15. Eq. 15 also shows that if a low
ionic strength pulsing medium is used, the allowable electric35 field exposure time calculated for a given AT­ is directly
proportional to the decrease in ionic strength; for example,
reducing the ionic strength by a factor of ten would increase
the allowable exposure time by about a factor of ten. Further-
more, since under low ionic strength conditions, the energy
40 transferred to the PEE treatment volume is reduced, for a
given desired total exposure time, the pulse frequency may be
increased without exceeding the predefined maximum tem-
perature rise, thus allowing for a more rapid isolation or
45 inactivation. Accordingly, the inventive PEE strategy can be a
very rapid approach to cell purging and cell isolation.
For a single- or multi-pass flow-through PEE treatment cell
embodiment of the invention, Eq. 15 can be manipulated to a
form that describes the temperature rise of a fluid element of
50 the pulsing medium as it traverses from the inlet to the exit of
the PEE treatment volume. This formulation represents an
upper bound on the temperature rise since it neglects heat
transferto the bounding electrodes as the fluid element passes
through the PEE treatment volume. If NP is the number of
55 electric field pulses applied during the residence time of thepulsing medium in the PEE treatment volume and tiP is the
duration of each of the electric field pulses, then the total
electric field exposure time is t NPtiP and the resulting tem-
perature rise is given by Eq. 15a below:
60	 ATY — tE2/(DPm p,,c,	 Eq. 15a
As illustrated above for the static PEE treatment cell embodi-
ment, reduction of the ionic strength of the pulsing medium,
which results in an increase in the resistivity of the pulsing
65 medium, can allow a corresponding increase in the number of
pulses that can be applied during the residence time of the
pulsing medium in the PEE treatment volume. Thus, for the
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flow-through PEE treatment cell embodiment, it can be ben- 	 electric field involves essentially equal current flows across
eficial to use the lowest ionic strength pulsing medium allow- 	 the sample for each applied polarity, the reversible electro-
able in order to maximize the number of pulses that may be	 chemical reactions induced by the applied electric field com-
applied in a single pass without exceeding the temperature 	 ponent having a first polarity, can be substantially reversed by
rise limitations beyond which thermal effects impact cell 5 the applied electric field component having the opposite
viability. The relationships given above provide guidance to	 polarity, thus yielding a situation characterized by no net
the skilled practitioner for selecting reasonable pulse repeti-	 electrochemical reaction over the treatment time.
tion frequencies that are appropriate, for a specific pulsing 	 There are a variety of ways to apply a bipolar electric field
medium and electric field pulse intensity and duration, for 	 to the sample as apparent to one skilled in the electrical
inactivating selected cells from a cell suspension having a io engineering arts. For some embodiments, the pulses across
maximum allowable temperature rise. 	 the sample are of essentially equal magnitude, duration, and
Another previously mentioned factor that can influence the 	 number, but alternate pulses are of opposite polarity, while for
way in which an applied electric field interacts with a cell	 other embodiments, the pulse having a first polarity maybe of
suspension, and the selectivity of an applied electric field at 	 greater magnitude but shorter duration while the pulse of the
inactivating cells based on a critical electroporation thresh- 15 reverse polarity is of lower magnitude and longer duration, so
old, is the shape and orientation of cells within the field. This	 that the total average current flow is essentially zero. In
factor is important for any cell inactivation involving non-	 another embodiment, an electric field pulse having a first
spherical shaped cells. A problem arises with such samples 	 polarity is utilized together with a DC current having an
because non-spherical cells, in a given sample, are typically 	 opposite polarity selected so that the magnitude and duration
randomly aligned with respect to the electric field direction. 20 of each is selected to yield an essentially zero net current in
While such a random alignment is not a problem for hemato- 	 order to achieve no net electrochemical reaction within the
poietic stem cells or other essentially spherical cells, random	 sample. In yet another embodiment for creating a desired
orientation can reduce the effectiveness, especially for cells 	 bipolar electric field, the pulse used to create the PEE field
with large aspect ratios, of cell inactivation with applied elec- 	 may also be utilized to charge a suitable capacitor. When the
tric fields. Eq. 1 shows that the transmembrane voltage, Vm, 25 original PEE pulse terminates, the capacitor then discharges
that results from an applied electric field E is directly propor- 	 back through the solution containing the cells at a rate deter-
tional to the projected length, 1, of the cell in the electric field	 mined in part by a resistance in the discharge path to produce
direction. Thus, for cells with large aspect ratios, 1 can be	 the desired bipolar field.
highly variable depending on the orientation of the cell. Since 	 In addition to reducing undesired electrochemical reac-
it is typically desirable to apply an essentially time-invariant 30 tions, bipolar PEFs canprovide an additional advantage inthe
transmembrane voltage for a predetermined length of time in 	 selective inactivation/lysing of larger cells. The additional
order to obtain more easily predictable and controllable pora- 	 advantage lies in that the first pulse component having a first
tion results, it is therefore desirable to align cells that are not 	 polarity results in a charge across the membrane of the cell
substantially spherical so that they have a more consistent and 	 which remains for some period of time after the first pulse
predictable orientation with respect to the electric field direc- 35 component terminates. If a second pulse component having
tion. For embodiments of the invention where it is desired to 	 an opposite polarity is applied across the cell during this time,
align the axes of cylindrical or oval shaped cells to achieve	 the voltage across the cell can be effectively doubled for a
maximum PEE inactivation efficiency, an AC field can be 	 short period of time. This doubling effect is greater for larger
applied across the sample to accomplish this function. The 	 cells than for smaller cells because of the larger membrane
AC field is preferably selected to provide an essentially uni-  40 charging time scale for larger cells (see Eq. 9). This effect can
form oscillating electric field during the PEE treatment	 potentially enhance size-selective destruction of the larger
period, and has a magnitude selected to be sufficient to align 	 cells, thereby enhancing the cell selectivity of the invention
the cells with their long dimensions parallel to the PEE field
	
for certain applications.
direction for optimum size selectivity by the PEE field, with- 	 Temperature may also be utilized to enhance cell inactiva-
out porating the cells or unduly overheating the pulsing 45 tion by the inventive methods. In general, biological cells are
medium. The theoretical treatment of this cell alignment tech- 	 less capable of repairing membrane damage at sub-physi-
nique is discussed in detail by Lynch (LynchP T and Davey M 	 ological temperatures. This behavior can be utilized to
R. Electrical Manipulation of Cells, Chapman and Hall, New 	 increase inactivation of cells in response to an applied electric
York, Chapter 4, 1996), herein incorporated by reference. 	 field. For example, in one embodiment the cells are subjected
Some preferred embodiments of the invention include the 50 to a PEE in a solution that is maintained within a physiologi-
use of an applied electric field for cell inactivation that is a	 cal range of temperatures (for most mammalian cells,
bipolar electric field. A "bipolar electric field" as used herein 	 approximately 33-39° C.), the porated cells are then resus-
refers to an electric field that is pulsed or otherwise applied to	 pended in a solution at a lower temperature, for example room
a sample so that the average current across the sample over the 	 temperature (approximately 25° C.) or lower, but above the
total treatment time is essentially zero. The use of bipolar 55 freezing temperature of the suspension. The lower tempera-
electric fields in the context of the present invention provides 	 ture solution delays repair of porated membranes and thus can
several advantages over non-bipolar fields. When an electric	 increase the degree of cell inactivation by colloidal osmotic
field is applied across a sample, particularly a blood sample, 	 lysis.
electrochemical reactions can occur which can produce free 	 Alternatively, since cell repair (i.e. the closing of pores in a
radicals, other deleterious compounds, and species that can 60 porated cell) will not take place when the cell temperature is
shift suspension pH and/or generate bubbles. Such electro-	 dropped much below body temperature, the PEE exposure
chemical effects are, as previously indicated, undesirable. 	 itself can be performed at a lower temperature, thereby per-
Within the context of the present invention, the inventors have 	 mitting irreversible poration to occur at an electric field
found that undesirable electrochemical effects can be reduced 	 strength that can be lower than that which would otherwise be
or eliminated by utilizing a bipolar electric field pulsed so that 65 required. In addition, utilizing a lower PEE subjecting tem-
the average current across the sample over the treatment time 	 perature for any given applied electric field strength can
is essentially zero. Because the application of the bipolar 	 improve the kill rate (i.e. reduce the surviving fraction) from
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that suggested by Eq. 8 as determined for the same given field
strength but a higher PEE subjecting temperature.
For embodiments of the invention involving applications
where it is desired to selectively inactivate one or more cell
types having a characteristic size greater than a predeter- 5
mined value while simultaneously leaving substantially
viable another desired cell type, or group of cell types, having
a characteristic size below the predetermined value, the
greater the difference between the predetermined value of
size and the characteristic size of the desired cells, in general, io
the easier and more selective the isolation. "Substantially
viable" as used herein indicates that at least about 10% of the
cells in the population are viable, preferably at least 50%,
more preferably at least 90%, and most preferably at least
95%, while conversely, "substantially non-viable" as used 15
herein indicates that at least about 25% of the cells in the
population are non-viable, preferably at least 75%, more pref-
erably a least 90%, more preferably at least 95%, and most
preferably essentially all of the cells in the population are
non-viable. For applications where the difference in charac- 20
teristic size of the desired cell type and the undesired cell type
is small, a variety of strategies can be utilized to improve the
performance of the PEE isolation protocol. One method is to
remove the cells that are close in size to the desired cells by
performing a preliminary cell separation step that separates 25
cells on some basis other than a difference in size. Depending
upon the particular application, suitable cell separation meth-
ods include but are not limited to: flow cytometry; affinity cell
chromatography; and centrifugation.
For example, in an application involving the isolation of 30
hematopoietic stem cells from other blood or bone marrow
cells, both red blood cells (about 7 µm diameter) and resting
lymphocytes (about 7 µm diameter) are dimensionally the
closest to the stem cell (about 6 µm diameter). Because the
number of red blood cells is much greater than the number of 35
all of the nucleated cells combined, and because the red cells
have a higher density than the nucleated cells, they are typi-
cally separated from a sample by density gradient centrifu-
gation, using for example a Ficoll-Paque single gradient hav-
ing a density of 1.07 g/cm 3 (which will also remove 40
polymorphonuclear leukocytes such as neutrophils), before
PEE application. If the size selectivity of the PEE isolation for
a particular embodiment is not sufficient to select stem cells
over the resting lymphocytes with the desired level of purity,
the resting lymphocytes, or other small cells, can be removed 45
from the pulsing medium prior to PEE treatment. This can be
achieved, by a variety of cell separation methods known in the
art including CD34 targeted antibody affinity binding tech-
niques that are selective for CD34 cells, such as hematopoi-
etic precursor cells including some stem cells. An alternative 50
is to add an agent to the cell suspension that can preferentially
modify (increase or decrease) the critical electroporation
threshold of a subset of the cells to make them more or less
susceptible to inactivation by electric fields. For example in
one embodiment, the small resting cells, such as resting lym- 55
phocytes, may be eliminated by activating the resting lym-
phocytes using an agent that forces the resting lymphocytes
into their active state so as to achieve their mature size (typi-
cally about 12 µm) where they can be more easily inactivated
without adversely affecting the stem cell population. A vari- 60
cry of suitable activating agents are known in the art including
protein agents, such as cytokines, lymphokines, chemokines,
anti-cell surface marker antibodies, and cell receptor antago-
nists. Other suitable stimulants include lectins, such as
Phaseolus vulgaris lectin (PHA), and concanavalin A. As 65
specific examples, monoclonal anti-CD40 antibody, CD40
ligand, or interleukin-4 (IL-4) can efficiently activate resting
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B-cells (see Valle A, Zuber C E, Deffrance T, Djsou, et al.,
Activation of human B lymphocytes through CD40 and Inter-
leukin 4. Eur Jimmuno 19:1463-1467, 1991. Banchereau 7,
de Paoli P, Valle A, Garcia E, et al., Long term human B cell
lines dependent on Interleukin 4 and anti-CD40. Science
251:70-72, 1991. both incorporated herein by reference),
while interleukin-2 (IL-2) and concanavalinA can efficiently
activate T-cells (Berger S L, Lymphocytes as resting cells.
Methods in Enzymology. (eds) 7akoby W and Pastan I. Aca-
demic Press. Vol LVIII:486-494, 1979. Waxman 7 and Balk-
will. (eds) Interleukin-2. Blackwell Science Publications,
Oxford, 1992. both incorporated herein by reference).
Another factor that can affect the performance of selective
cell inactivation by electric fields on the basis of a difference
in a characteristic electroporation threshold based on cell size
is a concurrent difference in the dielectric membrane break-
down voltage, for example, due to a difference in the effective
membrane thickness, between cell types. In such cases, it can
be advantageous to add an agent to the cell suspension, prior
to or concurrently with electric field application, that can
modify (increase or decrease) the dielectric membrane break-
down voltage of one or more cell types. For example, for
applications where a larger, undesirable cell type possesses a
thicker effective membrane thickness than a smaller desired
cell type, as previously discussed, the larger cell having the
thicker effective membrane thickness will typically have a
higher critical dielectric membrane breakdown voltage and
thus require a larger electric field strength for inactivation
than a comparably sized cell having a thinner membrane.
Depending on the difference in characteristic size and effec-
tive membrane thickness between the two cell types, the
ability of the electric field to selectively porate the larger cells
while not affecting the smaller cells can be diminished or
eliminated. A specific example of an application where this
phenomenon may arise is in the use of PEFs for selectively
inactivating certain tumor cells from tissue samples or
hematopoietic cell suspensions. A variety of tumor cells, for
example many epithelial tumor cells, have associated with
their plasma membrane a relatively thick layer of muco-
polysaccharide, known as the glycocalyx, that can increase
the effective thickness of the membrane dielectric layer mak-
ing the cells less susceptible to the PEE. For applications
where this phenomenon is an important consideration, e.g.
when cell kills are substantially less than would be predicted
based on cell size alone, the performance of the PEE method
can be improved by removing the glycocalyx layer prior to
subjecting the cell suspension to the PEE treatment. Agents
that can be used for effectively reducing or eliminating the
glycocalyx layer on cell membranes include enzymes such as
hyaluronidase, collagenase, pronase, elastase, and trypsin
(Gruenert D C, Basbaum C B, and Widdicombe 7 H. Long-
term culture of normal and cystic fibrosis cells grown under
serum-free conditions, In Vitro Cell. Deu Biol. 26, 411-418,
1990. Lechner 7 F, Babcock M S, Mamell M, Narayan K S,
and Kaighn M E. Normal human prostate epithelial cell cul-
tures, Methods in Cell Biology, 21B, 195-225, 1980. Stamfer
M R. Isolation and growth of human mammary epithelial
cells, Journal of Tissue Culture Methods, 9, 107-115, 1985.).
Alternatively, an agent that preferentially increases the
dielectric membrane breakdown voltage of a desired cell type
could be used, in addition to or instead of the above men-
tioned agents, in some embodiments to make the cells less
susceptible to inactivation by electric fields.
In some embodiments, where it is desired to alter the appar-
ent membrane breakdown voltage or characteristic size of one
or more subpopulations of cells in a heterogeneous popula-
tion of cells, for example when the electroporation thresholds
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of desirable and undesirable cellular subsets are comparable,
such alterations can be effected by attaching material to cel-
lular subsets using antibodies that have immunospecificity
for the cells, especially monoclonal antibodies. For example,
metallic beads coated with a monoclonal antibody that can
bind the bead to a specific cell surface antigen can produce
two distinctly different effects depending upon the surface
density of the beads attached to the cell. If the surface density
of the attached beads is very high, such that an almost con-
tinuous layer of metallic beads exists on the surface of the
cell, then the resulting metallic structure will behave as a
Faraday cage, which will shield the cell from the effects of the
imposed electric fields. If the surface density of the beads on
the cells is low, however, then the each bead will behave as an
antenna, which can make the effective size of the cell larger,
thereby making the cells more susceptible to the lethal effects
of the imposed electric fields than implied by the original size
of the cell. Thus, agents, such as antibody coated metallic
beads, can be used to alter the electroporation thresholds of
specific cells, thereby enhancing PEE selection or inactiva-
tion characteristics.
Atypical stem cell, shown in FIG. 2a, also possess a unique
morphology that can make them less susceptible to poration
by electric fields than their size would suggest. Morphologi-
cally, stem cells are typically small in size (-6 µm in diameter
for hematopoietic stem cells) with a faint halo of cytoplasm
72 between the nuclear sack 74 surrounded by nuclear mem-
brane 73, and outer (plasma) membrane 71. The next larger
nucleated hematopoietic cells, resting lymphocytes (-7-8 µm
in diameter), typically have a much larger gap between their
nuclear and outer membranes. The arrangement of the stem
cell's nuclear 73 and outer membranes 71 being separated by
a very small distance can cause the nuclear 73 and outer
membrane 71 to become electrically coupled and to charge
together as one effective dielectric layer of thickness approxi-
mately equal to the sum of the thicknesses of the nuclear and
outer membranes. Provided the electric field pulse length is
small compared to the discharge time scale of the nuclear
membrane, electric field strengths considerably greater than
the value implied by the diameter of the stem cell and the
critical transmembrane voltage, V„ ^, for the outer membrane
71 will be needed to form temporary or irreversible pores in
stem cells. Specifically, for PEE pulse durations less than the
characteristic discharge time scale of the nuclear membrane
73, the critical electric field required for the onset of poration
would be:
E,o, —E,(tom+t„m)ltom 	 Eq. 16
where Ego P is the required electric field strength to porate the
cell for electrically coupled nuclear 73 and outer 71 mem-
branes, E, is the critical field strength as calculated from Eq.
7, tom is the effective thickness of the outer membrane 71, and
t„m is the effective thickness of the nuclear membrane 73.
FIG. 2b illustrates electrically the reasons the nuclear and
outer membranes of the stem cell can charge as one mem-
brane when the electric field pulse duration is small compared
to the discharge time scale of the nuclear membrane. The
poles 81, 82 of the cell are defined as those two points on the
surface of the cell which are closest to the electrodes impos-
ing the electric field. The membrane gap is defined as the
smallest distance between the nuclear and outer membranes.
The pole-to-pole membrane gap resistance 80 is the resis-
tance in the membrane gap between opposite poles of the cell.
The membrane gap resistance 77 is the gap resistance
between the inner and outer membranes. When the membrane
gap is very small, the membrane gap resistance 77 will be
much less than pole-to-pole membrane gap resistance 80.
This is typically the case for the stem cell. Under these con-
ditions the nuclear and outer membranes will charge together
as one membrane of thickness approximately equal to the
5 sum of the thicknesses of the nuclear and outer membranes.
When the gap is significant, which will be the case for most
other cells in the blood and immune system, the pole-to-pole
membrane gap resistance 80 is less than the membrane gap
resistance 77, and the nuclear membrane does not participate
io significantly in electric field effects, so that just the outer
membrane charges. If RPP is taken as the pole-to-pole mem-
brane gap resistance 80 and CPP is the capacitance of the dual
membrane system, then the discharge time scale of the
nuclear membrane will be no greater than tin_<RPPCPP. Pro-
15 vided the electric field pulse is significantly less than ti„m, the
nuclear and outer membranes will behave electrically as one
membrane of thickness equal to the sum of the nuclear and
outer membrane thicknesses (see Eq. 16) and during this
time, electric field strengths much greater than implied by the
20 diameter of the stem cell (see Eq. 7) will be required to form
irreversible pores. This effect can enhance the ability to iso-
late stem cells utilizing the PEE methods of this invention and
can reduce the need to activate cells that are close in size to the
stem cells in order to increase the difference in characteristic
25 size.
While the discussion above has been with respect to the
poration of larger cells to isolate or segregate stem cells which
typically have a smaller size, there are also applications where
it may be desirable to porate the stem cells. Heretofore, an
so effective technique for electroporating stem cells has not
existed. Poration of stem cells can be achieved according to
the present invention by initially using the PEE method to
isolate stem cells, and subjecting the isolated stem cells to an
electric field of appropriate magnitude for porating the stem
35 cells. For example, if the electric field pulse duration, tiP,
being utilized is less than T,_, then the appropriate magnitude
would be determined by employing Eq. 16 in combination
with Eq. 7; however, if the pulse duration is longer than ti„m,
then the appropriate magnitude would be determined by
40 employing Eq. 7. The objective in porating stem cells can be
reversible, non-lethal poration or irreversible poration to lyse
or kill the cells. One embodiment of the present inventive
methods can enable the temporary, reversible poration of the
stem cells to allow, for example, genetic material to enter the
45 stem cells, producing genetic mutations or recombinations
for gene therapy. The inventive stem cell transfection tech-
nique may be preferable to many currently employed tech-
niques, such as using viral transfection, since the PEE pora-
tion technique can enable the genetic material to enter a larger
50 percentage of the stem cells and can result in a higher survival
rate for the mutated stem cells. Such mutated stem cells can,
for example, be utilized in a variety of gene therapy tech-
niques, for cloning, or to provide immunity against specific
adverse biological agents such as viruses, bacteria, and vari-
55 ous toxins.
Since a variety of known methods exist for extracting
viable cells from mixtures containing viable/dead cells and
cellular debris, selective inactivation of cells by the methods
provided by the present invention represents a potentially
60 important step toward achieving high purity isolation. PEE
cell inactivation can, via post-PEF spontaneous cell lysis
(colloidal osmotic lysis), transform the PEE inactivated cells
into ghost membranes and free nuclei dispersed in the cellular
suspension. Single or multiple gradient centrifugation tech-
65 piques can then be used to separate the viable cells, and, if
desired, any residual intact non-viable cells, from the cellular
debris composed primarily of ghost membranes and free
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	nuclei. Viable cells can also be extracted from the PEF-treated	 one or more cell types, etc. For applications involving the
	
mixture of viable/dead cells and cellular debris by using cell
	
isolation of hematopoietic stem cells from blood or bone
	
sorting, e.g. FACS or flow cytometry, or antibody binding	 marrow, typically during this step, mononuclear cells are
	
strategies that are commercially available for a variety of cell 	 purified from the sample from step 1 by using a standard
types. Alternatively, if the population of selected viable cells 5 Ficoll-Paque density gradient centrifugation technique, fol-
	
are to be expanded, there may be no need to remove the 	 lowed byACK (product 10-548, BioWhittaker, Walkersville,
	
post-PEF non-viable cells and debris, since the expansion 	 Md.) lysis of residual erythrocytes. The mononuclear cells are
	
process can produce a post-expansion population of viable 	 then washed and resuspended in an appropriate pulsing
	
cells that will render insignificant the relatively small num- 	 buffer. Optionally, an activating agent, such as those men-
bers of inactivated cells and residual cellular debris, or the io tioned previously, may be added to the suspension to activate
	
debris will simply decompose during the expansion culture.	 resting lymphocytes, or, if tumor cells having a thick glyco-
	
FIG. 3 presents a flow chart summarizing the steps of a 	 calyx layer are present, an enzyme may be added to at least
	
typical PEE cell isolation strategy according to the invention. 	 partially remove this layer.
	
It should be reemphasized that for any given cell suspension 	 The third step 63 of the method 60 involves subjecting the
and desired cell isolation or inactivation, the PEE parameter 15 cell suspension to the pulsed electric field. Electric field
	
values for optimal performance must be selected based on 	 strengths and durations may be selected for this step that are
	
routine experimentation and optimization with guidance 	 sufficient to cause irreversible poration and inactivation of the
	
from the theoretical development presented previously. The 	 porated cells, or alternatively, that are sufficient to reversibly
	
general procedures described below may be employed both 	 porate but not inactivate porated cells. For some purposes, the
during screening tests to determine optimal PEE parameters 20 PEE treated cell suspension produced during this step is in a
	
for cell isolation, and during actual cell selections with pre-	 final, usable form; however, for many applications, additional
determined optimal parameters. 	 post-PEF steps are required or desirable for attaining a final
	
Initially, before the beginning of the procedure, PEE oper- 	 cell suspension.
	
ating parameters (e.g. electric field strength, total exposure 	 The fourth step 64 of the method 60 is an optional step
time, pulse duration and frequency, etc.) are selected as 25 performed to inactivate cells that are porated but not inacti-
	
described previously based, in part, upon a difference in a 	 vated in the previous step 63. This step 64 is typically
	
characteristic electroporation threshold difference between	 employed for embodiments where the PEE parameters cho-
	
desired and undesired cells (determines choice of electric 	 sen in step 63 are sufficient to porate but not inactivate the
	
field strength) and a desired degree of cell inactivation (deter- 	 undesired cells; however, the step may also be employed for
mines choice of exposure time). The first step 61 of the 30 embodiments utilizing PEE conditions selected for inactiva-
	
procedure 60 is to prepare the cell suspension. The cell sus- 	 tion in order to, for example, increase the total fraction of cells
	
pension is prepared by uniformly dispersing and suspending	 inactivated, speed up the inactivation process, or physically
	
cells in a physiologically compatible, conductive medium. In 	 disrupt the structure of the inactivated cells by irreversible
	
some cases, e.g. blood, the sample to be treated may already 	 lysis. As previously discussed, the methods of this step typi-
be suspended in a suitable medium, in other cases, e.g. cells 35 cally involve resuspending the PEE treated cells in an inacti-
	
from solid tissue or organs, the cells may need to be dispersed	 vation medium, or adding one or more supplemental agents to
	
and resuspended in a suitable medium. The viability, concen-	 the PEE medium to create an inactivation medium in situ,
	
tration and identity of the cells present in the pre-PEF treated
	
designed to accelerate colloidal osmotic lysis, prevent cell
	
suspension can be determined by a variety of methods known 	 membrane repair, or both. As previously discussed, the inac-
in the art. Viability, for example, for many cells, such as 40 tivation medium for use in this step typically will have one or
	
mammalian cells, can be determined by trypan blue dye 	 more of the following properties: a higher ionic strength than
	
exclusion. Concentration may be determined by manual or 	 the pulsing medium; a higher osmolality than the pulsing
	
automated cell counting techniques, for example manual	 medium; a lower temperature than the pulsing medium; or an
	
counting with a hemacytometer, or automated counting by 	 agent (e.g. Ca") that specifically promotes colloidal osmotic
light scattering techniques. Individual cell types can be enu- 45 lysis of porated cells.
	
merated and marked for further tracking by standard immu- 	 The fifth step 65 is an optional step performed to remove
	
nophenotyping techniques known in the art, such as by using	 inactivated cells and cellular debris from the suspension con-
	
cell-specific dyes or dye-labeled antibodies (e.g. fluores- 	 taining viable PEE isolated cells. This step can be performed
	
cently labeled antibodies) that have specificity for certain cell 	 by a variety of techniques apparent to the skilled artisan,
surface antigens specific to certain cell types. The labeled 50 including, but not limited to centrifugation, filtration, and
	
cells can then be quantified by standard techniques, for	 adsorption. In some embodiments, suitable agents may be
example, fluorescence microscopy or flow cytometry. 	 added in order to break up or reduce cellular debris, such
	
The second step 62 of the procedure 60 includes various	 agents including, for example DNase, trypsin, or other
	
optional pre-treatment methods, or pre-PEF cell separations,	 enzymes. For applications involving hematopoietic cell iso-
used to enhance the performance of the PEE treatment. A 55 lations, after PEE treatment, the stem cell enriched suspen-
	
variety of such methods were discussed previously and 	 sion is typically subjected to a Ficoll-Paque gradient density
	
include: isolation of a subpopulation of cells by cell separa- 	 centrifugation to remove inactivated cells and cellular debris.
	
tion methods such as centrifugation, for example, density	 For selected applications, it may be desirable to further
	
gradient centrifugation; osmotic cell lysis of red blood cells; 	 purify, isolate or treat a subpopulation of cells from the PEE
cell affinity chromatography; fluorescence activated cell sort- 60 treated cell suspension. Such secondary, or supplemental cell
	
ing (FACS); etc. Other treatments that can be employed at this 	 separation or other treatments comprise an optional sixth step
	
step include treatments designed to enhance a difference in 	 66. Any of the previously mentioned cell separation tech-
	
characteristic electroporation threshold, such as: hypotonic 	 niques can potentially be employed for this step. In some
	
swelling of the cells; treatment with an agent to remove a 	 cases, the secondary purification may be used to further
glycocalyx layer from one or more cell types to reduce the 65 enrich or purify the subpopulation initially isolated by PEE
	
effective membrane thickness; treating the cell suspension	 treatment, while in other cases, the secondary isolation may
	
with an activating agent to increase the characteristic size of
	
involve separating a sub-subpopulation of cells from the PEE
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isolated subpopulation, which sub-subpopulation may not be 	 the PS on the inside of the plasma membrane, since this stain
distinct with respect to a critical electroporation threshold. 	 has access to the inside of the cell due to membrane disrup-
Such a secondary separation is potentially useful, for 	 tion. Thus, ghost cells should have a bright Annexin-V fluo-
example, for applications where it is desirable to separate a 	 rescence signature. Therefore, gating based on both PI and
particular type of progenitor cell from a PEF isolated stem 5 Annexin-V has been found by the investigators to give the
cell suspension. As previously discussed, preferred stem cell
	
best screening for viable cells. Additional markers specific to
suspensions isolated by PEF can contain a variety of different 	 cancer cells can also be included for applications involving
lineage committed colony forming cells in addition to the 	 cancer cell purging.
pluripotent cells. One or more of these cell sub-types may be	 While the above description in association with FIG. 3 is
isolated by, for example, FACS by utilizing one or more io intended to illustrate some representative methods and strat-
labeled antibodies with immunospecificity to cell surface 	 egies for performing the inventive cell isolations, it should be
markers present on particular cell sub-types. 	 understood that the above description is only illustrative and
The final optional seventh step 67 comprises any treat- 	 exemplary, and that the invention can be performed otherwise
ments that are performed on or using the PEF treated cell 	 than described above without departing from the spirit and
suspensions. Such treatments can include, for example, 15 scope of the invention as presented in the appended claims.
expansion and/or differentiation of the selected cells by in 	 Also, the above description presents and describes various
vitro cell culture techniques, transfection or other genetic 	 methods and techniques that can for certain embodiments and
modification of selected cells, etc. For example for applica- 	 applications be associated with the invention; however, addi-
tions involving the isolation of stem cells, since the fraction of 	 tional or substitute methods may be used as apparent to the
stem cells present in a typical pre-treatment sample is very 20 skilled artisan, and details and descriptions that, in some
small (about 1:106 in bone marrow aspirate), depending on 	 cases, may be necessary to perform the invention but that are
the volume of sample processed, the final quantity of isolated
	
known or available to those skilled in the art are not neces-
stem cells may not be sufficient to engraft a patient (typically 	 sarily included or described herein.
about 106 CD34' cells/kg body weight are required). In such 	 The inventive electric field cell/discrete object isolation/
cases, the quantity of stem cells can be amplified through 25 inactivation methods can potentially be performed using a
standard stem cell amplification and expansion techniques 	 wide variety of electroporation equipment known in the art
(Zandstra, A. 7., et al. `Advances in hematopoietic stem cell 	 (see for example: Gene Pulser II, BioRad, CA; ECM-2001,
culture," Curr Opin Biotechnol 9:146-151(1998)). Cell cul- 	 BTX, CA; Multiporator, Eppendorf, NY, Electroporator II,
ture techniques can also be employed to activate the isolated 	 Invitrogen, CA; PA-4000, Cytopulse, MD). Although there
stem cells to differentiate along desired lineage paths, thus 3o are numerous electroporation systems available, they are not
increasing the number of committed progenitor cells rein- 	 ideally suited for cell selection/inactivation discussed herein
fused into a patient. An additional post-PEF isolation treat- 	 because they have been designed for electroporation or elec-
ment that can optionally be performed on the isolated stem	 trofusion applications for which cell preservation is key, not
cells, for example for gene therapy applications, is reversible 	 cell inactivation. They are also typically not capable of pro-
poration and transfection of the cells with genetic material 35 cessing the number of cells appropriate for either research or
using PEFs to electroporate the stem cells. 	 clinical implementations of the cell selection/inactivation
In most applications, and especially when screening to 	 strategies discussed herein, since they are limited by the elec-
determine optimal PEF parameters, it is desirable to charac-	 tric field pulse energies they can deliver. FIG. 4 shows one
terize the post-PEF treatment cell suspension with regard to 	 embodiment of a batch system 85 including elements useful
cell quantity, cell viability, and cell identity in order to evalu-  40 for performing the inventive PEF methods. The main compo-
ate performance. The techniques described for characterizing	 nents of the illustrated system are: an electric field pulse
the pre-treatment suspensions can also be employed to char- 	 driver 101, which applies voltage pulses to the PEF electrode
acterize the post-treatment populations. From comparison of 	 enclosure assembly 95 (which includes the PEF treatment
the pre- and post-treatment cell suspensions, yield, selectiv- 	 cell); a power supply 102, which can be external or internal to
ity, enrichment, and depletion determinations can be inferred. 45 the pulse driver; an optional oscilloscope 103 for electric field
The inventors have found that for analyzing post-PEF sus- 	 waveform monitoring; a trigger generator 104; and a control/
pensions of hematopoietic cells, an effective and convenient	 data acquisition system 105, preferably including a computer,
method to simultaneously determine cell viability, cell apo-	 for controlling the system and gathering and processing data.
ptosis, and cell concentration, and cell identity, is to stain the 	 The control/data acquisition system 105, trigger generator
post-PEF cells obtained after the third step 63 or the fifth step 50 104, oscilloscope 103, power supply 102, and pulse generator
65 above with a combination of propidium iodide, Annexin- 	 101 are electrically coupledvia appropriate electrical connec-
V, and fluorescently labeled antibodies specific to CD3,	 tions 106, and together comprise an electric field generating
CD14, CD19, CD45, CD34, and CD38 cell surface markers. 	 mechanism 90. The pulse driver 101 of the generating mecha-
These cell specific fluorescently labeled markers allow enu-	 nism 90 is electrically coupled to the PEF electrode enclosure
meration of lymphocytes (CD3+, CD45+), monocytes (CD 55 assembly 95 via cathode connecting line 100 and anode con-
14+, CD45+), primitive progenitor cells (CD34+), and cer- 	 necting line 99. Also included in the overall system 85 is an
tain hematopoietic stem cells (CD34+, CD38—). The viability 	 optional forced circulation cooling system 98 which forces
stain propidium iodide is a DNA stain. Thus for cells with 	 cooling fluid through the PEF electrode enclosure assembly
disrupted membranes, yet still containing a nucleus, this dye 	 95 through lines 96 and 97 to remove heat from the treatment
will stain non-viable cells. Annexin-V, however, stains phos- 60 cell that is generated by the electric field and for controlling
phatidylserine (PS) which migrates from the inside to the 	 the temperature of the treatment cell.
outside of the plasma membrane during normal apoptosis. 	 The PEF electrode enclosure assembly 95 of system 85 is
Thus it is normally used as an indicator of apoptotic, not yet	 shown in greater detail in FIG. 5. The electrode enclosure
non-viable cells. Whether or not the PS migrates to the exter- 	 assembly 95 includes a PEF treatment cell 110 that is
nal surface of the cell as a result of PEF treatment is unim- 65 designed to physically mate with cathode 114 and anode 112.
portant. What is important is that should PEFs result in the 	 FIG. 5 is a cross-sectional view of the PEF electrode enclo-
discharge of the nucleus from the cell, Annexin-V will stain 	 sure assembly 95 takenby slicing the PEF electrode enclosure
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assembly 95, as oriented in FIG. 4, into the plane of the
drawing. The PEE electrode enclosure assembly 95 also
includes an annular enclosure 122 that is sealingly mated to
the top plate 113 and bottom plate 111. Top plate 113 and
bottom plate 111 are connected to each other at spaced inter-
vals using a plurality of spacer rods 120 which are transversed
by a threaded rod 126 with threadingly attached nuts 121
which may be tightened to securely connect the top 113 and
bottom 111 plates, or loosened and removed for disassembly
of the PEE electrode enclosure assembly 95. Annular enclo-
sure 122 circumscribes and defines an enclosed space 123
that may be evacuated via evacuation port 125 or pressurized
with a gas via pressurization port 124 in order to more thor-
oughly insulate the electrical components of the assembly.
The treatment cell 110 and cathode 114 is supported by a
fluid-cooled cathode support rod 115 that includes cooling
fluid channels 116 and 117. The anode 112 also preferably
includes fluid cooling channels 118 and 119 to provide addi-
tional heat removal capacity from the treatment cell 110. The
fluid cooling channels are in fluid communication with forced
circulation cooling system 98 shown in FIG. 4. Forced circu-
lation cooling system 98 is preferably sized and designed to
maintain the cathode 114 and anode 112 at a selected tem-
perature controlled to +/-0.1 degrees C. over a temperature
range of at least 4-50 degrees C. Heat removal and tempera-
ture control of the pulsing medium is effected by conductive
heat transfer from the medium to the temperature controlled
anode 112 and cathode 114. The PEE electrode enclosure
assembly 95 should be constructed with appropriate seals so
that enclosed space 123 can be maintained under high
vacuum without significant leakage. The PEE electrode
enclosure assembly 95 can be constructed from a variety of
materials apparent to one of skill in the art. The anode assem-
bly 112, and cathode 114, should be constructed from con-
ducting materials such as metals. In one particular embodi-
ment, the cathode 114 and anode 112 are constructed of
copper. In some preferred embodiments, anode assembly 112
is removable from bottom plate 111 to allow easy access and
removal of test cell 110 without the need to disassemble the
entire PEE electrode enclosure assembly 95. The top 113 and
bottom 111 plates can be constructed of any strong stiff
material. Preferred plates are constructed from an insulating
material such as a strong plastic, for example Lexan. Annular
enclosure 122 is preferably constructed from a transparent
material such as plexiglass.
The static test cell 110 is shown in exploded view in FIG. 6.
The test cell comprises an anode end block 131, which mates
to anode 112 via element 138, a cathode end block 132, which
mates to cathode 114 via element 144. Each end block
includes a plate 137, which is circular in the illustrated
embodiment, and a plurality of holes 136 through which
connecting elements pass in order to assemble and seal the
treatment cell 110. The end blocks are in contact with plate
electrodes 133 and 134 which are in turn separated by the
fluid containing annular spacer 135. Annular spacer 135
includes a channel 139 that, when the treatment cell 110 is
assembled, provides a passage in fluid communication with
an internal volume 140 defined by the annular wall 141 of the
spacer 135 and the planar walls 142 of plate electrodes 133
and 134. In operation, the cell suspension to be treated is
inserted and removed from the treatment volume 140 via
channel 139. The treatment cell 110 is sized to provide a
treatment volume having a desired total volume. Small scale
experimental systems typically have a treatment volume of
about 1-5 ml, while large scale clinical devices preferably
have a treatment of 0.1-1 liter.
End blocks 131 and 132 can be constructed of any suitable
conducting material. Preferred end blocks are constructed
from metal. Particularly preferred end blocks are constructed
from copper and subsequently gold plated, or are constructed
5 from tungsten. Annular spacer 135 is constructed from an
insulating material that is preferably biocompatible. A pre-
ferred material for constructing the annular spacer 135 is
tempered glass (e.g. Pyrex(k glass). Electrodes 133 and 134
can be constructed from any suitable conducting material,
io with preferred electrodes being constructed from conducting
materials that are biocompatible and which do not release
toxic amounts of electro -catalyzed reaction products during
application of the electric field to the sample. Particularly
preferred electrodes 133 and 134 are constructed from graph-
15 ite carbon. For embodiments utilizing porous graphite elec-
trodes 133 and 134, the electrodes are preferably degassed
after introduction of a pulsing medium or cell suspension into
test cell 110 so that bubbles are not released from the elec-
trodes into the medium during application of the PEFs.
20 Degassing can be accomplished by a variety of methods
apparent to the skilled practitioner, for example the pulsing
medium can be added to the assembled test cell 110 at sub-
ambient temperature and subsequently heated to ambient or
physiological temperature to release gas bubbles, or the puls-
25 ing medium can be added to an assembled treatment cell 110
maintained under vacuum during the adding step. A particu-
larly preferred electrode arrangement that can reduce or
eliminate the release of bubbles trapped in the porous matrix
is constructed from graphite which is subsequently sealed
so with a sealing agent so that the surfaces 142 in contact with
the pulsed suspensions are rendered essentially non-porous.
In preferred embodiments, the porous matrix is sealed with a
thin layer of pyrolytic carbon. The test cell 110 is also pref-
erably constructed and arranged so that an essentially spa-
35 tially uniform electric field is applied to the treatment volume
140. During use, it is important that the suspension undergo-
ing treatment completely fill treatment volume 140 so that
there is no meniscus that can distort the electric field distri-
bution. Also, preferred treatment cells 110 are constructed
4o and lapped to have very smooth mating surfaces on compo-
nents 131, 133, 135, 134, and 132, so that when assembled,
the treatment cell 110 is fluid tight without the need for
supplemental seals, such as washers or O-rings.
A schematic diagram of a preferred continuous flow PEE
45 system 150 is illustrated in FIG. 7. The system includes a
flow-through treatment cell 151 having two electrodes 152
and 153 in fluid contact with a flowing suspension being
treated that enters the treatment cell 151 through line 168 and
exits through line 169. The electrodes 152 and 153 are elec-
50 trically coupled to a generating mechanism 90, which can be
essentially identical in arrangement as that previously
described. System 150 also includes pump 160 for pumping
cell-free pulsing medium through the system, and pump 161
forpumping a cell suspension throughthe system. Pumps 160
55 and 161 pump fluid via lines 162 and 163 respectively, into
line 164, which is in fluid communication with three-way
valve 165. Three-way valve 165 can be set to direct the
pumped fluid to the treatment cell 151 via line 168 or to a
waste container 167 via line 166. Pulsing medium or treated
60 suspension exiting the treatment cell 151 via lines 169 and
172 can be controllably directed to a sample container 177 via
line 176 or a waste container 175 through adjustment of
three-way valve 173. Particularly preferred embodiments of
system 150 also include a supplemental pump 170 which
65 controllably pumps a desired substance into the stream of
PEE treated cells via line 171. The desired substance can be a
variety of materials useful in the fourth step 64 through the
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sixth step 66 of the exemplary procedure 60 discussed previ-
ously in reference to FIG. 3. For example, the substance
supplied by pump 171 can be DNase or be Trypsin, added to
inactivate released DNA and reduce cellular debris, or a
medium added to raise the ionic strength and/or osmolality of
the suspension in order to accelerate or bring about inactiva-
tion through colloidal osmotic lysis. The system as arranged
allows the treatment cell 151 to be initially primed with
pulsing medium before addition of cell suspension, and also
allows the treated suspension to be diverted to waste until
optimal PEF conditions are established. Also optionally
included in the system 150 but not shown are mechanisms
downstream of the treatment cell 151 for removing inacti-
vated cells or cellular debris, such as filters or flow cytom-
eters. In addition, for some embodiments, it may be advanta-
geous to provide a cooling system, such as system 98 in FIG.
4, to remove heat from the flow-through treatment cell 151.
The preferred flow-through treatment cell 151 includes
graphite electrodes constructed from similar material as dis-
cussed for electrodes 133 and 134 previously. The electrodes
can be enclosed in a flow chamber constructed of an insulat-
ing material such as a plastic, or preferably, Pyrex glass. The
electrodes 152 and 153 are elongated in shape and are posi-
tioned so that their long axis is parallel to the direction of fluid
flow and have extended planar surfaces 154 and 155 in con-
tact with the fluid in treatment volume 178. The electrodes are
preferably constructed and arranged so that the electric field
applied to the fluid in treatment volume 178 is substantially
spatially uniform and so that the electric field strength
upstream and downstream of the main electric field treatment
region (the region bounded by the portion of the electrodes
152 and 153 that have surfaces, which are in contact with the
cell suspension during operation, that are essentially parallel
to one another) essentially never exceeds the strength in the
main electric field treatment region. In order to accomplish
this, preferred electrodes include contoured regions 156 and
157 (scale exaggerated in the Fig.) adjacent the inlet and
outlet regions of the test cell 151. Well established electrode
profiles exist (e.g. Rogowski, Ernst, or Chang profiles) that
can be implemented to obtain the purpose of contours 156 and
157. The treatment volume 178 of the test cell 151 is defined,
for rectangularly shaped test cells, as the product of the length
179, the gap width 195, and the height h (into the plane of the
figure and not shown) so that vTV-1 w h, where vTV is the total
volumetric capacity of treatment volume 178,1 is the length of
the test cell 151, and w is smallest gap width 195 between
electrodes 152 and 153. These dimensions are chosen for a
particular application to yield a desired volumetric through-
put having a desired total treatment residence time in the
treatment volume 178 and a shear rate below the value that
can cause damage to the cells. For a test cell having an
essentially uniform rectangular cross-section for flow, the
average residence time tires of fluid in the treatment volume
vTVis:
TY =VTVIU_lWh/u	 Eq. 17
where a is the volumetric flow rate of the fluid. The maximum
laminar shear rate F can be approximated by:
F-2u(w+h)/(w h)' 	 Eq. 18
The treatment cell dimensions and throughput flow rate
should be selected to provide a desired total exposure time t to
the electric field for a given applied pulse duration, ti P, and
pulse frequency F. For example, if the desired total treatment
time is t, then the necessary pulse frequency would be:
T=(u t)/(l w hT,)	 Eq. 19
For one exemplary embodiment of treatment cell 151, length
179 is 37.3 mm, the gap width 195 is 8 mm, and the height
(into the plane of the figure) is 4 mm.
Startup and operation of the flow-through system 150 can
5 proceed as follows. The system, in this exemplary embodi-
ment, employs syringe pumps for pumps 160, 161, and 170.
With pump 160 loaded with cell-free pulsing medium, pump
161 loaded with the cell suspension to be treated, and pump
170 loaded with pulsing medium supplemented with DNase,
io three-way valve 165 is positioned to direct fluid to the treat-
ment cell 151, and three-way valve 173 is positioned to direct
fluid to waste container 175, and the lines and treatment cell
151 is flooded with pulsing buffer by activating pump 160 in
order to remove bubbles from the system. Next, pump 160 is
15 stopped, three-way valve 165 is repositioned to direct fluid to
waste container 167, and pump 161 is activated to pump cell
suspension to waste container 167 in order to remove any
bubbles from line 163. Three-way valve 165 is then switched
to direct the cell suspension to the treatment cell 151 and the
20 generating mechanism 90 is activated to apply PEFs to the
treatment volume 178. As soon as it is determined that the
system is functioning properly, three-way valve 173 is posi-
tioned to direct the treated cell suspension into cell collection
container 177. When a desired quantity of cell suspension has
25 been processed, pump 161 is shut off and the generating
mechanism 90 is switched off. Pump 170 may be operated as
desired during PEF treatment to add DNase to the treated cell
suspension to prevent coagulation of any cellular debris. The
sequence of events just described is preferably computer con-
30 trolled and pertinent PEF system data is automatically col-
lected and stored by a data acquisition system. In alternate
embodiments of flow through system 150, instead of passing
through the treatment cell 151 only once, the cell suspension
can be recycled back to the inlet of the treatment cell for a
35 plurality of PEF treatments. Also in some embodiments,
instead of supplying a pulsed electric field to the treatment
volume 178, the field is maintained at an essentially constant
value during the PEF subjecting step, and the average expo-
sure time of the cells in the suspension is simply the average
4o residence time of the cells in the treatment volume 178 deter-
mined by the suspension flow rate.
Pulse driver 101 (see FIG. 4) for use in systems 85 and 150
can be any suitable pulse driver known in the art that is
capable of producing pulsed electric fields within the PEF
45 treatment volume of sufficient magnitude and duration for
inactivating discrete objects of interest. Preferred pulse gen-
erators are able to induce an electric field magnitude of at least
about 5 kV/cm, more preferably at least about 10 kV/cm, and
most preferably at least 20 kV/cm in the treatment volume.
50 Preferred pulse generators are able to supply an electric field
pulse duration above a set point electric field strength of
between about 2-20 µs at pulse frequencies between about 0
to 10 kHz. Preferred pulse drivers are able to produce a
substantially rectangular pulse shape, as previously dis-
55 cussed, with rise and fall times not exceeding about 0.5 µs.
Preferred pulse driver mechanisms also include control cir-
cuitry to allow the maximum pulse voltage to be controllable
by the user and to terminate pulsing upon detection of an
electrical short circuit or arc. While pulse drivers based on gas
60 switches, such as thyratrons and spark gaps, can be employed
for use in the invention, because of their typically superior
durability and reliability, pulse drivers based on all-solid-
state switch technology are preferred.
Design specifications for the pulse driver are determined
65 from the required maximum applied electric field strength,
maximum required electric field pulse duration, the size of the
treatment volume, and the electrical resistivity of the suspen-
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sions being treated. The pulse driver for use in a particular
application must be designed to supply a maximum pulse
energy, eP (Joules/pulse), determined by:
,,-,, ,El p,,	 Eq. 20
where tiP is the maximum pulse duration, v,,is the treatment
volume, E is the maximum required electric field strength,
and pp, is the resistivity of the sample being treated. For
impedance matched conditions, the load voltage, V i, is one-
half the maximum charge voltage of the pul se driver. The load
voltage requirements of the pulse driver can be determined
by:
ViE w	 Eq. 21
where E is the maximum required electric field strength, and
w is the distance between the electrodes (see FIG. 7). The
resistance load of the treatment cell which the pulse driver
must be able to handle is determined by:
R=pp,W21V7V 	 Eq. 22
where R is the impedance load (62), pp, is the resistivity of the
sample being treated, w is the distance between the elec-
trodes, and v,v is the treatment region volume.
FIG. 8 is a block diagram of one embodiment of a pulse
driver system 180 for use in the inventive PEE systems. The
pulse driver 180 produces the substantially rectangular bipo-
lar pulse shown in FIG. 9. The bipolar rectangular pulse
shown in FIG. 9 has short rise 201 and fall 202 times sepa-
ratedby flatregions 203 of substantially constant voltage. The
trailing opposite polarity segment 204 of the waveform serves
to reduce and/or reverse electrochemical reactions that oth-
erwise can produce hydrogen and chlorine bubbles, which
can degrade performance and affect suspension pH. In other
embodiments, instead of supplying a bipolar pulse as shown
in FIG. 9, the pulse generator may instead supply a 30 uni-
polar pulse, as shown in FIG. 10, while simultaneously sup-
plying a reverse polarity DC current properly matched to
essentially equal the time-averaged current of the electrical
field pulses. The pulse shape shown in FIG. 10 is not substan-
tially rectangular in shape but is instead in the shape of a half
sine-wave. As previously discussed, such pulse shapes will, in
general, yield poorer electroporation threshold selectivity
than more rectangularly shaped pulses.
The pulse driver system in FIG. 8 that produces the wave-
form shape shown in FIG. 9 includes two pulse driver circuits
205 and 206, one 205 for a positive polarity voltage pulse, the
other 206 for a trailing, negative polarity pulse. Each of the
pulse drivers includes a DC power supply (182 and 183), a
storage capacitor 184, and a stack of integrated bipolar tran-
sistors (IGBTs) 185 and 187, which are solid state switches
that apply the electrical energy stored in the storage capaci-
tors 184 to the PEE treatment cell 191. The IGBTs each
include a switch stack and gate trigger 186, 188, and a diode
189, 190 on the output line. The IGBTs are stacked in series
and parallel combinations to provide enhanced voltage and
current capabilities. Power is supplied to the pulse driver
system from a source 181 of facility line power. Preferred
pulse driver systems also include circuitry 193 for process
control and circuitry 192 for system diagnostics and data
acquisition as known in the art. In preferred embodiments, the
electric field strength developed in the PEE treatment cell 191
is determinedby circuitry 192 for system diagnostics and data
acquisition by use of a calibrated high voltage probe/oscillo-
scope system. The current waveform can be measured using
a Pearson coil and is, in preferred embodiments, recorded on
the same oscilloscope as the voltage waveform. The time
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integrated product of the current and voltage waveforms can
then be used to determine pulse energy. Pulse energy thus
determined, together with measurements of the pulse repeti-
tion frequency and the temperature of the electrodes in the
5 treatment cell 191 can be used, together with a heat transfer
mathematical model describing the heat transfer characteris-
tics of the treatment cell 191, to calculate the temperature
evolution of the pulsed suspension. Alternatively, the tem-
10 
perature of the pulsed suspension can be directly measured in
a plurality of locations within the treatment volume with
suitable temperature probes or thermocouples. Diagnostic
192 and control 193 systems also, in preferred embodiments,
include one or more computer elements, for example inte-
15 grated personal computers, to control system operation and
perform data reduction and analysis.
The function and advantage of these and other embodi-
ments of the present invention will be more fully understood
from the examples below. The following examples are
20 intended to illustrate the operation of the present invention,
but not to exemplify the full scope of the invention.
EXAMPLES
25
Introduction
The experimental examples that follow, presented as five
separate cases, demonstrate pulsed electric field cell-size
selectivity, hematopoietic primitive progenitor cell enrich-
30 ment, and tumor cell purging. Two PEE cell-size selection
examples are presented (Cases I and 2). In Case I PEFs were
applied to a suspension of peripheral blood mononuclear cells
resulting in a step-wise reduction in size distribution of the
35 PEE treated viable cells as a function of electric field strength
and total electric field exposure time. In Case 2 PEFs were
applied to a suspension of peripheral blood mononuclear
cells, illustrating lymphocyte enrichment by selective inacti-
vation of monocytes in PEE treated specimens as a function of
40 electric field strength and electric field exposure time. Case 3
illustrates the enrichment of hematopoietic stem cells in PEE
treated peripheral blood progenitor cell specimens. In Case 3,
PEFs were applied to mobilized peripheral blood specimens
harvested from a patient by leukopheresis. Case 3 illustrates
45 the dependence of stem cell enrichment on electric field
strength for a fixed electric field exposure time. Two cases are
presented that illustrate PEE tumor cell purging (Cases 4 and
5). In Case 4, PEFs were applied to a suspension of peripheral
blood mononuclear cells seeded with a megakaryocyte tumor
50 cell line (CMK). This case illustrates the selective inactiva-
tion of the tumor cells with simultaneous preservation of
lymphocyte and monocyte cells as a function of electric field
strength and fixed total electric field exposure time. In Case 5
PEFs were applied to a suspension containing only mammary
55 gland breast tumor cells (MCF-7). This case illustrates the
PEE inactivation characteristics of this breast tumor line as a
function of electric field strength, pulse duration, and total
electric field exposure time. The examples given by Cases 1-5
were performed under non-optimized PEE conditions. Thus,
60 these results represent a lower end demonstration of the capa-
bility of the PEE cell selection strategy.
Methods and Materials
65 The methods and materials for the five example cases are
given together below and are broken into three categories: cell
preparations, cell assays, and PEE apparatus.
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Cell Preparations	 the supernatant was aspirated, and the resulting pellet was
Four cellular systems were used in the example cases:	 resuspended in the desired pulsing buffer.
peripheral blood mononuclear cells (PBMCs), mobilized 	 For Case 4, PBMCs, prepared as described above for Cases
peripheral blood mononuclear cells (hereafter referred to as 	 1, 2 and 4, were seeded with a megakaryocyte tumor cell line
peripheral blood progenitor cells, (PBPCs)), megakaryocyte 5 (CMK, Sato T. et al., Br. J. Haematol. 1989 June; 72(2):
tumor cells (CMKs), and mammary gland breast tumor cells 	 184-90). For Case 5, a suspension containing only mammary
(MCF-7s).	 gland tumor cells (MCF-7, ATCC no. HTB-22) was exposed
PBMCs were used in Cases 1, 2, and 4. The PBMCs were 	 to PEFs. Preparation of the MCF-7s for PEE treatment is
obtained from healthy donors by harvesting approximately 	 described below with modifications to the procedure for the
60 ml of peripheral blood per test day by venipuncture io CMK line noted. MCF-7 (ATCC no. HTB-22) cells were
through a 21G, 1 inch needle (Beckton Dickinson, 305175) 	 thawed under the following conditions. A vial of cells was
into a syringe (Beckton Dickinson, 309663) containing 1 ml	 thawed at 37° C., then transferred to a 50 ml tube (Fisher,
Heparin (5000U, Elkins-Sinn, Inc., A-0400H). The PBMCs	 14-959-49A) containing 30 ml of 1 x Iscove's medium with-
cells were separated from the whole blood using standard 	 out glutamine (IMDM, Fisher, MT15 016LV) and centri-
density gradient centrifugation techniques. Under sterile con-  15 fuged at 1500 RPM for five minutes at room temperature. The
ditions, the blood was diluted with twice its volume with 1 x 	 supernatant was discarded and the pellet was resuspended in
phosphate buffered saline (PBS, Mediatech, 21-031-CV) and 	 20 ml of MCF-7 culture-medium and cultured at 37° C., 5%
then aliquoted (30-40 ml) into 50 ml conical centrifuge tubes. 	 CO2 . The MCF-7 culture medium used was lx Dulbecco's
Ficoll-Paque (Pharmacia Biotech, 17-0840-03) was slowly 	 modification of Eagle's medium, without glutamine, includ-
dispensed into the bottom of each centrifuge tube, and the 20 ing 4.5 g/L glucose, and supplemented with 2 mM
tubes were centrifuged (IEC, Centra GP8R, rotor no. 228) at 	 L-glutamine (Fisher/Cellgro, MT-25-005-LI), 50 I.U./ml of
2000 RPM for 30 minutes with the brake off. The PBMCs at 	 penicillin, and 50 µg/ml streptomycin (Fisher/Cellgro,
the density interface were collected by aspiration with a 5 ml 	 MT-300-01-LI) and 20% FCS. The cells were split upon
pipet. The recovered PBMC layers were combined into a 	 reaching confluence, typically every three to four days, as
single 50 ml centrifuge tube. The resulting PBMC suspension 25 follows. Culture supernatant was aspirated and replaced with
was then diluted l Ox using PBS, aliquotting into as many 50 	 5-6 ml of trypsin (2.5 g/L 1:250 in HBSS without calcium or
ml centrifuge tubes as required, followed by centrifugation at 	 magnesium, Fisher/Cellgro, 25-050-11). After incubation at
1500 RPM for 5 minutes. The supernatant was aspirated, and	 room temperature for 5 minutes, the flask was rinsed using 10
one pellet was resuspended in 10 ml PBS. This 10 ml suspen- 	 ml of 1 x Dulbecco's Phosphate buffered saline without cal-
sion was then used to resuspend the pellets of all remaining 30 cium or magnesium (PBS, Fisher/Cellgro, MT-21-031-CV)
tubes. PBS was then added to the resulting suspension, bring- 	 supplemented with 1% fetal calf serum (FCS, Sigma,
ing the total volume to 50 ml. This 50 ml suspension was 	 T-2442). The rinse solution was then transferred to a 50 ml
centrifuged at 1500 RPM for 5 minutes; the supernatant was 	 tube, and the volume was made up to 50 ml with PBS, supple-
aspirated; the pellet was then resuspended in 20 ml IMDM 	 mented with 1% FCS, before centrifuging the tube, as
(Sigma, 12762) with 10% fetal calf serum (FCS, Sigma, F 35 described above. After centrifugation, the supernatant was
2442), and then transferred to a flask and placed in an incu- 	 discarded and the pellet was resuspended in 10 ml of MCF-7
bator at 37° C. overnight in preparation for PEE treatment the 	 culture medium. Five milliliters of this suspension was trans-
next day. The next morning the contents of the flask were 	 ferred to one of two 75 cm 2 flasks, each containing 15 ml of
transferred to a 50 ml centrifuge tube. The flask was washed 	 MCF-7 culture-medium, prior to reculture under the above
three times with 10 ml PBS: these PBS wash volumes were 4o described conditions. If there were more than two flasks to be
added to the 50 ml tube containing the bulk of the PBMC 	 split, then the excess cells were frozen as follows. The cells
specimen. The resulting suspension was then centrifuged at	 were trypsinized and washed as previously described, and
1500 RPM for 5 minutes; the supernatant was aspirated, and 	 then resuspended in 1 ml of freezing medium (10% DMSO,
the cells were suspendedinthe desired pulsing buffer. Pulsing 	 Fisher, D128-500, 90% FCS), per flask and transferred to
and post-PEF treatment buffers are discussed in more detail in 45 labeled cryovials (Fisher, 5000-1020) prior to transfer to a
a subsequent section.	 —70° C. freezer. MCF-7 PEE treatment commenced the morn-
Cell preparation for Case 3 was identical to that for Cases 	 ing after these cells achieved half-confluency in the culture
1 and 2 with the following exceptions. The cells for Case 3 	 flasks. On the morning of a PEE experiment, the MCF-7s
were obtained by leukopheresis from a cancer patient that had	 were tryp sinized using the above protocol, the recovered cells
been administered granulocyte colony stimulating factor 50 were then washed using PBS, and the centrifuge pellet was
(G-CSF). More specifically, mobilization of the patient's 	 then suspended in pulsing buffer in preparation for PEE treat-
peripheral blood was effectedby administering G-CSF (10 µg 	 ment.
per kg body weight per day) subcutaneously for 4-6 days, 	 For the CMK line, the cell suspensions were thawed as
with apheresis collections beginning on day 4 until 2.5x106	 previously described for the MCF-7 line and cultured in CMK
CD34+cells per kg body weight were obtained. The resulting 55 culture medium at 37° C., 5% CO 2. The CMK culture
cell suspension contained approximately 2x10' leukocytes in 	 medium comprised IXRPMI 1640 medium, without
approximately 2 ml PBS. This cell preparation was used, 	 glutamine, supplemented with 2 mM L-glutamine (Fisher/
instead of the whole blood in the protocol described above for	 Cellgro, MT-25-005-LI), 50 I.U./ml of penicillin, and 50
obtaining PBMC preparations. Before suspending the PBPCs 	 µg/ml streptomycin (Fisher/Cellgro, MT-300-01-LI) and
in the pulsing buffer, the resting lymphocyte population was 6o 20% FCS. The CMKs were split 1:10 every 3-4 days by
activated to move these cells to their larger, active state in 	 transferring about 2 ml of the cell suspension to a new 75 cm2
order to improve for stem cell enrichment. To activate the 	 flask containing 18 ml of CMK culture medium. Excess cells
lymphocytes, the PBPC suspension, interleukin-2 (IL-2, 50 	 were frozen as previously described. On the morning of a PEE
IU/ml, R n' D Systems) and PHA (0.25 µg/ml, Sigma) were 	 treatment experiment, the CMKs were transferred from the
added to a culture medium (20 ml, IMDM, 10% FCS) and 65 culture flasks to 50 ml Falcon tubes (Becton Dickinson,
incubated at 37° C. for 36 hours. After activation (incubation), 	 2098). As part of this transfer, the cells were passed through
the suspension was centrifuged at 1500 RPM for 5 minutes, 	 a separation filter (Miltenyi Biotec, Inc., 414-07) to remove
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large-scale debris. The cells were then washed in PBS and
resuspended in the pulsing buffer in preparation for PEF
treatment.
Pulsing Medium
For Cases 1 and 2, IMDM was used as the medium in which
the PBMCs were suspended for PEF treatment. After PEF
treatment, the treated specimens were combined with an
equal volume of IMDM. The resulting specimen remained at
room temperature until preparation for flow cytometry analy-
sis.
For Cases 3, 4, and 5, the cells were suspended in a low
ionic strength medium (10% v/v PBS, 90% v/v isotonic
sucrose solution). This low ionic strength pulsing medium
was formulated to be isotonic. After PEF treatment, the
treated specimen was combined with an approximately equal
volume of IMDM. The inactivation protocol using a low ionic
strength pulsing medium, followed by resuspension in a
higher ionic strength medium, was used in these cases to
investigate whether the combination would result in more
extensive post-PEF fragmentation of PEF porated cells by
colloidal osmotic lysis. The low ionic strength pulsing buffer
was formulated as follows. Twenty milliliters of 1 x sterile
PBS was combined with 180 ml of distilled/deionized water.
To this solution, 16.6 g of powdered sucrose was added
(Fisher, BP220-212). This solution was then sterilized by
passing it through a 0.2 µm filter (Nalgene, 291-3320). The
pH of the resulting solution was checked using a Beckman
(^40 pH meter and was found typically to lie in the range
7.4-7.6. Prior to final preparation of the cellular suspensions
for pulsing, trypan blue exclusion using phase contrast
microscopy was employed to enumerate the number of viable
cells present in PBS suspensions of the various cells. Given
the number of cells desired in the cellular suspensions for
pulsing, the trypan blue results were used to determine the
volume of PBS cell suspension required to provide the
desired number of cells, which volume was then centrifuged
to pellet the cells. The pellet was then suspended in the
required amount of pulsing buffer.
Cell Assays
Pre- andpost-PEF cell enumerations were performedusing
both trypan blue exclusion, using a hemacytometer (Fisher,
02-671-10) under phase contrast optical microscopy, and a
wide variety of well established flow cytometry protocols.
Trypan blue exclusion was used primarily for determining the
number of viable cells to suspend in the pulsing medium for
each experiment. Flow cytometry, using a variety of viability
and conjugate antibody fluorescent stains, was used to enu-
merate pre- and post-PEF viable cell numbers, including
lymphocytes (B- and T-cells), monocytes, primitive progeni-
tor cells (including stem cells), and tumor cells (CMK and
MCF-7). A Becton Dickinson FACScan flow cytometer was
used to perform the analytical assays. For Cases 1, 2, 3, and 4,
cell viability was determined by flow cytometry using either
propidium iodide (PI, Molecular Probes, P-3566) or TO-
PRO-3 (Molecular Probes, T-3605) DNA staining combined
with light scatter characteristics. Viable lymphocytes were
identified as those cells scoring low for the particular DNA
viability stain used (either PI or TO-PRO-3) while staining
brightly for CD3 (T-cells, Fisher, OB9515-02 or-09) or CD19
(B-cells, Fisher, Becton Dickinson, 340409 or 340364).
Viable monocytes were identified as those cells scoring low
for the DNA viability stain used while staining brightly for
either CD11b (Becton Dickinson, 347557), CD13 (Fisher,
OB9555-02 or -09), or CD14 (Fisher, OB9560-02 or -09) and
CD45 (leukocytes, Fisher, OB9625-02 or -09). Viable
hematopoictic stem cells were identified as those cells scor-
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ing low for the DNA viability stain used while staining
brightly for CD34 (Fisher, OB9595-02 or -09) and dimly for
CD38 (Fisher, OB9610-02 or -09). Viable CMK tumor cells
were identified as those cells scoring low for the DNA viabil-
5 ity stain used, staining dimly for CD14, and staining brightly
for CD45, while also being outside of the light scatter com-
partments for lymphocytes and monocytes (light scatter gat-
ing).
For Case 5, involving the PEF inactivation characteristics
to of MCF-7 tumor cells, viable MCF-7s were identified as
those cells scoring low forboththe apoptotic membrane stain
Annexin-V (Caltag, Annexin V VOI -3) and the DNA stain PI.
Light scatter gating was also used to discriminate cells from
cell debris that was smaller than the smallest of the MCF-7
15 cells. Both PI and Annexin-V viability stains were used for
MCF-7 analysis based on the following considerations. Pro-
pidium iodide is a DNA stain. Thus, for cells with disrupted
membranes, yet still containing a nucleus, this dye will stain
non-viable cells. Annexin-V, however, stains phosphati-
20 dylserine (PS) which migrates from the inside to the outside
of the plasma membrane during normal apoptosis. Thus, it is
normally used as an indicator of apoptotic, but still viable
cells. Whether or not the PS migrates to the external surface of
the cell as a result of PEF treatment is unimportant. What is
25 important is that should PEFs result in the discharge of the
nucleus from the cell, Annexin-V will stain the PS on the
inside of the plasma membrane, since this stain has access to
the inside of the cell due to membrane disruption. Thus, ghost
cells should have a bright Annexin-V fluorescence signature.
30 Therefore, gating based on both PI and Annexin-V has been
found by the inventors to give the best screening for viable
MCF-7 cells.
Test and Control Specimens
35 On a given test day, both control specimens and PEF
treated specimens were prepared. Two types of controls were
prepared: 1) a stock cell control specimen and 2) a PEF test
cell control specimen. Stock cell suspension refers to the
cellular suspension in pulsing medium from which fixed vol-
40 ume aliquots were taken for loading into the PEF treatment
cells. The stock cell suspension controls were prepared by
placing the same volume of stock cell suspension into a 15 ml
centrifuge tube as would be loaded into the PEF treatment
volume. An additional 5 ml of IMDM was then added to the
45 same tube. The PEF treatment cell controls were prepared by
loading a PEF treatment cell with the appropriate volume of
cell suspension and allowing it to stand at room temperature
for the period of time it would normally take to treat a speci-
men with PEFs; however, during this time, no PEFs were
50 applied to the PEF treatment cell control specimens. When
the standing period expired, the specimen was removed from
the PEF treatment cell and placed in a 15 ml centrifuge tube
to which 5 ml of IMDM was added. The PEF treated speci-
mens were handled in the same way as the PEF treatment cell
55 controls, except PEFs were applied to the treated specimens.
The control specimens served two purposes. First, a com-
parison of the total viable cell counts, as provided by flow
cytometry, between the stock cell controls and treatment cell
controls gave an indication of the fraction of cells lost simply
6o by virtue of residence in the PEF treatment cells. Second, the
cytometry counts from the treatment cell controls for each
cell type were used to normalize the cytometry counts for
each cell type for the PEF treated specimens. This allowed for
computation of the surviving percent for each cell type for
65 each set of PEF conditions. To obtain consistent and mean-
ingful cytometry counts, the following general procedure was
followed. By virtue of the fact that the PEF treatment cells
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employed had a fixed volume, and that the stock cell suspen-
sion controls were prepared using a stock cell specimen hav-
ing the same volume as the PEF treatment cells, all of the
specimens prepared on a given test day had the same number
of input cells. When preparing the control and PEF treated
specimens for flow cytometry analysis, all cellular material
present prior to PEF treatment was ultimately contained in the
aliquot the cytometer drew from when performing the flow
cytometry assays. Thus, if the volume of each cytometry
aliquot was the same for all specimens on a given test day,
then acquiring counts for a fixed acquisition time for all
specimens would provide viable counts that could be com-
pared across the specimens prepared on a given test day. Most
importantly, the viable counts for the treatment cell controls
could then be used to normalize the viable counts for each
PEF treated specimen, thereby providing the information
needed to compute surviving percent for each PEF-exposed
specimen.
Flow Cytometry
The following procedures were used during preparation of
the control and PEF-treated specimens for flow cytometry
analysis. 100 ld of DNase I (100 mg; 500 Kunitz-units per mg
solid, Sigma, DN-25) was added to each specimen to mini-
mize coagulation by released DNA. The specimens were then
vortexed and centrifuged for 6 minutes at 1500 RPM. The
supernatant was aspirated and the pellet was washed with 5
ml PBS. When preparing for PI and Annexin-V staining, the
specimens were centrifuged again for 6 minutes at 1500
RPM; the supernatant was aspirated, and 100 ld of 1 x calcium
buffer was added (Bender MedSystems, BMS306BB), fol-
lowed by addition of 150 ld of propidium iodide (PE conju-
gate) and 5 ld of Annexin-V (FITC conjugate). These speci-
mens were incubated at room temperature for 15 minutes.
Next, 300 ld of lx calcium buffer was added, the sample
vortexed, and then the specimens analyzed under flow cytom-
etry. PI/Annexin-V staining was the only staining used for
Case 5 where the PEF inactivation characteristics of MCF-7s
(with no other cellular species present) is presented. PI stain-
ing, in conjunction with other conjugate monoclonal anti-
body stain, was used for Cases 1 and 2, where the inactivation
of PBMCs is presented: Annexin-V viability staining was not
used for these cases (Cases 1 and 2). For Case 1, the speci-
mens were also stained using the conjugate monoclonal anti-
bodies CD3 and CD13 in order to enumerate lymphocyte
(T-cells) and monocyte/granulocyte cells, respectively. For
Case 2, the specimens were also stained with the conjugate
monoclonal antibodies CD3 and CD13 in order to enumerate
lymphocyte (T-cells) and monocyte cells, respectively. For
Case 3, the washed pellets were resuspended in 200 ld PBS,
which was then aliquoted to two 100 ld specimens. The con-
jugate monoclonal antibody stains CD14 and CD45 were
added to one of these aliquots for enumeration of lymphocyte
and monocyte cells, respectively. The conjugate monoclonal
antibody stains CD34 and CD38 were added to the second
aliquot for enumeration of primitive progenitor cells (he-
matopoietic stem cells). Both aliquots were then incubated at
room temperature for 15 minutes. These aliquots were then
washed with 2 ml PBS, centrifuged for 6 minutes at 1500
RPM; the supernatant was then aspirated, and 500 ld of 1
µg/ml TO-PRO-3 viability stain was added to the tube. The
resulting aliquots were then incubated for 15 minutes at room
temperature, vortexed, and analyzed under flow cytometry.
The staining for Case 4 was very similar to Case 3, except the
specimens were not stained with the CD34/CD38 conjugate
monoclonal antibodies. Rather, these specimens were stained
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with the conjugate monoclonal antibodies CD3 and CD19 (in
addition to CD14 and CD45) in order to enumerate T- and
B-cells, respectively.
When analyzing Cases 1, 2, 4, and 5 under flow cytometry,
5 approximately 100,000 cytometer events were found to give
adequate resolution of the cell types of interest (lymphocytes,
monocytes, tumor cells). Due to their rare frequency, how-
ever, 500,000-1,000,000 cytometer counts were required to
identify the CD34+/CD38— stem cell population for Case 3.
10
PEF Apparatus
The apparatus used for the examples that follow was a
batch PEF treatment system, i.e., PEF treatment takes place in
a fixed, static PEF treatment volume. The batch PEF system is
15 comprised of a batch PEF treatment cell, an electrode enclo-
sure assembly that holds the PEF treatment volume during
exposure to PEF s, an electric field pulse generator that applies
voltage pulses to the PEF treatment cell, and a computer
control/data acquisition system.
20 The essential details of the PEF treatment cell used for the
examples is illustrated in FIG. 6. The treatment volume is
formed by stacking the end blocks 131, 132, graphite disk
electrodes 133, 134, and Pyrex annular spacer 135 as shown
in FIG. 6. This treatment cell has a sealless design, i.e., no
25 O-ring or gasket seals are employed to seal the PEF treatment
volume 140, defined by the mating of the Pyrex annular
spacer and graphite disks. Rather, all mating surfaces were
lapped to a waviness of no more than 2.5 µm over the diameter
(8.26 cm) of the disks involved the assembly. Furthermore, all
30 mating surfaces were lapped to a number 4 surface finish,
which had an RMS variation in surface deviations of +/-0.1
µm. The graphite disks were made of ISO-63 graphite, which
had an average pore size of 1 µm. The tolerances were chosen
to prevent blood cells, which are typically greater than 5 µm,
35 from finding their way into the interface regions of the mating
treatment cell components, or penetrating into the pores of the
graphite disk electrodes. Nylon screws were employed to
hold the treatment cell assembly together. Since all internal
surfaces of the treatment cell were either normal to the elec-
40 tric field direction (e.g. conducting surfaces) or were parallel
to the electric field direction (e.g. insulating surfaces), the
utilized treatment cell geometry provided very uniform elec-
tric field strength over the entire treatment volume. The end
blocks of the treatment cell were made of gold coated copper.
45 The gold coating was included to minimize surface oxidation
and to provide excellent electrical contact with the assembly
that holds the treatment cells during PEF treatment. The puls-
ing suspension was loaded and unloaded from the PEF treat-
ment cell through the radial channel 139 in the Pyrex annular
50 spacer by using a pipetting syringe (pipetting needles, Fisher,
14-825-16N); 10 ml disposable syringes, Fisher, 14-823-2A).
The treatment cell just described was used for Cases 1, 2, 3,
and 4. It is referred to hereafter as the Type A test cell. For
Case 5, a variant of the TypeA test cell was used. This variant
55 is referred to as the Type B test cell (not shown) and was
similar to the Type A test cell previously described with the
following differences. The type B test cell used tungsten
electrodes, rather than graphite and the annular spacer was
made of plexiglass that had four radial holes (1 mm I.D.),
60 equally spaced around its perimeter, that penetrated from the
outer surface through to the inner surface. A silicon washer,
which had an outside diameter equal to the inside diameter of
the plexiglass spacer and which was approximately 0.05 mm
thicker than the plexiglass annular spacer, was inserted inside
65 the plexiglass spacer during assembly of the Type B test cell,
which silicon washer ultimately formed the circumferential
bounding wall of the PEF treatment volume. Once the Type B
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test cells were assembled, they were loaded and unloaded
with cell suspension through the 1 mm I.D. holes using A 21 G
hypodermic needles mated to 1 ml syringes (21G needles,
Becton Dickinson, 305176; 1 ml syringes, Becton Dickinson,
5602).
The internal dimensions of the test cells that were critical
for the heat transfer and electric field strength calculations,
were as follows. For the Type  test cells, the diameter of the
cylindrical treatment volume was 4.45 cm, and the gap
between graphite electrodes, when the test cell is assembled,
was 3.2 mm, which yields a volume of 4.94 ml. For the Type
B test cells, the diameter of the cylindrical treatment volume
was 10.91 cm, and the gap between graphite electrode was 2.5
mm, which yields a volume of 0.72 ml. The parts making up
the test cells were fabricated using standard methods known
in the art.
In general, electrochemical reactions take place in the
region near the electrode surfaces when a current is passed
through the electrodes into an electrolyte solution. For the
present application, were thousands of electric field pulses
may be applied, gold is not a good electrode candidate. This
is because free chlorine ions can react with the gold, forming
a gold salt, which dissolves in the electrolyte. Tungsten is a
reasonably inert electrode material, but it can react with free
oxygen ions to form an oxide layer on the electrodes. Carbon
electrodes (graphite) are the preferred electrode material
since graphite is substantially inert with respect to the ionic
species formed during PEF treatment.
To demonstrate to the importance of controlling electro-
chemical reactions, separate experiments were performed
where electric field pulses were applied to isotonic potassium
chloride solutions. Plumes of bubbles were observed to be
released from both the anode and cathode electrodes of the
Type A test cell. Furthermore, after a thousand pulses, the pH
of the solution shifted from 7.0 to 6.0. However, when a DC
counter-current was driven through the test cell during puls-
ing, which had a current equal to and opposite of the time
average of the primary electric field pulses, no bubble forma-
tion was detected and the swing in pH was undetectable.
These experiments illustrated the ability of using a reverse
polarity current to control electrochemical reactions inunbuf-
fered aqueous solutions having high (i.e. physiological) ionic
strengths. Reverse polarity currents were not employed in the
example cases to follow since the pulsing media used for
those cases was typically of lower ionic strength and included
a buffer to counter the effects of low concentrations of elec-
trochemically produced products.
Once the test cells were loaded with the desired cellular
suspension, the test cells were then mounted in an electrode/
enclosure assembly that supports the test cell when the PEFs
are applied to the test cell. The electrode/enclosure assembly
used for the example cases following has essentially the same
features as the assembly shown in FIG. 5. This assembly
serves three purposes. First, it provides electrical contact
between the electric pulse generator and the PEF treatment
cell. Second, it provides temperature control for the test cell.
Third, it encloses the test cell during PEF treatment, thereby
protecting personnel in close proximity to the system from
high voltage components. With reference to FIG. 5, the tem-
perature of the test cells were controlled by contact with
temperature-controlled cathode 114 and anode 111 supports
of the electrode/enclosure assembly 95. The temperature of
the cathode and anode supports is controlled by circulating
temperature controlled water through these structures using a
heater/chiller system (Neslab, RTE-110). This system is
capable of setting the temperature of the test cells to +/-0.2°
C. over the range 0-50° C. After mounting the test cells in the
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electrode/enclosure assembly, the test cells were allowed to
reach thermal equilibrium with the temperature of the cath-
ode and anode structures in the electrode/enclosure assembly.
The electric pulse generator system used for the examples
5 consisted of an energy storage capacitor (3 W, 500 µf, Max-
well, 38683), which was connected to an all-solid-state pulse
driver designed and fabricated by the inventors for driving a
COz laser. The pulse driver (electric pulse generator) is
referred to as the COLD-I. This driver switches the energy
i0 stored in the 500 µf capacitor via solid-state SCR switches to
a 20:1 saturable core transformer into an impedance matched
load (-8 Q). This driver, as presently configured, can deliver
fixed duration voltagepulses (-5 µs duration) at voltages up to
8 W. Under these conditions, the deliverable pulse energy is
15 
—80 J. The storage capacitor was charged via a Maxwell (1
W, 5 0/s, CCDS 501 P372-208) high voltage charging power
supply. Normally, the voltage output of the COLD-I is to high
for use for PEF cell selection. This was remedied by using a
high power voltage divider circuit, which simply comprised
20 two resistors in series connected to ground. This voltage
divider circuit could attenuate the voltage pulses delivered to
the PEF test cell by factors of 4-20 simply by changing the
resistance of the two resisters in the circuit.
25 A Pearson coil current transducer was used to monitor the
current delivered to the PEF test cell. A second Pearson coil
transducer measured the current through a precision 100 Q
resister connected across the PEF test cell. The voltage
applied to the test cell was derived from the second Pearson
30 coil transducer signal by multiplying it by 100 Q. These
current and voltage signals were displayed on a LeCroy oscil-
loscope (9410). FIG. 10 presents the voltage waveform pro-
duced by the COLD-I driver when applied to a TypeA test cell
containing a room temperature isotonic potassium chloride
35 solution, which corresponds to imposing a 2.2 kV/cm electric
field in this saline solution.
An IBM personal computer clone was used for system
control and data acquisition. During PEF treatment, a control
program was run that issued pulse driver trigger signals. The
40 frequency and number of the trigger signals was set by the
operator based on the PEF conditions desired. The magnitude
of the voltage pulses delivered to the PEF test cell, however,
was set by a dial associated with the Maxwell charging power
supply. The output trigger signal from the PC control com-
45 puter was delivered to an opto-isolator circuit, which pre-
vented any electric noise from feeding back to the PC. The
output of the opto-isolator circuit was delivered to an HP
214-B trigger generator, which, in turn, sent a 100 volt, 2 µs
pulse to the COLD-I driver, which triggered the COLD-I,
50 thereby applying the desired electric field pulse to the PEF
test cell.
Upon completion of a PEF treatment experimental trial, the
voltage and current waveform data was downloaded from the
oscilloscope to the PC computer via a GPIB interface. After
55 the data was downloaded, post-processing computations
were performed. More specifically, the following quantities
were computed: peak voltages and currents, the resistance of
the test cell, the full-width at half-maximum (FWHM) elec-
tric field pulse length, and the energy delivered to the test cell
60 per electric field pulse. For the cases that follow, the electric
field strengths quoted were those based on the peak voltage of
the pulses delivered to the PEF test cell. Furthermore, the
electric field pulse lengths quoted were the FWHM values.
After computing the single pulse energy deposited to the test
65 cell, the average midplane temperature rise in the PEF test cell
and the temperature jump per electric field pulse for a given
PEF treatment trial was computed. These temperatures, when
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quoted in the cases that follow, were derived using Eqs. 14,
14a, and 14b given earlier in the detailed description.
Case 1. Step-Wise PEE Inactivation of PBMCs
The ability of PEFs to selectively inactivate cells in a
step-wise, size-dependent manner with increasing electric
field strength and exposure time is demonstrated in this case.
The stock cell suspension contained PBMCs suspended in
IMDM at a concentration of 1.1x10 6 cells/ml. The pulsing
medium was of standard physiological ionic strength. The
input cells and stock cell suspension were prepared as previ-
ously described. Type A test cells were used in the Case 1
trials. Pulsed electric fields, having strengths in the range
1.4-1.8 kV/cm, were applied to the specimens. The total
electric field exposure times were in the range of 0.18-5.97
ms, and the electric field pulse length was about 5.75+/-0.2 µs
(FWHM). The total electric field exposure time was varied
over the noted range by varying the number of applied electric
field pulses over a range of 30-1000 pulses. The single pulse
energy deposited to the test cells ranged from 0.54-0.88
7/pulse. The electric field pulses were applied at 1 Hz. The end
blocks of the test cells were maintained at 35° C.+/-0.2° C.
Based on Eqs. 14, 14a, and 14b, the average midplane tem-
perature varied over the range from about 35.2-35.4° C. and
the temperature jump per electric field pulse varied over the
range 0.03-0.04° C. One stock cell control specimen and one
test cell control specimen were prepared before commencing
PEE treatments, and one test cell control specimen was pre-
pared after all PEE treatments had been performed for the test
day in question. The control and PEE treated specimens
(about 5 ml each) were placed in 15 ml centrifuge tubes after
preparation, to which an approximately equal volume of
IMDM was added as previously described. These specimens
were then analyzed by flow cytometry for enumeration of
viable cell types and numbers as also previously described.
FIG. 11 presents total surviving percent of all viable cells,
on the y-axis, as a function of total electric field exposure
time, for three different electric field strengths. These results
indicate that PEE lethality, expressed as surviving percent,
increased with increasing electric field strength and total elec-
tric field exposure time as predicted by Eq. 8. Further, FIG. 11
indicates that the onset of significant cell inactivation
occurred at approximately 1.8 kV/cm. This measured thresh-
old strength is in reasonable agreement with the threshold
strength for the resting lymphocytes given in Table 2, which
would be expected since the most abundant population of
cells in the PBMC specimens were resting lymphocytes.
FIGS. 12a-12d show viability scatter plots that were
derived from flow cytometry assays of the specimens for this
case. The results given in these figures were generated for
specimens exposed to a fixed electric field strength of 1.8
kV/cm. FIG. 12a shows the scatter plot for the test cell control
specimen, whereas FIGS. 12b, 12c, and 12d show the scatter
plots for 30, 100, and 300 applied electric field pulses respec-
tively. The y-axes in these figures show relative propidium
iodide (PI) intensity, and the x-axes show forward scattered
(FSC-H) light angles, which are proportional to cell size.
High PI values are indicative of nonviable cells. High FSC-H
values are large cells. Regions represented by Rl and R2 in
these figures correspond to viable cells. In FIG. 12a, the
viable cells in Rl and R2 form a pattern that looks like a pan
with a handle. It can be seen that as one scans from FIGS. 12a
to 12d, the handle (i.e. viable cells in R2) disappears. These
figures also show that the fraction of cells that scored high for
PI increased with increasing total electric field exposure time
(total number of applied pulses). Thus, for a field strength of
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1.8 kV/cm, FIGS. 12a-12d indicate that the applied PEFs
were selectively killing the larger cells.
FIGS. 13a-13c present CDl lb/CD3 flow cytometry scatter
plots for the corresponding specimens shown in FIGS. 12a-
5 12d. FIG. Da shows results for the control specimen. Rela-
tive intensity of CD  lb staining is shown on the y-axes, and
relative intensity of CD3 staining is shown on the x-axes.
FIGS. 13b, 13c, and 13d correspond to PEE treated specimens
that received 30, 100, and 300 electric field pulses of 1.8
io kV/cm strength respectively. Cells scoring high for CDl lb
are predominately monocytes. Those scoring high for CD3
are predominately T-cells. Based on Table 2, the T-cells (a
subset of lymphocytes) are typically about 7 µm in size,
whereas the monocytes are typically about 15 µm in size. The
15 upper left quadrant of FIG. Da displays a distinct monocyte
population that diminishes significantly as one scans from
FIG. Da to FIG. 13b to FIG. 13c and finally to FIG. 13d. In
contrast, however, the T-cell population (lower right quad-
rant) has not been reduced as significantly as the monocyte
20 population. Thus, the 1.8 kV/cm PEFs have selectively
depleted the monocyte cells while preserving a significant
fraction of the T-cells.
Case 2. PEE Enrichment of Lymphocytes Over
25	 Monocytes
The ability of PEFs to enrich a PBMC specimen in lym-
phocytes by selective inactivation of the larger monocytes
was demonstrated in this case. The stock cell suspension
30 contained PBMCs suspended in IMDM at a concentration of
1.5x10 6 cells/ml. The pulsing medium was of standard physi-
ological ionic strength. The input cells and stock cell suspen-
sion were prepared as previously described. Type A test cells
were used for the Case 2 trials. Pulsed electric fields, having
35 strengths in the range 1.2-1.6 kV/cm, were applied to the
specimens. The total electric field exposure times were in the
range 0.15-5.70 ms, and the electric field pulse length was
about 5.17+/-0.3 µs (FWHM). The total electric field expo-
sure time was varied over the noted range by varying the
40 number of applied electric field pulses over a range of
30-1000 pulses. The single pulse energy deposited to the test
cells ranged from 0.36-0.77 7/pulse. The electric field pulses
were applied at 1 Hz. The end blocks of the test cells were
maintained at 35° C.+/-0.2° C. Based on Eqs. 14, 14a, and
45 14b, the average midplane temperature varied over the range
35.1-35.3° C. and the temperature jump per electric field
pulse varied over the range 0.02-0.04° C. One stock cell
control specimen and one test cell control specimen were
prepared before commencing PEE treatments, and one test
50 cell control specimen was prepared after all PEE treatments
had been performed for the test day in question. The control
and PEE treated specimens (about 5 ml EACH) were placed
in 15 ml centrifuge tubes after preparation, to which an
approximately equal volume of IMDM was added as previ-
55 ously described. These specimens were then analyzedby flow
cytometry for enumeration of viable cell types and numbers
as also previously described.
The data in FIG. 14 is presented in the same format as
shown previously in FIG. 11. The results indicate that PEE
60 lethality, inversely proportional to surviving percent,
increased with increasing electric field strength and total elec-
tric field exposure time as predicted by Eq. 8. The results
presented in this figure exhibit the same trends as the data
presented FIG. 11 for Case 1.
65 Using light scatter, viability stain gating, and CD3 and
CD13 antibody fluorescence, viable lymphocyte and mono-
cyte cells populations were enumerated independently. FIGS.
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15a-15j present the results in forward scatter histogram for- 	 35.0-35.1° C., and the temperature jump per electric field
mat with relative numbers of cells on the y-axes and size on 	 pulse varied from about 0.005-0.007° C. One stock cell con-
the x-axes. FIGS. 15a and 15f show the monocyte (FIG. 15a) 	 trol specimen and one test cell control specimen were pre-
and lymphocyte (FIG. 15j) histograms for the control speci- 	 pared before commencing PEE treatments, and one test cell
mens. Similarly, FIGS. 15b and 15g, 15c and 15h, 15d and 5 control specimen was prepared after all PEE treatments had
15i, and 15e and 15j show the monocyte and lymphocyte 	 been performed The controls and PEE treated specimens
histograms, respectively within each pair of Figs., for an 	 (each about 5 ml) were placed in 15 ml centrifuge tubes after
electric field strength of 1.4 kV/cm and total electric field	 preparation, to which an equal volume of IMDM was added
exposure times of 0.15 ms (30 pulses, FIGS. 15b and 15g),	 as previously described. The specimens were then analyzed
0.33 ms (65 pulses, FIGS. 15e and 15h), 0.70 ms (140 pulses, io by flow cytometry for cell identification and enumeration as
FIGS. 15d and 15i),1.50 ms (300 pulses, FIGS. 15e and 15i). 	 previously described.
The size difference between the monocytes and lymphocytes 	 Using viability (TO-PRO-3) and CD34, and CD38 anti-
can be inferred by considering the location of the correspond-	 body staining, viable primitive progenitor cells were enumer-
ing distributions on the forward scatter axis: the monocytes 	 ated in the control and PEE treated specimens. Hematopoietic
are farther to the right (i.e. larger) relative to the lymphocytes 15 stem cells were identified as those viable cells that scored low
(compare FIGS. 15a and 15f for example). Progressively 	 for the viability stain, high for the CD34 fluorescence marker,
comparing corresponding pairs of Figs. for related PEE treat- 	 and low for the CD38 marker (i.e., CD34+/CD38— or CD34
ment conditions and increasing electric field exposure times	 single positive cells). The results for thi s case are presented in
(i.e. comparing FIGS. 15a and 5f, then FIG. 15b and FIG. 	 FIG. 17 in bar chart format. The shaded bars in FIG. 17
15g, etc.), indicates that as total electric field exposure time 20 correspond to the surviving percent of all cells in the suspen-
increased, there was a large reduction in the number of mono- 	 sion. The unshaded bars correspond to stem cell enrichment,
cytes, with only a minor reduction in the number of lympho-	 which was defined as the ratio of viable stem cells to total
cytes. (Note that the scale for the monocyte histograms 	 viable cells in the PEE treated specimens normalized by the
changes from FIG. 15b to FIG. 15c, and again from FIGS. 15d	 same ratio for the control specimens. FIG. 17 shows that the
to 15e). FIGS. 15a-15j clearly demonstrate the size selective 25 total surviving percent of cells decreased with increasing
inactivation characteristics of PEFs for this cellular system. It 	 electric field strength. However, stem cell enrichment
is also noteworthy that the steepness of the tail on the right 	 increased with increasing electric field strength. In fact, at 1.9
hand side of the lymphocyte distributions increases with
	
kV/cm, enrichment approached 1 log. Significantly, the
increasing electric field exposure time, an indication that the 	 enrichment increased inversely proportional to the decrease
larger lymphocytes were inactivated before the smaller ones. 30 in total surviving percent. This indicates that the stem cell
The results for this case have been replotted in FIG. 16 as	 population was being preserved and demonstrates the ability
lymphocyte enrichment (y-axis) as a function of total electric	 of PEF's to enrich PBPC specimens for stem cells.
field exposure time x-axis) for three different electric field 	 It should be re-emphasized that these results were obtained
strengths. Lymphocyte enrichment was defined as the ratio of 	 under conditions that were not optimized for stem cell enrich-
lymphocytes to monocytes for the control specimen divided 35 ment. More specifically, the electric field waveform shape
by this ratio for the PEE treated specimens. This figure clearly 	 used for this case (see FIG. 10) was Gaussian in shape, rather
shows that lymphocyte enrichment increased with both elec- 	 than rectangular, and the length of the pulse (-5 µs) was very
tric field strength and total electric field exposure time. At a 	 short. As discussed previously, the electric field waveform
field strength of 1.6 kV/cm and a total electric field exposure 	 shape is preferably rectangular (with very short rise/fall times
time of —5 ms, essentially no monocytes were detected by 4o and with an essentially constant field strength between rise
flow cytometry thereby yielding an essentially infinite value 	 and fall) for obtaining more optimal size selectivity. Also, as
for lymphocyte enrichment.
	
	 discussed previously, short electric field pulses, such as the 5
µs pulses used in the present case are generally less effective
Case 3. PEE Enrichment of Stem Cells in PBPC 	 for cell inactivation than pulse durations greaterthan about 10
Preparations	 45 lls.
The ability of PEFs to enrich PBPC specimens for hemato- 	 Case 4. PEE Purging of CMK Tumor Cells in
poietic stem cells by selective inactivation of the larger cells 	 PBMCs
present in heterogeneous PBPC mixtures was demonstrated
in this case. The stock cell suspension contained PBPCs sus- 50	 This case demonstrates the ability of PEFs to purge PBMC
pended in a low ionic strengthpulsing medium (10% v/v PBS, 	 suspensions of tumor cells. The stock cell suspension
90% v/v isotonic sucrose solution) at a concentration of 6.6x 	 included PBMCs and CMK tumor cells suspended in a low
106 cells/ml. The PBPCs were harvested from patients, by 	 ionic strength pulsing medium (10% v/v PBS, 90% v/v iso-
leukopheresis, that had received G-CSF treatments as previ- 	 tonic sucrose solution) at 2.5x10 6 cells/ml. The CMK tumor
ously discussed. Prior to PEE treatment, the resting lympho- 55 cells represented about 14% of the total number of cells. The
cytes in the PBPC preparation were activated, as previously 	 CMKs are a megakaryocyte line whose size approximates
discussed, thereby stimulating these cells to their active state 	 epithelial tumor cell types. The PBMCs and CMKs were
which nearly doubled their size. Type A test cells were used	 prepared as previously described. Type  test cells were used
for the Case 3 trials. Pulsed electric fields, having strengths of
	
for the Case 4 trials. Pulsed electric fields, having strengths in
1.7, 1.8, and 1.9 kV/cm, were applied to the specimens. The 60 the range 1.2-1.8 kV/cm, were applied to the specimens. The
total electric field exposure time was 5.30 ms (1000 applied 	 total electric field exposure time was 3.6 ms (1000 applied
pulses), and the electric field pulse length was 5.30 µs 	 pulses), and the electric field pulse length was 3.6 µs
(FWHM). The single pulse energy deposited in the test cells 	 (FWHM). The single pulse energy deposited to the test cells
ranged from 0.11-0.15 7/pulse. The electric field pulses were 	 ranged from 0.04-0.10 7/pulse, and the electric field pulses
applied at 1 Hz. The end blocks of the test cells were main- 65 were applied at 1 Hz. The end blocks of the test cells were
tained at about 35° C.+/-0.2° C. Based on Eqs. 14, 14a, and	 maintained at 35° C.+/-0.2° C. Based on Eqs. 14, 14a, and
14b, the average midplane temperature varied from about 	 14b, the average midplane temperature varied from about
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35.02-35.04° C. and the temperature jump per electric field 	 and 20f are the light scatter, CD3/CD19 bivariate plots, and
pulse varied from about 0.002-0.005° C. One stock cell con- 	 TO-PRO-3 viability histograms, respectively, for the speci-
trol specimen and one test control specimen were prepared 	 men that was treated with 1000 electric field pulses, each
before commencing PEF treatments, and one test cell control
	
having a strength of 1.8 kV/cm. In FIG. 20a and FIG. 20d,
specimen was prepared after all PEF treatments had been 5 regions labeled R4, R6, and R7 correspond to the light scatter
performed. The controls and PEF treated specimens (each	 compartments that enclose the lymphocytes, inonocytes, and
about 5 ml) were placed in 15 ml centrifuge tubes afterprepa- 	 CMKs, respectively. The TO-PRO-3 viability histograms in
ration, to which an approximately equal volume of IMDM	 FIG. 20c and FIG. 20f were gated on R4, which means that
was added as previously described. The specimens were then 	 only events in the lymphocyte compartments in the light
analyzed by flow cytometry for cell identification and enu-  io scatter plots are displayed in FIG. 20c and FIG. 20f. FIGS.
meration as previously described. FIGS. 18a-18f show the 	 20b and 20e are gated on R8 (the TO-PRO-3 viability ranges
flow cytometry data from the analysis of the input cells for	 in either FIG. 20c or FIG. 20d) and R4 (the lymphocyte
this case. FIGS. 18a, 18c, and 18e are the light scatter plots 	 compartment in either FIG. 20a and FIG. 20d). Thus, FIG.
(no viability stain gating) for the CMK cells alone, the 	 20b and FIG. 20e display only the viable cells from the
PBMCs alone, and the CMK/PBMC mixture, respectively. 15 lymphocyte light scatter compartments. The conjugate mono-
FIGS. 18b, 18d, and 18f are viability stain histograms for the 	 clonal antibody fluorescence marker CD3 stains T-cells, a
CMKs alone, the PBMCs alone, and the CMK/PBMC mix-	 subset of lymphocytes. The fluorescence marker CD19 stains
ture respectively. Cells staining for the viability stain (TO- 	 B-cells. Thus, the upper left quadrants in FIG. 20b and FIG.
PRO-3) with an intensity greater than 10 2 were considered	 20e contain viable T-cells, whereas the lower right quadrants
dead. FIG. 18b indicates that the CMK cells had a component 20 contain viable B-cells. Comparison of FIG. 20b and FIG. 20e
(i.e. that population above 10 2 on the x-axis) that was either	 indicates there was little difference in the abundance of viable
dead or represented cell debris. These dead cells or debris 	 T- and B-cells for the control and PEF treated specimens.
showed up in the light scatter plot (FIG. 18a) as a band of dots	 However, FIGS. 19b and 19e clearly show that the CMK cells
that extend up and to the right from the origin. The viable 	 had been almost entirely eliminated under the same PEF
CMK population appeared as a cluster of dots that is centered 25 conditions.
vertically in FIG. 18a and slightly to the right of center 	 FIG. 21 presents the full set of data collected for this case.
horizontally. FIG. 18c indicates that were three clusters of 	 In this figure, the surviving percents of the relevant cell types
dots for the PBMCs. The cluster near the origin represents 	 (y-axis) are presented as a function of electric field strength
fine cell debris. The next cluster to the right represents the	 (x-axis). Recall that the total electric field exposure time was
lymphocyte population, and the cluster furthest to the right 30 constant for each field strength andwas produced by applying
represents the monocyte population. The lymphocyte, mono- 	 1000 electric field pulses. The total electric field exposure
cyte, and CMK clusters are evident in FIG. 18e. 	 time was 3.6 ms. This figure clearly shows that an almost
FIGS. 19a-19f qualitatively illustrate the effect of applying 	 2-log reduction in CMKs was achieved at 1.8 kV/cm without
1000 electric field pulses, each with a strength of 1.8 kV/cm, 	 impacting the viability of the lymphocytes. Also, it is evident
to the CMK/PBMC mixture. FIGS. 19a, 19b, and 19c are a 35 that the monocytes were just beginning to be affected at 1.8
light scatter plot, CD14/CD45 bivariate plot, and TO-PRO-3	 kV/cm, since the monocyte surviving percent curve is begin-
viability histogram, respectively for the control specimen. 	 ning to decrease at this field strength. Comparing the PBMC
FIGS. 19d, 19e, and 19f present the same corresponding 	 total surviving percent curves presented in FIGS. 11 and 14
information as FIGS. 19a, 19b, and 19c respectively, for the 	 with the lymphocyte surviving percent curve in FIG. 21,
specimen treated with 1000 electric field pulses, each having 40 shows the lethal effects of PEFs occurs at lower electric field
a strength of 1.8 kV/cm. As in FIG. 18e, the lymphocyte,	 strengths in FIGS. 11 and 14. As already indicated, the results
monocyte, and CMK populations are evident in FIG. 19a.	 presented in these examples have been acquired under non-
Circled region R1 (in FIGS. 19a and 19d) enclose the CMK 	 optimized conditions. The differences in PEF efficacy found
population. Bracketed region R3 (in FIGS. 19c and 19f) 	 by comparing FIGS. 11 and 14 with FIG. 21 may be due to
defines viable cells as judged by TO-PRO-3 viability staining 45 pulse length and pulsing medium ionic strength differences.
intensity. Scatter plots shown in FIGS. 19b (control) and 19e 	 The pulse length for the results in FIG. 21 was approximately
(PEF treated specimen) were gated on both R1 and R3, so the 	 30% shorter than for the results in FIGS. 11 and 14. Further,
cells appearing in these two figures represent viable cells in 	 the results in FIG. 21 were obtained using a low ionic strength
the R1 light scatter compartment, which is dominated by the 	 pulsing medium, rather than a standard physiological ionic
CMK tumor cells. The lower right quadrant of FIG. 19b 50 strength medium as used for the results presented in FIGS. 11
shows a well defined CMK population. The upper right quad- 	 and 14.
rant, however, shows that the R1 region also contained a small	 As noted, the pulsing medium used for this case was a low
number of monocytes. FIG. 19e shows that both the CMKs 	 ionic strengthpulsing buffer (10% v/v PBS, 90% v/v isotonic
and monocytes were eliminated by application of 1000 elec- 	 sucrose solution). This low ionic strength pulsing medium
tric field pulses of 1.8 kV/cm strength. However, the light 55 was used for two reasons. First, as previously discussed,
scatter plot (FIG. 19d) for the PEF treated specimen indicates 	 application of PEFs to cells in a low ionic strength pulsing
that the specimen still contained healthy lymphocyte and 	 medium, followed by resuspension in a standard physiologi-
monocyte populations. The change in the TO-PRO-3 viability 	 cal strength buffer, can lead to more extensive fragmentation
histograms (FIG. 19c and FIG. 19f) also indicates that only 	 of the of the PEF porated cells. It was observed during PEF
the CMK population had been affected by PEF treatment (the 60 cell selection experiments that post-PEF specimens that were
central peak in FIG. 19c, which is missing in FIG. 19f corre-	 treated with PEFs in a low ionic strength pulsing medium,
sponds to the CMK population, which was derived by con- 	 followed by resuspension in a higher ionic strength medium,
sidering FIG. 18b).	 included far fewer trypan blue stained cells than when treated
FIGS. 20a-20f examine the effect of PEFs on the lympho- 	 with PEFs under conditions where the pulsing buffer was of
cyte population. FIGS. 20a, 20b, and 20c are light scatter, 65 standard physiological ionic strength, even though the reduc-
CD3/CD19 bivariate plots, and TO-PRO-3 viability histo- 	 tions in viable cells were comparable. This result indicates
grams, respectively, for the control specimen. FIGS. 20d, 20e,	 that the combination of a low ionic strength pulsing buffer and
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a higher ionic strength post-PEF resuspendion buffer led to
greater fragmentation of the PEE porated cells by colloidal
osmotic cell lysis than for conditions where the pulsing buffer
was of standard physiological ionic strength. Secondly, a
lower ionic strength pulsing medium requires lower energy
input to achieve the same electric field strengths.
Case 5. PEE Inactivation Characteristics of Breast
Tumor Cells
The efficacy of PEE inactivation of breast tumor cells was
investigated in this case. The stock cell suspension contained
only breast tumor cells (MCF-7), which were suspended in a
low ionic strength pulsing medium (10% v/v PBS, 90% v/v
isotonic sucrose solution) at a total concentration of 1.2x106
cells/ml. The MCF-7s were prepared as previously described.
Type B test cells were used for the Case 5 experiments. Pulsed
electric fields, having field strengths in the range of 1.0-2.0
kV/cm were applied to the specimens. Two electric fieldpulse
lengths were used for this case: 3.50 and 5.25 µs (FWHM).
The total electric field exposure time was 3.5 ms (1000
applied pulses) for the shortest electric field pulse length,
whereas the total electric field exposure time for the longest
electric field pulse was 4.7 ms (900 pulses). The slight reduc-
tion in pulse number for the longer pulse length experiments
was included to keep the total electric field exposure time for
the longerpulse length experiments, based on the pulse length
at 95% of the peak electric field strength, approximately the
same as for the shorter pulse length experiments. The single
pulse energy deposited to the test cells was in the range of
0.003-0.020 7/pulse. The electric field pulses were applied at
1 Hz. The end blocks of the test cells were maintained at about
35° C.+/-0.2° C. Based on Eqs. 14, 14a, and 14b, the average
midplane temperature varied over the range from 35.01-
35.04° C., and the temperature jump per electric field pulse
varied over the range 0.001-0.007° C. One stock cell control
specimen and test cell control specimen were prepared before
commencing PEE treatments, and one test cell control speci-
men was prepared after all PEE treatments had been per-
formed for each set of tests. The controls and PEE treated
specimens (each about 0.72 ml) were placed in 15 ml centri-
fuge tubes, to which about 5 ml of IMDM was added as
previously described. These specimens were then analyzed
by flow cytometry for enumeration of viable MCF-7s, also as
previously described.
For this case, viable MCF-7s were identified as those cells
that fluoresced dimly for both propidium iodide (PI) and
Annexin-V stains. FIG. 22 presents results typical of PEE
inactivation experiments using the MCF-7 cell line. More
specifically, this figure illustrates the combined effect of
increasing electric field pulse length and exposure time, as
well as electric field strength. The curve shown by the dashed
line represents data obtained by applying 1000 electric field
pulses, each pulse having a 3.5 µs FWHM pulse length. The
curve shown by the solid line represents data obtained by
applying 900 electric field pulses, each pulse having a 5.3 µs
FWHM pulse length. Thus, the total electric field exposure
time for the dashed curve was 3.5 ms, whereas the total
electric field exposure time for the solid curve was 4.7 ms.
FIG. 22 clearly shows that increasing PEE pulse length and
exposure time resulted in increased tumor cell purging effi-
cacy. Further, the 5.3 µs pulse length produced about a 2.3 log
reduction in viable tumor cells. It is important to note that the
2.3 log reduction shown may significantly understate the
efficacy of the PEE process. Optical microscopy indicated
that the input cell population included clumps of agglomer-
ated cells, each clump containing from about 3-10 cells. Thus,
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the number of viable MCF-7 cells in the control specimens,
which were used to normalize the data for viable cells con-
tained in the PEF-treated specimens, could be low by about a
factor of 3-10. Thus, the surviving percents reported for the
5 PEF-treated specimens could be high by a factor of 3-10. In
addition, application of PEFs to this cell line had two effects:
1) the PEFs breakup the clumps of aggregated cells, and 2)
inactivation of the cells. The breakup of cells was clearly
observed by the increase in total events recorded by the
io cytometer. Total events were observed to increase by at least
a factor of two once PEFs had been applied to a specimen. It
is also believed the inflection points in the curves of FIG. 22
could be due to an increase in cell numbers due to disaggre-
gation by the PEFs, followed by subsequent inactivation.
15 Significantly, some of the cells in clumps will be shielded
from the PEFs until such clumps are completely reduced to
monodispersed cells. Once monodispersed, they can then be
inactivated by the PEFs. Thus the presence of clumped cells
in the cell suspension before treatment would imply that not
20 all of the cells in the specimens experienced the same effec-
tive electric field exposure time. Thus, increasing the electric
field pulse length, may be an effective way to lead to more
efficient PEE clump disaggregation, which, in turn, could
allow the use of lower field strengths and possibly shorter
25 exposure times to achieve inactivation of cells that tend to
clump, like the MCF-7 tumor cells. The MCF-7 tumor cell
inactivation results presented here show that at least a 2.3 log
reduction in this breast cancer line was achieved at PEE
conditions which led to a 1 log enrichment of stem cells,
30 without significant loss of viable stem cells, in Case 3 pre-
sented above.
Case 6: Enzymatic Removal of a Glycocalyx
Membrane Layer
35
A small fraction of the cells within a given epithelial cell
line, such as the MCF-7 line, secrete a mucopolysaccharide
(mucin), which can coat the cell plasma membrane. This
mucin coat can function to increase the effective thickness of
40 the membrane of these cells, which can, in turn, require
higher electric field strengths for their inactivation. The
inventors have experimentally determined, using standard
mucin stains and optical microscopy, that a fraction of the
MCF-7 cells have a mucin coat and that the coat can be
45 removed by enzyme digestion. To achieve this, the MCF-7s
were subjected to a hyaluronidase digestion protocol just
prior to their suspension in the pulsing medium. The mucin
digestion protocol involved resuspending the trypsinized
cells in a digestion solution (500 ug/ml hyaluronidase, Sigma,
50 H4272 30 mg; 94 mM potassium phosphate monobasic,
Sigma, P8416; 6 mM Sodium phosphate dibasic, Sigma,
S-5136) and incubating the solution for 30 minutes at 37° C.
Using standard techniques for mucin staining under optical
microscopy it was found that this digestion protocol essen-
55 tially entirely removed the extracellular mucin coats.
While the invention has been shown and described above
with reference to various embodiments and specific
examples, it is to be understood that the invention is not
limited to the embodiments or examples described and that
60 theteachings ofthis invention maybe practiced by one skilled
in the art in various additional ways and for various additional
purposes.
What is claimed is:
1. A system for creating, from a biological sample having a
65 given cell population of at least a first and a second cell type,
a suspension containing a viable subpopulation of said given
cell population, the system including:
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a generating mechanism configured to generate an electric
field of a selected, essentially uniform magnitude for a
selected duration sufficient to irreversibly porate a sub-
stantial fraction of cells of said first cell type while
maintaining substantially viable cells of said second cell
type; and
a treatment cell comprising an electrode electrically con-
nected to said generating mechanism and adapted to
contain a cell suspension, wherein said electrode is con-
structed of porous graphite and sealed with pyrolytic
carbon.
2. A system as in claim 1, wherein said generating mecha-
nism includes an electric pulse driver.
3. A system as in claim 1, wherein said generating mecha-
nism generates a magnetic field that induces said electric
field.
4. A system as in claim 1, wherein said treatment cell is
constructed and arranged to provide a treatment volume for
batch treatment of a cell suspension therewithin.
5. A system as in claim 1, wherein said system includes a
cooling system constructed and arranged to control the oper-
ating temperature of said treatment cell.
6.A system as in claim 5, further comprising a cooling fluid
contained within the cooling system.
7. A system as in claim 1, wherein said treatment cell is
constructed and assembled without the need for supplemental
seals.
8. A system as in claim 1, further including a mechanism
operative on the suspension to remove inactivated cells and
cell debris therefrom.
9.A system as in claim 1, wherein said first and second cell
types have a difference in at least one property affecting a
characteristic electroporation threshold.
10.A system as in claim 9, wherein said property affecting
a characteristic electroporation threshold of said selected
viable subpopulation is an average characteristic cell size that
is less than or equal to a predetermined threshold size, said
predetermined threshold size being less than the average
characteristic cell size of said first cell type.
11. A system as in claim 1, wherein the average character-
istic cell size of said first cell type is greater than the average
characteristic cell size of said second cell type.
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12. A system as in claim 1, wherein the treatment cell is
constructed and arranged such that, when said electric field is
applied to said biological sample by said generating mecha-
nism, at least 90% of the cells of said first cell type are
5 selectively inactivated while a substantial fraction of the cells
of said second cell type remain substantially viable, thereby
creating the viable subpopulation of said given cell popula-
tion.
13. The system of claim 1,
10 wherein the treatment cell has a shape such that no menis-
cus is formed that can distort the electric field when the
treatment cell is completely filled with a pulsing
medium, wherein said treatment cell includes a flow
path having an inlet and an outlet and is constructed and
15	 arrange to provide a treatment volume for continuous
flow treatment of a cell suspension therewithin.
14. The system of claim 1,
wherein the generating mechanism is configured to gener-
ate a bipolar electric field.
20	 15. A system as in claim 1, further comprising:
a cooling system comprising a circulation system for a
fluid configured to circulate cooling fluid in thermal
communication with said electrode; and
a control system able to determine temperature of the sus-
25	 pension and able to control the temperature of the sus-
pension by controlling the cooling system.
16. A system as in claim 15, wherein the control system
further comprises one or more temperature probes and/or
thermocouples.
30 17. A system as in claim 1, wherein the electrode is shaped
to generate electric field strengths outside of a main electric
field treatment region that do not exceed the electric field
strengths in the main electric field treatment region.
18. A system as in claim 1, wherein the treatment cell is a
35 flow-through treatment cell having an inlet and an outlet.
19. A system as in claim 1, wherein the generating mecha-
nism is able to generate electric field pulses at a pulse fre-
quency of less than 10 kHz.
20. A system as in claim 1 wherein the generating mecha-
4o nism is able to generate an electric field pulse having a sub-
stantially rectangular pulse shape.
